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Background: Clinicians rely on nuclear medicine for the treat-
ment of numerous diseasesimpacting millions of patients annu-
ally. Recently, Targeted Radiotherapy (TR) has been successfully
advanced with the US FDA approval of several radionuclide
based drugs]. Combinations of several types of radionuclide
emissions for therapy (i.e., α-therapeutic agent combined with
β- therapeutic) could lead to even more effective treatment op-
tions. One of the limiting factors in the development of TR as a
widely adopted treatment option is the availability of select ra-
dionuclides with optimum emission properties (both in volume
and periodicity of delivery), which poses a challenge due to
the fact that different radionuclides typically require different
target materials and/or nuclear reaction pathways for their
formation.
Materials and methods: We already published a successful strategy
for the isolation of 225/227Ac from irradiated thorium targets [5]. We
also published the recovery of Pa isotopes [6] from proton irradiated
thorium. In this work, we propose the isolation of several other med-
ically related radionuclides namely 103Ru, 223/225Ra, 111Ag from the
same target material.
Results: Several methods based on ion exchange chromatog-
raphy and solid phase extraction show promise for the co-
extraction of 103Ru and Ra isotopes from thorium irradiated tar-
gets. Anion exchange in HCl media proved to be an efficient
method for the isolation of 103Ru, while a combination of cation
exchange resin/citrate and DGA resin/HNO3 is suitable for Ra iso-
topes separation.
Discussion/conclusion: Production yields for the proposed radio-
nuclides were evaluated by comparison of actual product yields
with calculated (predicted) yields. Radiochemical strategies for
co-extraction of 103Ru and 223/225Ra isotopes based on ion ex-
change and solid phase extraction chromatography will be
discussed.© 2016 The Author(s). Open Access This article
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Background: The arginine-glycine-aspartic (RGD) peptide sequence
serves as a high-affinity antagonist of the integrin αvβ3 receptor that
plays an important role in tumor angiogenesis. Recently we reported
[68Ga]FSC(succ-RGD)3, a trimeric RGD peptide, exhibited excellent
targeting properties for αvβ3 integrin expression and significant
improved tumor uptake compared to monomeric [68Ga]NODAGA-
RGD.(1) Here we report the PET imaging properties of [68Ga]FSC(-
succ-RGD)3 in different xenograft tumor model and compared them
with [68Ga]NODAGA-RGD.
Materials and methods: The PET imaging properties of [68Ga]FSC(-
succ-RGD)3 were studied in nude mice bearing M21 human mel-
anoma xenografts and human glioblastoma U87MG xenograft
tumor. A parallel PET imaging of 68GaNODAGA-RGD in same
mouse bearing U87MG xenograft tumor was performed as a
comparison.
Results: The static PET image of [68Ga]FSC(succ-RGD)3 in nude
mice showed highly visualized tumors of M21 (positive) whereas
nonvisualized tumor of M21-L (negative) tumor xenografts 1 h
post injection confirming receptor-specific activity accumulation.
The dynamic PET images of [68Ga]FSC(succ-RGD)3 showed rapid
clearance of [68Ga]FSC(succ-RGD)3 from the circulation while the
tumor remained clearly visible. A direct comparison of [68Ga]FSC(-
succ-RGD)3 with [
68Ga]NODAGA-RGD in nude mice bearing
U87MG xenograft tumor using PET/CT resulted comparable tar-
get/background ratio (tumor/kidneys ratio = 1.3 and 1.6, tumor/
muscle ratio = 4.9, 5, respectively, 90 min post injection). The
time activity curves from dynamic PET data showed an increase
of the activity concentration of [68Ga]FSC(succ-RGD)3 in tumor
firstly, then remained almost constant whereas that of [68Ga]NO-
DAGA-RGD decreased quickly. The significant enhanced tumor
uptake (3.8 vs. 1.6 % ID/g) in addition to the slower washout rate
from tumor for [68Ga]FSC(succ-RGD)3 not only allows the PETis distributed under the terms of the Creative Commons Attribution 4.0
rg/licenses/by/4.0/), which permits unrestricted use, distribution, and
e appropriate credit to the original author(s) and the source, provide a link to
changes were made.
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achieve the same image contrast using less radioactivity as well
as detect low-level integrin expression.
Discussion/conclusion: [68Ga]FSC(succ-RGD)3 shows the advantages
in the respect of delayed imaging, reduced radiation dose as well as
monitoring low-level integrin expression in tissues in comparison to
[68Ga]NODAGA-RGD, therefore it is a promising agent for integrin
αvβ3 receptor imaging.
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Background: NPY-Y1 receptor (NPY-Y1R) is a promising target for
breast cancer imaging. Previously, our group prepared and tested a
series of truncated NPY analogs derived from BVD-15 (; [Pro30, Tyr32,
Leu34]NPY(28-36)-NH2) for
64Cu-labeling). Unfortunately the biological
half-live of the most potent tracer, [Lys(64Cu/DOTA)4]BVD15, when
injected in mouse plasma was shorter than 15 minutes. In this study,
we improved the design of BVD15 in order to increase its stability
in vitro and in vivo and maintain its targeting capability.
Materials and methods: Modifications of the peptide backbone, the
chelator and the use of D- and non-naturel amino acids were pro-
posed to improve the peptide tracer stability. The peptides were syn-
thesized on solid phase and conjugated to NOTA chelator. Binding
studies on MCF-7 human breast cancer cells (2) were performed after
each structural modification to make sure that the potency and the
selectivity of the new NOTA-peptide conjugates to NPY-Y1R were
maintained. Once active compounds were identified, they were radi-
olabeled with 64Cu for performing plasma stability, cellular uptake, in-
ternalization, and blocking studies on MCF-7 cells in order to rapidly
identify the promising candidates for in vivo studies.
Results: A 64Cu/NOTA-BVD15 derivative presenting a very low Ki (9
nM) and showing a very high stability in plasma up to 20 h and
in vivo for 30 minutes has been identified. Cell assays showed a
constant uptake and internalization over the whole experiment. The
internalized fraction after 2h was ~20%. The radiopeptide uptake
was blocked in presence of an excess of unlabeled peptide.
Discussion/conclusion: We have identified a new 64Cu-labeled peptide
presenting a good stability and an excellent affinity to NPY-Y1R. On the
basis of the cellular results, the 64Cu/NOTA-BVD15 derivative appears to
have a potential for the targeting of NPY-Y1R positive tumors.
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Background: Multivalency has shown to enhance accumulation of
receptor targeted radiopharmaceuticals, due to the avidity effect
and increased apparent tracer concentration. For metabolically
unstable peptides multimerisation may also delay metabolic pro-
cesses like oxidation and enzymatic cleavage leading to loss ofbinding affinity. The aim of this study was to show the benefit of
multimeristation on the targeting behaviour using a CCK2-
receptor targeting, metabolically unstable Minigastrin peptide
(MG11).
Materials and methods: Fusarinine C, a cyclic siderophore bearing
three amino residues, was chosen as chelating agent and up to three
peptide sequences (MG11= D-Glu1, desGlu2-6]-minigastrin) were
conjugated by using maleimide chemistry. Radiotracers were labelled
with 68Ga as well as with 89Zr following standard radiolabeling pro-
tocols. For in vitro characterisation stability studies, determination of
the partition coefficient and cell uptake studies were performed. In
vivo experiments included biodistribution studies (1h p.i) and static
micro PET/CT imaging and were carried out in tumour xenograft
bearing balb/c nude mice.
Results: Peptide conjugates could be labelled with 68Ga (5-15min
RT, pH4-5) and 89Zr (60min, RT, pH7) achieving radiochemical
yields of more than 98%. All complexes showed excellent stabili-
ties in the presence of EDTA, DTPA, FeCl3 and in human serum
after certain timepoints. Partition coefficient (logP) values ranging
from -1 to -3 revealed a hydrophilic character of the radiotracers.
As expected a decrease of hydrophilicity correlated with increas-
ing grade of multimerisation. The cell uptake ranged from 10 to
15% per mg protein and could be reduced significantly by block-
ing with human minigastrin indicating specific receptor binding
of all conjugates. Biodistribution studies showed a tumour uptake
ranging from 5% (monomer) to approximately 10% ID/g (multi-
mer) one hour post injection. Tumour to organ ratio was de-
creased by multimerisation and especially the kidney retention
was increased significantly by the di- and trimeric radiotracers.
Static animal imaging one and two hours after injection of 68Ga
labeled conjugates confirmed the outcome of the biodistribution
studies. 89Zr labeled counterparts showed very similar results but
after 24 hours post injection the trimeric bioconjugate showed
much better tumour imaging ability than the corresponding
mono- and dimer.
Discussion/conclusion: Though these results are preliminary multi-
merisation seems to correlate with higher tumour uptake leading to
better late timepoint imaging but high kidney retention seems to be
a major limitation. Stability studies are ongoing.
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Background: Recently a new bifunctional chimeric RGD peptide
(RGDechi), comprising a cyclic Arg-Gly-Asp pentapeptide covalently
bound to an echistatin domain, has been reported1. In vitro and
in vivo biological studies evidenced that this chimeric peptide select-
ively binds to αvβ3 integrin and does not cross-react with αvβ52. In
order to obtain an optimal SPECT radiotracer, a series of
[99mTc(N)PNP] labelled peptides has been prepared and their
pharmacological properties investigate.
Materials and methods: RGDechi-hCit (1) and three truncated peptide
derivatives [RGDechi1_17 (2), RGDechi1_16 (3) and RGDechi1_14 (4)]
lacking the two, three and five C-terminal amino acids, were synthetized
in solid phase by Fmoc chemistry and conjugated with a cysteine linked
to the Lys1 side chain to allow the labeling with [99mTc(N)PNP43]-syn-
thon (PNP43 = (CH3)2P(CH2)2N(C2H4OCH3)(CH2)2P(CH3)2). In vitro stability
and pharmacological parameters of the corresponding compounds,
99mTc1-4, were assessed. Challenges with an excess of glutathione and
cysteine and Log P values were also investigated. Furthermore, radiola-
beled peptides (99mTc1-4) were applied to study in vivo stability and the
pharmacokinetic profiles on tumor bearing mice.
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values demonstrate the hydrophilic nature of the radiolabeled pep-
tides ranging from -2.96 to -2.12. No significant variations in RCPs of
the complexes were detected in challenge experiments with an ex-
cess (10 mM) of glutathione and cysteine. In general, a high in vitro
stability was observed after incubation in human and mice sera as
well as in mice liver homogenate; a slight degradation of 99mTc1-4
was found in kidneys homogenate. Cell uptake assays showed that,
excluding 99mTc4 compound, 99mTc1-3 radiolabeled peptides accu-
mulate selectively in cells expressing αvβ3 integrin and does not
accumulate in cell expressing moderate levels of αvβ5 and undetect-
able levels of αvβ3 integrins. In agreement with in vitro findings, bio-
distribution studies showed that the 99mTc1-3 radiolabeled chimeric
peptide selectively localizes in tumor xenografts expressing αvβ3 and
fails to accumulate in those expressing αvβ5 integrin.
Discussion/conclusion: 99mTc-labeled RGDechi, RGDechi1_17 and
RGDechi1_16 chimeric peptides can be used for highly selective αvβ3
expression imaging by SPECT technology. Among the tested com-
pounds, 99mTc2 possess the best distribution profile and highest
localization in tumor expressing αvβ3. This research was supported
by MIUR through PRIN 20097FJHPZ-004 and FIRB “RINAME”2010-RBA-
P114AMK, by Programma Operativo Nazionale Ricerca e Competiti-
vita PON 01_02388 and by Italian Association for Cancer Research
AIRC IG 13121.
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Introduction: In cancer research, pretargeted PET imaging has
emerged as an effective two-step approach that combines the affin-
ity and selectivity of antibodies with the rapid pharmacokinetics and
favorable dosimetry of smaller molecule radiolabeled with short-lived
radionuclides. This approach can be based on the bioorthogonal
inverse-electron-demand Diels-Alder (IEDDA) “click” reaction between
tetrazines and trans-cyclooctene (TCO) derivatives. Our project aims
to develop new [18F]TCO-dienophiles with high reactivity for the
IEDDA reaction, improved in vivo stability and favorable pharmaco-
kinetics. New dienophiles were synthesized using an innovative
continuous-flow micro-photochemistry process, and their reaction
kinetics with a tetrazine were determined. In vivo stability studies of
the most promising 18F-radiolabeled-TCO-derivative ([18F]trans-EB-70)
was investigated, and its potential for pretargeted PET imaging was
assessed.
Materials and Methods: Organic chemistry Fluoro-cis-cyclooctene de-
rivatives and mesylate precursors for radiofluorination were synthe-
sized in 5-8 steps. Structures of intermediates and final compounds
were confirmed by NMR and HRMS. Photochemistry Trans-for-cis
isomerization was performed using a microfluidic setup. Kinetics Re-
actions between dienophiles and 3,6-di(pyridin-2-yl)-1,2,4,5-tetrazine
in MeOH at 25°C were monitored by UV-spectrophotometry at 290
nm (pseudo-first order conditions). 18F-radiolabeling (semi-auto-
mated) Nucleophilic substitution of mesylate trans-EB-77 using
[18F]KF,K222 was achieved in MeCN at 90°C for 15 min. [
18F]trans-EB-
70 was purified by HPLC. In vivo stability [18F]trans-EB-70 was evalu-
ated in healthy NMRI mice, by ex vivo biodistribution (2, 10, 30, 60
min p.i.). In vitro pretargeting Prostate tumor slices (LNCaP and PC-3
cells) were successively incubated with a prostate-specific membrane
antigen (PSMA) inhibitor modified with 3-(4-(trifluoromethyl)phenyl)-
6-phenyl-1,2,4,5-tetrazine, and [18F]trans-EB-70. Direct incubation with
the corresponding [18F]”preclicked”-compound, and blocking experi-
ments (2-(phosphonomethyl)pentane-1,5-dioic acid) were performed.Results Fluoro-cis-cyclooctene derivatives and mesylate precursors
were synthesized in 3-35% overall yields. The trans-for-cis micro-
photoisomerization reached yields of 48%. Reaction kinetics of
the new dienophiles are fast, with k2 ranging from 475.6±32.8 to
1913.0±195.9 M-1.s-1. Radiosynthesis of [18F]trans-EB-70 was
achieved in 60 min, with 12% radiochemical yield (decay-cor-
rected), a radiochemical purity >99% (for at least 2h), and 70-188
GBq.μmol-1 specific activity. Biodistribution of [18F]trans-EB-70 in
mice demonstrated absence of in vivo defluorination and a fast
clearance via urinary and hepatobiliary systems. Regarding
in vitro experiment, the binding on LNCaP tumor slices (express-
ing PSMA receptors) subjected to pretargeting was PSMA-specific
and slightly inferior to the binding of [18F]”preclicked”-compound.
No significant binding was observed in PC-3 cells (negative
control).
Discussion/conclusion: We demonstrated that [18F]trans-EB-70 is a
suitable dienophile for the IEDDA “click” reaction and for pretarget-
ing applications. Therefore, [18F]trans-EB-70 will be investigated
further in pretargeted μPET experiments.
Research support: SBO MIRIAD (IWT Flanders)
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Introduction: The Al18F-labelling strategy involves formation of alu-
minium mono[18F]fluoride ({Al18F}2+) which is trapped by a suitable
chelator –mostly bound to a biomolecule- in aqueous medium.1At this
moment however, the need for elevated temperatures (100-120 °C)
limits its widespread use. Therefore, we designed new restrained com-
plexing agents (RESCAs) for use of this strategy at moderate
temperature. RESCA1 is an acyclic pentadentate ligand with a N2O3 co-
ordinative set that is able to complex {Al18F}2+ efficiently at 25 °C. To
evaluate the stability and kinetic inertness of the chelate in vivo,
RESCA1 was conjugated to human serum albumin (HSA) and labelled
with {Al18F}. The Al18F-labelled conjugate was monitored in vivo for 6
h p.i.
Materials and methods: HSA was reacted with RESCA1-TFP.
RESCA1-HSA (7.5 mg, 110 nmol) in 750 μl sodium acetate buffer
(0.1 M, pH 4.5) was added to a freshly prepared {Al18F}2+ solu-
tion (1.4 GBq, 50 nmol AlCl3, 12 min, RT). The product was
purified using a PD-10 column and RCP was determined with
SEC-HPLC. To test stability in serum, Al18F-RESCA1-HSA in 100 μl
PBS was added to rat serum (900 μl), kept at 37°C and moni-
tored up to 4 h. Ex vivo biodistribution was studied at 1 h, 3 h
and 6 h p.i. of Al18F-RESCA1-HSA (2-7.5 MBq) in healthy female
rats. Small-animal whole-body PET imaging was performed using
a FOCUS 220 tomograph.
Results: RESCA1-HSA was obtained with a chelator-to-protein ratio
of 3, estimated by ESI-TOF-HRMS analysis. Al18F-RESCA-HSA was
prepared in high RCY (>70%) and purity (>95%) in < 30 min.
91% of product was still intact in rat serum after 4 h incubation.
Distribution in rats showed high retention in blood with 5.42 ±
0.23% ID/g, 4.93 ± 0.22% ID/g and 3.66 ± 0.06% ID/g at 1h, 3h
and 6 h respectively from which the blood biological half-life was
calculated to be 8.6 h. No significant increase in bone uptake
was observed, indicating excellent in vivo stability of the Al18F-
labelled construct.
Discussion/conclusion: We successfully labelled for the first time a
heat-sensitive biomolecule via the Al18F-method in one radiolabelling
step. Al18F- RESCA1-HSA showed excellent stability and favourable
properties for PET blood pool imaging applications.
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Introduction In the last years, the Cu(I)-catalyzed Huisgen [3+2]
cycloaddition between terminal alkynes and azides emerged as a
powerful tool in F-18 radiolabelling of biomolecules such as peptides,
because of its regioselectivity, mild aqueous organic conditions, re-
duced reaction times, and high yields.(1).A weak point of the method
is the lack of suitable commercially available, stable precursors.(2) In
this paper we report the synthesis and F-18 radiolabelling of a new,
versatile, easy to handle, and stable azido precursor useful for click-
chemistry.
Materials and methods: Reagents and solvents were purchased
from Sigma-Aldrich. [18F]Fluoride was produced with an IBA Cyc-
lone 18/9 cyclotron. Radioactive synthesis were carried out on a
fully automated radiosynthesis module (GE TracerLab FX-FN Pro),
and analyzed by analytical RP-HPLC with UV and radiochemical
detectors. Non-radioactive compounds were fully characterized by
NMR, ESI-MS and IR.
Results: A series of bifunctional precursors, bearing the azido moiety
and different leaving groups (e.g. tosylate, mesylate, iodo), coupled
to a short polyetyleneglycol chain (to improve their stability and
hydrophilicity) were designed and successfully prepared following a
ten-step synthetic pathway. A protection-deprotection strategy of
functional groups achieved the precursors and the fluorinated refer-
ence with good yield and purity. Precursors were radiolabelled with
F-18 and then coupled to propargylglycine as alkyne counterpart.
[18F]Fluoride was purified following standard procedure, and nucleo-
philic displacement of the iodo leaving group took place at 100° C,
in 20 min. The resulting labelled azide was successfully purified using
a Sep-Pak tC18 cartridge (51% radiochemical yield not decay cor-
rected, 93% radiochemical purity). The purified azide was then conju-
gated to propargylglycine, showing 52% conversion within 30 min at
room temperature. Purification and formulation have still to be
optimized.
Discussion/conclusion: A new optimized precursor useful for F-18
radiolabelling and click-chemistry was prepared. It demonstrated to
be effective in radiolabelling non-protected alkynyl-modified aminoa-
cids, by a fully automated synthetic procedure. Good results, in terms
of radiochemical yield and purity, were obtained from the iodo-
derivative precursor. Purification and formulation of the final cyclo-
addition product are in progress.
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Introduction: Radiopharmaceuticals are released for administration
by a quality control procedure against pre-set specifications. One of
these release specifications is the chemical purity of the drug prod-
uct, determined with High Pressure Liquid Chromatography (HPLC)
and UV detection. In the European Pharmacopeia (EP) hardly any
specifications are given for the chemical purity of a radiopharmaceu-
tical. When unknown impurities are present in the chromatogram,the decision if the radiopharmaceutical can be released, is very fre-
quently based on unclear parameters like ‘no unidentified UV signals
present’. There is a need for an objective specification in order to
have a save and reliable release.
Aim: The purpose of the presented work is to define a generally
applicable method to define tolerances for unidentified impurities in
radiopharmaceuticals.
Materials and methods: A retrospective analysis was performed on
HPLC analysis results of [11C]Flumazenil, [11C]PIB, [11C]Erlotinib,
[11C]DPA713, [18F]PK209 and [18F]FES. Quantification of the carrier
signal in the UV chromatogram was determined by use of calibration
curves, utilizing Chromeleon® 6.8. Unidentified impurities were semi-
quantified utilizing the surface area in the UV chromatogram relative
to the quantified carrier signal. Based on the EP. monography of
[11C]Flumazenil and [18F]FET, the specification for unidentified UV
impurities was determined to be 0.22 pmol/injection volume for a
single unidentified impurity and 0.88 pmol/injection volume for the
total of unidentified impurities. This specification was tested for over
500 batches of the radiopharmaceuticals and compared to the less
specific parameter ‘no unidentified UV signals present’.
Results: In a pilot assessment we encountered in 5-10% cases
unidentified UV impurities leading to rejection of the batch,
based on the specification ‘no unidentified UV signals present’.
Of these rejected batches 25% was also rejected with the new
defined specification. Reason for this reduced number of rejec-
tions is that with the new specification the presence of unidenti-
fied impurities is evaluated objectively. The analysis of the full
database is currently on-going.
Discussion/conclusion: With this method the amount of unidentified
impurities can be estimated in an optimal and objective way, utiliz-
ing EP limits of [11C]Flumazenil and [18F]FET, without operator
variability.
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Introduction: The 18F-labeling of peptides for PET applications has
been used for many years.1 However, the sensitivity of these pep-
tides does not allow their direct radiolabelling under harsh condi-
tions, except few recent examples. A solution is to use a prosthetic
group, an easily radiolabeled small molecule, subsequently coupled
in mild condition to the peptide. In continuation of our previous
work,2 we therefore propose to develop and use new C-glycoside-
based prosthetic groups. The use of sugar derivatives as prosthetic
group would improve bioavailability and pharmacokinetic properties
of peptides.
Materials and methods: These C-glycoside derivatives should have a
good leaving group thus allowing easy substitution by fluorine-18,
i.e. triflate. A copper catalyzed azide alkyne cycloaddition (CuAAC)
was then used for coupling these carbohydrates with a peptide.
Some model peptides containing a cysteine residue as RGDC and
c(RGDfC) are used. The high nucleophilicity of the thiol function can
thus be exploited to prepare S-propargylated derivatives. The fully
automated radiosynthesis of these [18F]fluoro-glycopeptides was per-
formed on an AllInOne® (Trasis) synthesizer.
Results: Triflated precursors of these C-glucosides prosthetic groups
and the non-radioactive references were synthesized in alpha and
beta configuration. Fluoride-18 radiolabeling was optimized and the
automated radiosynthesis of [18F]fluoro-glycopeptides with some
model peptides (RGDC, c(RGDfC)) was presented.
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 5 of 37Discussion/conclusion: The synthesis and radiosynthesis of 6-[19F/
18F]fluoro-C-glycosides displaying a three carbon arm terminated
with an azide group were optimized. CuAAC of fluoro-C-glycosides
with RGD derivative peptides gave [19F/18F]fluoro-glycopeptides in
good yields.
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Introduction: In nuclear medicine a remarkably high demand of
68Ga-radiotracers has emerged during the last decade. For a var-
iety of non-68Ga-containing radiotracers a microfluidic approach
for their syntheses could be established, enabling an enhance-
ment of yields due to high surface-to-volume ratios1,2. In this
proof-of-principle study, the 68Ga-radiolabeling of PSMAHBED-CC
and NODAGA-RGD using a microfluidic approach was evaluated.
Furthermore, adding TWEEN 20 (a surfactant suitable for in vivo
applications) and its impact on the radiochemical yield was
explored.
Materials and methods: The syntheses of 68Ga-PSMAHBED-CC and
68Ga-NODAGA-RGD (both precursors from ABX) were performed
using an Advion NanoTek LF microfluidic device. The system incorpo-
rates a flow-through reactor that consists of a silica capillary (l=2 m,
Ø100 μm, V=15.6 μL). 68Ga3+ was obtained from a 68Ge/68Ga-gener-
ator (3.7 GBq; Obninsk) according to a fractionized protocol. The pre-
cursor and 68Ga3+ were loaded in two storage loops and distinct
volumes thereof were pushed through the reactor with different
flowrates (30, 50, 80 μL/min) at different temperatures (25, 50, 80,
100, 120, 150°C) using NaOAc and HEPES for pH adjustment, respect-
ively. Additionally, the influence of TWEEN 20 as a surfactant, to re-
duce known adsorption effects in microfluidic tubing, was
investigated.
Results: Accomplished experiments revealed feasibility of 68Ga-la-
beling of PSMAHBED-CC and NODAGA-RGD using a microfluidic
device. All temperatures and flowrates resulted in mean radio-
chemical yields in a range of 20-55%. Syntheses at higher tem-
peratures and flowrates proved to be more efficient. For
instance, HEPES buffered syntheses at 100°C and flowrate of 80
μL/min yielded 68Ga-PSMAHBED-CC in 42.6 ± 22.1 % (n=10) and
68Ga-NODAGA-RGD in 49.7 ± 32.5 % (n=7). Applying the same
parameters, TWEEN 20 could strikingly improve the yield of
68Ga-PSMAHBED-CC to 70.8 ± 16.8 % (n=13).
Discussion/conclusion: This study provides the proof-of-principle
of 68Ga-labeling in a microfluidic “flow-through” system. The
application of TWEEN 20 led to drastically increased yields of
68Ga-PSMAHBED-CC due to its surfactant nature. As a result, this
microfluidic approach will be pursued to increase availability of
68Ga-radiopharmaceuticals according to the dose-on-demand
principle.OP16
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Introduction: Aryliodonium salts have recently emerged as versa-
tile precursors for the synthesis of 18F-radiolabeled compounds
for PET imaging.1,2 However, little is known about the applicabil-
ity of these reagents for labeling with the heaviest radiohalogens
iodine and astatine, both useful for nuclear imaging and/or ther-
apy.3 In this study, we aimed at probing the reactivity of radio-
iodide (125I) and astatide (211At) towards diaryliodonium salts in
order to assess their usefulness for radiolabeling biomolecules of
interest in nuclear medicine.
Materials and methods: First, parameters of radio-iodination and
astatination reaction (solvent, temperature, duration and counter-ion
of iodonium) were studied on model compounds. Bifunctional iodo-
nium salts were then designed, allowing the synthesis of [125I]-SIB
and [211At]-SAB, two prosthetic groups widely used for radio-
iodination and astatination of biomolecules. Both [125I]-SIB and
[211At]-SAB were conjugated to the multiple myeloma targeting mAb
9E7.4 (anti-CD138). Conjugation yields and resulting immunoreactiv-
ity were compared with the conventional arylstannane chemistry
approach.
Results: Initial reaction parameters studies highlighted a striking
difference of reactivity between radio-iodide and astatide that
could not be anticipated from the trends observed within the
halogen series. Not only the astatination reaction was highly
efficient at much lower temperature than iodination, but it
appeared also solvent and counter-ion independent (not
iodination). Thermochemical studies highlighted a large differ-
ence of activation energy in acetonitrile between both halogens
with Ea = 23.5 kcal/mol and 17.2 kcal/mol for radio-iodination
and astatination, respectively. Quantum chemical calculations
support the hypothesis that astatination occurs via a monomeric
iodonium complex whereas iodide occurs via a dimeric complex
which requires more energy for the reaction to proceed. This
explains the large reactivity difference observed. Radiolabeling
of an antibody with specifically designed iodonium salts outper-
formed conventional arylstannane chemistry approaches in
terms of global efficiency (radiochemical yields >90%, conjuga-
tion yields ≈ 75%, and simpler purification: no HPLC needed)
with excellent preservation of immunoreactivity of the IgG with
both radionuclides and less concerns regarding the toxicity of
precursors and side products.
Discussion/conclusion: In comparison with the conventional aryl-
stannane approach, aryliodonium salts appear as more efficient
precursors for preparation of radio-iodinated and astatinated
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 6 of 37compounds. Furthermore, they allow simpler purification proce-
dures (easy transfer to automation), with the additional advan-
tage of a much lower toxicity, which is of primary importance for
human use. Most of all, the unexpected reactivity of astatine we
unveiled highlights that a lot is still to be discovered about the
chemistry of this radioelement which remains to date largely
unexplored.OP17
64Cu-NOTA-pertuzumab F(ab')2 fragments, a second-generation
probe for PET imaging of the response of HER2-positive breast
cancer to trastuzumab (Herceptin)
Lam K1, Chan C1, Reilly RM1,2,3
1Department of Pharmaceutical Sciences, University of Toronto, Toronto,
Canada; 2Department of Medical Imaging, University of Toronto,
Toronto, Canada; 3Toronto General Research Institute, University Health
Network, Toronto, Canada
Correspondence: Lam K – Department of Pharmaceutical Sciences,
University of Toronto, Toronto, Canada
EJNMMI Radiopharmacy and Chemistry 2016, 1(Suppl 1):OP17
Introduction: SPECT/CT imaging with 111In-BzDTPA-pertuzumab de-
tected trastuzumab (Herceptin)-mediated HER2 downregulation in
human breast cancer xenografts in mice and was correlated with a
good response to treatment. This agent is now being studied in a
Phase I/II clinical trial sponsored by OICR (PETRA; ClinicalTrials.gov
identifier: NCT01805908). Our objective was to develop and
characterize a second-generation positron-emitting analogue for
PET/CT imaging, 64Cu-NOTA-pertuzumab F(ab')2, to provide greater
sensitivity, more accurate radiotracer quantitation and a lower radi-
ation absorbed dose.
Materials and methods: To determine the optimal dose, mice with
subcutaneous HER2-overexpressing tumours were injected with 5,
50, 100 or 200 μg of 64Cu-NOTA-F(ab')2 (2.2±0.6 MBq) and sacri-
ficed at 24 h p.i. for biodistribution. To determine the normal
tissue distribution, pharmacokinetics and radiation dosimetry of
64Cu-NOTA-F(ab')2, non-tumour bearing Balb/c mice were adminis-
tered 50 μg of 64Cu-NOTA-F(ab')2 (2.9±0.3 MBq) and sacrificed at
select time points. Three groups of mice bearing HER2-
overexpressing tumours were injected with 64Cu-NOTA-F(ab')2 (50
μg; 10.6±0.4 MBq) with or without administration of pertuzumab
(1 mg) 24 h before, or with 64Cu-NOTA-F(ab')2 prepared from
nonspecific human IgG (50 μg; 8.2±1.9 MBq) to demonstrate spe-
cificity. Mice were imaged with PET/CT at 24 and 48 h p.i. and
sacrificed for biodistribution.
Results: The 50 μg dose of 64Cu-NOTA-F(ab')2 showed the highest
tumour to blood ratio, followed by the 100, 5, and 200 μg doses
(18.2±7.2, 15.4±0.8, 14.0±5.0, and 10.9±1.8, respectively). In non-
tumour bearing mice, only the kidney retained significant radio-
tracer uptake at 24 h p.i. (49.1±5.9 %ID/g). Initial estimates for
t½α and t½β were 1.2 h and 6.0 h, respectively. The projected
total body radiation absorbed dose to humans was 0.02 mSv/
MBq, half that estimated for 111In-BzDTPA-pertuzumab. Tumour to
normal tissue contrast of PET/CT images appeared similar be-
tween the 24 and 48 h p.i. imaging time points. Tumour accumu-
lation of 64Cu-NOTA-F(ab')2 was significantly higher in mice
administered 64Cu-NOTA-F(ab')2 without pertuzumab blocking (8.4
±3.4 %ID/g) relative to mice pre-injected with 1 mg of pertuzu-
mab (3.9±0.5 %ID/g; P < 0.05), and mice administered 64Cu-
NOTA-F(ab')2 prepared from non-specific human IgG (2.7±0.5
%ID/g; P < 0.05).
Discussion/conclusion: 64Cu-NOTA-F(ab')2 is HER2 specific and can
visualize HER2-overexpressing tumours at 24 or 48 h p.i. with
PET/CT imaging. The lower projected radiation absorbed doses
for 64Cu-NOTA-F(ab')2 compared to
111In-BzDTPA-pertuzumab may
make this a more attractive imaging agent to detect trastuzumab-
mediated HER2 downregulation in breast cancer. Supported by grants
from the OICR Smarter Imaging and High Impact Clinical Trials (HICT)
Programs.OP18
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Introduction: Targeted radionuclide therapy (TRT) of solid tumors
has a limited efficacy mainly because these tumours have high radio-
resistance and take up limited amounts of radiolabeled vectors. Strat-
egies to overcome this include the use of small peptides combined
with radionuclides that emit highly cytotoxic particles, namely high
linear energy transfer (LET) particles such as alpha particles and
Auger electrons. We have chosen to target the epithelial-specific in-
tegrin αvβ6, which is weak or absent on normal tissues but is upreg-
ulated on many cancers where it is strongly associated with reduced
survival. One targeting vector is a 20 mer peptide, A20FMDV2 which
we have previously used to image αvβ6-positive tumours with SPECT
(In-111) or PET (F-18, Ga-68). The peptide showed extremely high kid-
ney retention when radiolabelled with radiometals, but this was not
seen with the F-18 analogue. Due to anticipated dose-limiting
toxicity in kidney for radiometal-based TRT, we have developed a
peptide suitable for radiohalogenation with the Auger electron emit-
ter I-125 and the alpha particle emitter At-211.
Materials and methods: The 20 mer high affinity αvβ6-targeting
peptide, A20FMDV2 used in previous work has been derivatised
to contain a trimethylstannyl benzamide moiety so that it can be
radiolabelled with I-125 and At-211. The peptide has been radi-
olabelled with I-125 and radioligand binding and internalization
assays have been carried out in cells that overexpress αvβ6 and
compared with that of the 111In-DTPA-A20FMDV2 studied previ-
ously. Clonogenic assays have been carried out on both the non-
radiolabelled peptide and the radiolabelled analogue in both
αvβ6-positive and negative cells to determine the effect of high
LET irradiation.
Results: Radiolabelling efficiency with I-125 was >91 % and the
analogue showed high binding affinity and rapid internalisation.
Clonogenic assays showed that the non-labelled peptide alone was
able to inhibit cell growth and that this effect was not seen on αvβ6-
negative cells. This effect was enhanced when radiolabelled with a
high LET particle emitter.
Discussion/conclusion: The αvβ6-specific peptide when radiolabelled
with a high-LET particle emitter shows promise as an agent for
targeted radionuclide therapy.
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Introduction: Successful radiotracers result from a favorable combin-
ation of target density, ligand affinity, nonspecific binding and per-
meation. All these parameters can be measured independently and
the interplay between some of them is well known: for instance,
Bmax/Kd > 10. Importantly, the required affinity of a tracer is also
correlated to nonspecific binding: An increased affinity is beneficial
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 7 of 37only if the nonspecific binding remains constant. This work aimed at
identifying an index taking into account the relationship between
these two parameters, to guide optimization from the early stage of
tracer development projects.
Materials and methods: Similarly to the Ligand Efficiency (LE)
index, we explored the usefulness of the Ligand Specific Effi-
ciency index (LSE), which we defined as the ratio between affinity
(expressed as e.g. pIC50 or pKd), and the logarithmic value of the
experimental non-specific binding measurement, CHI(IAM).[Jiang]
LSE provides a measure of affinity, normalized to non-specific
binding. It shows how efficient the ligand is at binding to the
desired target, compared to all other non-specific binding
partners.
Results: A series of well-described PET tracers was evaluated to set
the LSE threshold. This analysis showed that an LSE > 5 and prefera-
bly LSE > 5.4 is required for a successful tracer. This concept was
applied to the development of a prostacyclin receptor (IPR) tracer.
Our chemical starting point was Ro1138452,[Clark] which we selected
based on encouraging overall properties, including a high affinity for
IPR (Ki = 0.23 nM). In contrast, its CHI(IAM) value of 58 clearly indi-
cated a high tendency for non-specific binding. Despite such high
non-specific binding, Ro1138452 has a LSE value of 5.1, which is
close to the minimum value that would be expected for a successful
PET tracer. This raised hope that some improvement in binding spe-
cificity would allow the use of a close derivative for imaging pur-
poses. The use of LSE during the IPR tracer optimization will be
presented.
Discussion/conclusion: LSE is based on a rather intuitive concept, in
the sense that a good PET tracer candidate should have the
optimum balance of affinity and binding specificity. It is a convenient
index to evaluate and compare molecules based on measured, rather
than in silico values, and is applicable independently of target and
chemotype. It is a useful index from the beginning of a project, facili-
tates the selection of the most promising scaffold and guides their
optimization.
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Introduction: Brown adipose tissue (BAT) is an interesting type of
tissue that receives major interest as a target to combat obesity.
It was (re-)discovered in 2009, when PET-CT studies with [18F]-
FDG showed its presence and metabolic activity even in adult
humans [1]. It is however difficult to quantitatively assess this
metabolic activity using [18F]-FDG, as BAT mainly uses lipids as
an energy source. Radiolabeled fatty acids, such as [18F]-FTHA,
can provide useful information, but are not optimal considering
the lipid uptake mechanism BAT is not based on singular fatty
acids, but instead triglycerides (in lipoproteins). As such, we aim
to develop a radiolabeled triglyceride, hoping this will shed
more light on the lipid burning of BAT, thus allowing to calcu-
late the impact of BAT on the total metabolism of the human
body.
Methods: A fatty acid (C16) BODIPY-Fl dye is radiolabeled with F-18
using an F-18/F-19 exchange reaction of the boron-fluoride core of
the BODIPY dye to yield a bimodal PET/fluorescent imaging tool.
BODIPY-C16 is esterified with 1,3 – Diolein and assistance of thio-
nylchloride yielding the resulting fluorescent triglyceride (TG). In vitro
experiments with BODIPY-C16 are conducted to investigate the
applicability the dual-modality imaging probe.Results: BODIPY-C16 could be radio-labeled in a Lewis Acid assisted
F-18/F-19 exchange reaction in a reasonable yield (66%, not cor-
rected for decay) and a final purity after C18 Sep-Pak purification of
more than 97%. Esterification of BODIPY-C16 resulted in a BODIPY-TG
with a yield of more than 90% within 30 minutes. First in vitro experi-
ments showed specific uptake of BODIPY-C16 in BAT and WAT as the
compound was located within the lipid droplets of the cell. Direct
radiolabeling of the BODIPY-TGL was also successful (60% yield,
>97% purity).
Discussion/conclusion: First experiments implied radiolabeled
BODIPY-C16 is a promising BAT PET tracer with the opportunity to
resolve its metabolic character on a sub-cellular level due to its
dual-modality. In vivo imaging of radiolabeled BODIPY-C16 and
BODIPY-TGL, incorporation into micelles as well as further in vitro
experiments will be conducted in the near future to investigate the
applicability of this tracer in lipid metabolism imaging of BAT.
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Introduction: Image-guided cancer surgery using fluorescence
imaging has high clinical impact and already shows potential to im-
prove the outcome of oncological surgery (1). As first clinical experi-
ences with the 68Ga-labeled PSMA-targeting inhibitor Glu-urea-Lys-
Ahx-HBED-CC (PSMA-11) demonstrated high and specific tracer up-
take in prostate cancer lesions a fluorescence dye conjugate of
PSMA-11 might represent a promising bimodal tracer. The combin-
ation of preoperative staging by means of PET/CT and PET/MRI,
followed by image-guided surgery will further improve the accuracy
of detecting PSMA-positive tumor lesions by merging the strengths
of both techniques. Therefore, various fluorescent dyes were conju-
gated to the inhibitor PSMA-11 to determine the impact of the dye
conjugation on the ligand’s in vitro and in vivo characteristics.
Materials and methods: The optical-dye labeled tracer PSMA-HBED-CC-
FITC, PSMA-HBED-CC-AlexaFluor488 and PSMA-HBED-CC-IRDye800CW
were synthesized based on PSMA-11. The binding properties were ana-
lyzed in a competitive cell binding assay followed by internalization ex-
periments in human PSMA expressing LNCaP cells. Biodistribution
studies were performed in LNCaP tumor-bearing mice (BALB/c nu/nu) to
determine specific tumor uptake and pharmacokinetic properties.
Results: Comparative cell binding experiments revealed a high affin-
ity to PSMA expressing cell lines for all conjugates, which is in line
with the values obtained with the reference 68Ga-PSMA-11. The radi-
olabeled fluorescent-dye conjugates showed specific cell uptake and
were effectively internalized into the PSMA expressing cell line
LNCaP. First in vivo results indicated slightly varying pharmacokinetic
properties depending on the fluorescent dye. The FITC- and
AlexaFluor488-conjugates revealed a higher tumor uptake compared
to 68Ga-PSMA-11, while a minor, but still satisfying uptake was de-
tected for the IRDye800CW-conjugate.
Discussion/conclusion: Conjugation of a fluorescent dye to the well-
established imaging agent PSMA-11 showed rather minor dye-
dependent impact on cell binding properties, tumor uptake and the
pharmacokinetic characteristics. In order to further improve the
biodistribution profile of the IRDye800CW-conjugate, structural
optimization will be done. These first preclinical results emphasize
the potential of a dual-labeled PSMA inhibitor to serve as a
multimodal imaging agent, enabling sensitive pre-, intra- and
post-therapeutic identification of metastases with one and the
same molecule.
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Introduction: Melanoma is a highly malignant cutaneous tumor of
melanin-producing cells. Early detection of melanoma is the best
way to reduce mortality. Several radiolabeled imaging probes have
been evaluated for melanoma imaging. MEL050 is a synthetic
benzamide-derived molecule that specifically binds to melanin with
high affinity. Our aim was to implement a fully automated radio-
synthesis of [18F]MEL050, including HPLC purification and formula-
tion, using for the first time, the AllInOne radiosynthesis platform
(Trasis, Ans, Belgium), and to validate this PET radiotracer in vivo in a
mouse model of melanoma.
Materials and methods: [18F]MEL050 was synthesized using a
one-step bromine-for-fluorine nucleophilic heteroaromatic
substitution. Briefly, [18F]MEL050 was prepared from a bromo-
precursor, using no-carrier-added 18F-KF-Kryptofix 222 (dimethylforma-
mide, 150°C, 6 min), followed by preparative HPLC purification (C18
column (300x7.8 mm, 7 μm), isocratic elution with acetonitrile/20
mM ammonium bicarbonate (20:80, v/v), 3.0 ml/min) and
cartridge-reformulation (Sep-Pak® Plus C18 environmental) of the
collected fraction. Radiochemical and chemical purity, stability
and specific activity measurements were monitored using analyt-
ical HPLC. Chemical identity of the labeled compound
[18F]MEL050 was assessed by co-injection with non-radioactive
standard MEL050. Experimental model of pulmonary metastatic
melanoma was obtained by IV injection of B16-F10 cells in NMRI
mice. Mice (n=8) were imaged 15 days after inoculation, using
INVEON microPET/CT device (Siemens), after IV injection of 0.36
±0.04MBq/g of [18F]MEL050. Dynamic and static acquisitions were
acquired from time of injection to 2h after tracer injection. The
maximum percentage of [18F]MEL050 Injected Dose per g of lung
tissue (%ID/g Max) was determined using ROIs manually drawn
on 1h-post injection PET images, and correlated to ex-vivo
findings.
Results: The fully automated radiosynthesis of [18F]MEL050
required an overall radiosynthesis time of 60 min, with an end-
of-synthesis yield of 20-26% (n=12). Isocratic semi-preparative
HPLC allowed efficient separation of [18F]MEL050 from the reac-
tion mixture. The radiotracer was consistently produced with
radiochemical purity higher than 99%. The specific activity was
in the range of 177-325GBq/μmol and the product stability was
maintained at RCP>98% over 6 h. PET/CT images retrieved
known biodistribution of [18F]MEL050 in mice, and allowed clear
visualization of <1mm lung tumours with [18F]MEL050 %/ID/g
Max of 4.7±2.6%.
Discussion/conclusion: We successfully implemented the radio-
synthesis of [18F]MEL050 using the AllInOne radiosynthesis
platform, including HPLC separation and formulation. In vivo PET/
CT validation of the radiotracer was obtained in a mouse model
of metastatic pigmented melanoma, showing high specific
[18F]MEL050 uptake in sub-millimetric lung tumours.OP26
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Introduction: Urea-based inhibitors of the prostate-specific mem-
brane antigen (PSMA) are well known and promising candidates
for the diagnosis (1, 2) and therapy of prostate cancer. The aim
of the project was the development of F-18 labeled PSMA ligands
based on the theranostic compound PSMA-617. The compounds
evaluated during the preliminary experiments showed a high up-
take in non-target organs caused by their relatively high lipophi-
licity. Therefore we currently reduce this lipophilicity by the
addition of charged amino acids to the linker region of our PSMA
inhibitors (3).
Materials and methods: The PSMA binding motif Glu-NH-CO-NH-Lys
was synthesized by a well-established method (4) using solid phase
chemistry and subsequently an amino acid linker was built up by
fmoc-based solid phase peptide synthesis (SPPS). The non-
radioactive reference compounds were also prepared analogically
and eventually conjugated by 6-fluoronicotinic acid. After separation
from the resin and deprotection the peptidomimetics were labeled
using the TFP-ester of 6-[18F]fluoronicotinic acid as prosthetic group.
The Ki values of all compounds were determined by competitive
binding assays on PSMA-positive LNCaP cells against 68Ga-PSMA-10
(5) using the respective cold reference compounds. Additionally, the
cellular internalization of the radiofluorinated ligands was
determined.
Results: All 18F-labeled PSMA-inhibitors presented in this study
showed low nanomolar affinities towards PSMA, usually paired with
high internalization ratios of more than 15 %, shown in vitro. Among
those PSMA-1007 showed an outstandingly high internalization ratio
of about 70 % while the Ki was in the typical range (6 nM). Hence
PSMA-1007 was further evaluated in vivo. The organ distribution
showed a high and specific tumor uptake of 8.0±2.4 %ID/g. Finally,
the PSMA-targeting potential of PSMA-1007 was further demon-
strated by dynamic μPET experiments.
Discussion/conclusion: Based on our experience with PSMA-617 and
preliminary results we developed a series of radiofluorinated PSMA
inhibitors with high affinities and internalization ratios. Among those
a promising candidate for further translation into the clinic has
already been found. This candidate – namely PSMA-1007 – is cur-
rently transferred into first-in-man studies. Nevertheless further
optimization of the lead compound is still ongoing.
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expressed in a wide variety of prostate cancers, hence its interest as
a potential biomarker. As such, previous work used different radiola-
beled GRPR-binding peptides to specifically target tumors in vivo (1,
2). Recently, we synthesized a novel bifunctional chelator bearing
hydroxamic acid arms, called DOTHA2, for which our group demon-
strated fast and stable complexation to 64Cu (3). The goal of this
study was to develop a GRPR antagonist, D-Phe-Gln-Trp-Ala-Val-Gly-
His-Sta-Leu-NH2 (RM26), conjugated to the novel [
64Cu]-DOTHA2 to
visualize prostate tumor by PET imaging.
Material and methods: DOTHA2-PEG-RM26 was synthesized on solid
support. The inhibition constant (Ki) was measured on PC3 cells.
Dynamic PET images were acquired during 60 minutes after bolus
administration on nu/nu male mice bearing PC3 tumors. Biodistribu-
tion studies were performed at different time points, using balb/c
male mice and nu/nu male mice bearing PC3 tumors. To assess
specific binding, a cohort received 500 nmol/kg of unlabeled peptide
15 minutes prior tracer injection for both PET and dissection studies.
Results: The Ki of Cu-DOTHA2-PEG-RM26 was in the low nanomolar
range (0.68 nM). DOTHA2-PEG-RM26 complexed
64Cu with fast kinet-
ics at room temperature. The radiopeptide showed high stability, low
residual activity in various tissues and fast clearance in normal mice.
Small animal blocking experiments showed a significant uptake drop
compared to tracer by biodistribution in the GRPR-rich pancreas for
both balb/c and nu/nu mice (respectively p< 0.05 and p < 0.01 at 30
min). A significant uptake decrease from 5.3±0.8%ID/g to 3.4
±1.4%ID/g was also observed in PC3 tumors when unlabeled peptide
was added in biodistribution experiments at 30 minutes, whereas a
significantly reduced tumor uptake was also assessed by PET imaging
from 20 to 60 minutes (p<0.05) post-injection.
Discussion/conclusion: The use of [64Cu]-DOTHA2-PEG-RM26 is prom-
ising for visualizing prostate tumors. These preliminary data suggest
that DOTHA2 can be used to develop many other peptide- and
protein-derived PET tracers.
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Aim: [18F]-2-(3-fluoropropyl)-6-methoxynaphtalene ([18F]Amylovis®) is
a new naphthalene-derivative for detecting β-amyloid plaques in
Alzheimer’s disease. The aim of the study is the assessment of the
animal biodistribution of this new radiotracer.
Material and methods: [18F]Amylovis® was synthesized by nucleo-
philic substitution of the tosyl group of the precursor. Thirty five
healthy male Balb/C mice of 10-12 weeks were divided into 6 groups
of 5 animals each and injected with similar doses of [18F]Amylovis®
through a lateral tail vein. Blood samples were collected and the ani-
mals were sacrificed at 5, 15, 30, 45, 70 and 180 minutes. Organs of
interest were removed and washed with saline. Radioactivity of
blood, plasma, urine, faeces, brain, cerebellum, heart, liver, stomach,
spleen, bowel, colon, left kidney, muscle, bone and tail was measured
in a well counter. To assess protein binding, plasma samples were di-
luted with acetonitrile and centrifuged at 4000 g. Pellets of proteins
and supernatants were separated and their radioactivity measured in
a well counter. RadioTLC analysis of plasma were performed for the
same purpose in silicagel 60 and mobile phase of acetonitrile/water
(95/5). 20μL of each supernatant was analysed by HPLC-RP using a
C18 column and acetonitrile/water (75/25) as mobile phase toidentify plasma metabolites. Pharmacokinetic parameters (AUC, t1/2,
Cmax, Cl, Vss) were calculated using non-compartmental analysis
(NCA). Dynamic PET/CT images of healthy and transgenic APPSwe/
PS1dE9 mice were acquired for 2.5 h after i.v. administration. Immu-
nohistochemistry of control and transgenic mice brains were
performed to identify β-amyloid plaques.
Results: [18F]Amylovis® crossed blood brain barrier. PET/CT images
showed significant differences between healthy and transgenic mice,
expressed in Cortex to cerebellum SUV ratio, with maximum differ-
ence at 30 minutes. Postmortem studies of immunohistochemistry
showed also differences in healthy vs transgenic mice (amyloid posi-
tive). Plasma T1/2 of 37 min. No significant protein binding was ob-
served. Renal and hepatic pathways were the main excretion routes.
Some amount of in vivo degradation metabolites appeared in blood
from 1 h post-administration.
Conclusion: [18F]Amylovis® could be a promising PET radiotracer for
amyloid plaques visualization.
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Introduction: Colony stimulating factor-1R (CSF-1R) is also called
as Feline McDonough Sarcoma (FMS), is a type-III kinase recep-
tor. FMS widely expressed and considered to regulate develop-
ment, maintenance and functioning of mononuclear phagocyte
lineage such as monocytes, macrophages, dendritic cells, langer-
hans cells, microglia and osteoclasts1. Over expression of FMS
have been implicated in number of disease states including can-
cer, rheumatoid arthritis, Crohn’s disease and Bone disorders.
FMS also known to play a key role in microglia differentiation
and activation and assuming that it was key mediator in neu-
roinflammatory process.
Materials and methods: All the chemicals and reagents used in the
experiments were obtained from commercial sources and used with-
out any further purification. Synthesis of 5-cyano-N-(4-(4-methylpiper-
azine-1-yl)-2-(4-methylpiperidin-1-yl)phenyl)furan-2-carboxamide and
5-cyano-N-(2-(4-methylpiperidine-1-yl)-4-(piperazine-1-yl)phenyl)fur
an-2-carboxamide molecules were done according to literature
methods available with slight modifications for radiolabeling ex-
periments3. The [11C]-methyl triflate reacts with the precursor in
presence of a base at room temperature for 2 minutes gives the
carbon-11 radiolabeled [11C]BA-1 which was purified by using
semi-preparative reversed-phase high pressure liquid chromatog-
raphy (RP-HPLC). The peak corresponding the reference com-
pound will be collected and checked for the purity using
analytical RP-HPLC. Baseline biodistribution study was performed
at 2, 10, 30 and 60 min. respectively. Blocking experiment (10
mg/kg cold compound) was performed at 30 min time point in
healthy female adult mice n=3 and compared with vehicle
treated batch. In vitro autoradiography experiments were carried
on rat brain slices by incubating tracer and cold blocking solu-
tion. MicroPET imaging studies were performed on a Focus™ 220
microPET scanner with female rats.
Results: Reference and precursor molecules were synthesized
with comparable purities and yields reported in the literature,
the radiochemical yield (Alkylation yield with [11C]CH3I) 60 %
and radiochemical purity of 98 % and specific activity (n=5)
247.3 GBq/μmol. Biodistribution study shows higher tracer up-
take into the brain % ID 4 at 2 min time point, main route of
excretion via renal and hepatobiliary circulation. High lung up-
take was observed with % ID 14 at 2 min. Blocking with cold
compound did not observe any blocking effect in brain but we
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 10 of 37observed blocking in peripheral organs like liver and spleen, also
observed slight blocking in pancreas and kidneys. We did not
observed any blocking with in vitro autoradiography experi-
ments. Baseline microPET scans suggests good uptake of tracer
into brain with SUV 1.2 but with blocking we did not observed
any blocking effect despite we observe higher uptake in brain
with SUV 2.
Discussion/conclusion: We successfully synthesized, [11C]-BA1. In
preclinical evaluation we did not observe any significant blocking
effect in the brain, we are currently looking for other high affinity
molecules for CSF-1R.
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Introduction: The melanin concentrating hormone receptor 1
(MCHR1) is predominately expressed in the lateral hypothalamus
and is playing a key role in energy homeostasis and obesity.
Recently, it has been shown that the MCHR1 is expressed in the
ependymal cells of the 3rd ventricle where it is involved in the
regulation of cilia beat frequency [1]. This beating facilitates
cerebrospinal fluid circulation, which is crucial for brain func-
tion, as defects in ventricular cilia result in hydrocephalus. Our
aim was to investigate the potential of the MCHR1 ligand
[18F]FE@SNAP [2] for PET-imaging of the MCHR1 in the ventricu-
lar system.
Materials and methods: In vivo experiments were conducted in
naïve male Sprague Dawley rats. For small-animal PET/CT/MR ex-
periments, rats were anesthetized by isoflurane. 25min after
[18F]FE@SNAP iv injection (47.8±1MBq; SA: 19.7±6GBq/μmol), ve-
hicle (baseline group, n=3) or 15mg/kg SNAP-7941 (blocking
group, n=3) were administered through the tail vein. 75min after
tracer injection, the rats were sacrificed. Radioactivity concentra-
tions in brain were calculated and expressed as SUVs. In another
set of experiments, [18F]FE@SNAP (51.3±26MBq; SA: 36.1±28GBq/
μmol) as well as vehicle (baseline group, n=3) or 15mg/kg SNAP-
7941 (blocking group, n=3) were injected into conscious freely
moving rats via a permanent catheter implanted into the jugular
vein, thus excluding an influence of anaesthesia. 45min after
tracer application, rats were sacrificed, the brain was removed
and cut for ex vivo autoradiography. Subsequently, brain slices
were put on Phosphor Imager plates for exposure and analyzed
with a Cyclone Phosphor Imager the following day. Regions of
interest (ROIs) were drawn for the hypothalamic region, the ven-
tricle and a non-target region. ROIs resulted in normalized DLU/
mm2); ratios of ventricle/non-target were calculated.
Results: PET/CT/MR experiments: the SUV in the ventricular system
was 0.73±0.11 for the baseline group and 0.34±0.07 for the blocking
group, which represents a significant reduction. Ex vivo autoradiog-
raphy showed a distinct uptake in the ventricular, which was signifi-
cantly reduced in the blocking group.
Conclusion: [18F]FE@SNAP evinced specific uptake in the ven-
tricular system of naïve rats regardless their state of conscious-
ness and is therefore a suitable imaging agent for cilia beat
function.OP32
Synthesis of the first carbon-11 labelled P2Y12 receptor antagonist
for imaging the anti-inflammatory phenotype of activated
microglia
B. Janssen1, D.J. Vugts1, G.T. Molenaar1,2, U. Funke1,2, P.S. Kruijer2,
F. Dollé3, G. Bormans4, A.A. Lammertsma1, A.D. Windhorst1
1Department of Radiology & Nuclear Medicine, Neuroscience Campus
Amsterdam, VU University Medical Center, Amsterdam, The Netherlands;
2BV Cyclotron VU, Amsterdam, The Netherlands; 3CEA, Institut d’Imagerie
BioMédicale, Service Hospitalier Frédéric Joliot, Orsay, France;
4Laboratory for Radiopharmacy, Department of Pharmaceutical and
Pharmacological Sciences, KU Leuven, Leuven, Belgium
Correspondence: B. Janssen – Department of Radiology & Nuclear
Medicine, Neuroscience Campus Amsterdam, VU University Medical
Center, Amsterdam, The Netherlands
EJNMMI Radiopharmacy and Chemistry 2016, 1(Suppl 1):OP32
Introduction: Activated microglia are a hallmark of neuroinflam-
mation (NI), which in turn is associated with neurodegenerative
diseases. The P2Y12 receptor (P2Y12R) is upregulated in the anti-
inflammatory phenotype of activated microglia, and is not
expressed on macrophages and other brain cells. Therefore,
P2Y12R could be an interesting new target for PET imaging of
microglial activation in NI. Recently, a series of P2Y12R antago-
nists with high binding affinity was reported. Based on this
series, the purpose of the present study was to label urea de-
rivative 5 (IC50 = 6 nM) with carbon-11.
Materials and methods: The synthesis of sulfonylurea 5, as reference,
and azetidine amine 3 and sulfonyl azide 6, as precursors for the
radiosynthesis of [11C]5, is depicted below. Carbon-11-labelling was
performed via a rhodium(I)-mediated [11C]CO carbonylation reaction
[4,5]. [11C]5 was evaluated using in vitro autoradiography of healthy
mouse brains and ex vivo biodistribution and radiometabolite ana-
lyses in healthy male Wistar rats.
Results: Compound 5 and precursors 3 and 6 were successfully syn-
thesised. [11C]5 was obtained in a radiochemical yield of 10±2 %
(corrected for decay, calculated from [11C]CO2 (n=6)), and high
(radio)chemical purity (≥98%) and specific activity (79±32 GBq·μmol-
1 (n=6)). In in vitro autoradiography studies of the healthy mouse
brain, [11C]5 could be blocked (81%) with ticagrelor, indicating spe-
cific binding to P2Y12R. However, rapid metabolism in rat plasma
was observed with only 30±4% (n=3) of [11C]5 left at 45 min p.i.. In
addition, ex vivo biodistribution revealed that [11C]5 did not enter
the rat brain.
Discussion/conclusion: [11C]5 is not suitable for in vivo studies, but
can still be used in vitro to validate P2Y12R as a target for imaging
the anti-inflammatory phenotype of activated microglia.
Acknowledgement: This research has received funding from the Euro-
pean Union's Seventh Framework Programme (FP7/2007-2013) under
grant agreement n° HEALTH-F2-2011-278850 (INMiND).OP33
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ous diseases ranging from different kinds of cancers (ovarian,
breast, prostate,..) to neurological deficiencies (Alzheimer’s dis-
ease, Huntington’s disease, amyotrophic sclerosis,..) [1,2]. Still
many characteristics and functions of HDAC6 in these pathologies
are unrevealed. Hence, we aim to develop a selective HDAC6 PET
tracer to visualize the dynamics of HDAC6 in normal and disease
states. Recently, Lu and coworkers synthesized [11C]KB631, a
highly potent (IC50=1.4 nM) and selective (3700-fold selectivity
against HDAC1) PET tracer for HDAC6 imaging in the brain, which
showed similar pharmacokinetic properties as tubastatin A [3].
However, [11C]KB631 showed low brain bioavailability [4]. In this
regard we opted to use this tracer as a more peripheral imaging
agent. The radiosynthesis was redesigned and preliminary results
were obtained with a biodistribution study and autoradiography
experiments in brain and tumor slices.
Materials and methods: [11C]KB631 was synthesized through methy-
lation of the corresponding precursor (300 μg) with [11C]-MeI in an-
hydrous DMSO (250 μL) at 100 °C for 4 min. The biodistribution was
studied in NMRI-mice at 2, 10, 30 and 60 min (n = 3/time point) post
injection (p.i.). Organs and tissues were harvested and radioactivity
was counted in a gamma-counter. Autoradiography studies were car-
ried out with [11C]KB631 on wild-type Wistar rat brain tissue and
PC3/LNCaP prostate tumor slices. Slices were incubated with 18.5
MBq/400μL (brain) or 18.5 MBq/250 μL (tumor) of tracer with/without
100 μM of cold authentic reference compound (KB631) or non-
structural related pan-HDAC inhibitor Suberoylanilide hydroxamic
acid (SAHA) [5].
Results: Based on prep HPLC integration, the methylation yield
was 55 % with a radiochemical purity of 97 % and a specific ac-
tivity of 48 GBq/μmol. Biodistribution studies indicated low brain
uptake (<0.1 %ID at 2, 10, 30 and 60 min) and renal and hepato-
biliary excretion. Autoradiography experiments showed regional
binding. Binding in brain/tumor slices was highly displaceable in
the presence of 100 μM non-labeled reference KB631 (up to 90%
for brain, PC3 and LNCaP) or 100 μM SAHA (73% brain, 39% PC3
and 59% LNCaP).
Discussion/conclusion: We successfully radiolabeled and evaluated a
potential carbon-11 labeled radiotracer for in vitro and ex vivo
visualization of HDAC6. However, biodistribution studies indicated
low brain uptake, peripheral potency still needs to be further exam-
ined. Autoradiography studies showed regional and displaceable
binding. Furthermore, radiometabolite studies followed by μPET on a
mice tumor model will be performed.
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Introduction: (R)-[11C]verapamil is widely used as a PET tracer for in-
vestigating P-glycoprotein (P-gp) function in patients with epilepsy,
Alzheimer´s disease and other neurodegenerative diseases [1].
Recently, we have developed the fluorine-18 analogues (R)-N-
[18F]fluoroethylverapamil (1) and (R)-O-[18F]fluoroethylnorverapamil
(2), potentially enabling P-gp studies in centres without an on-site
cyclotron. These analogues showed specific P-gp substrate behav-
iour, but metabolic stability was poor. The purpose of the present
study was to assess whether deuterated analogues would have bet-
ter metabolic stability.Materials and methods: To a dried 18F/K2.2.2/K2CO3 complex, 2-
bromoethyl-d4-tosylate in DMF was added and reacted for 10 min at
90°C to obtain 2-bromo-[18F]fluoroethane-d4. This was distilled at 100 °C
through an AgOTf column at 200 °C into a cooled (0 °C) vial containing
1.5 mg of (R)-normethyl verapamil (1a) and 3 mg of K2CO3 in ACN. While
stirring, this reaction mixture was heated at 120 °C for 15 min and puri-
fied by HPLC, resulting in 1b. Tracer 2b, 3b and 4b were obtained by dir-
ect fluorination of precursors 2a, 3a and 4a and only 2b required final
Boc-deprotection with TFA. 1b and 2b were administered to Wistar rats,
and the level of labelled metabolites was measured in blood plasma
and brain samples.
Results: 1b, 2b, 3b and 4b were obtained in a radiochemical yield of
3, 6, 5 and 10%, respectively, a purity >98% and a specific activity
>80 GBq·μmol-1. Results of the metabolite analysis are presented.
The deuterated analogues showed improved metabolic stability com-
pared with the non-deuterated compounds.
Discussion/conclusion: Labelling of tracers 1b-4b was successful.
Although, both 1b and 2b showed significantly increased metabolic
stability, total intact tracer levels at 15 min are still lower than
desired. The resulting effect of increased metabolic stability for PET
imaging will be evaluated in P-gp KO mice. To determine the effect
of a deuterated N-methyl group, tracer 3b and 4b were designed
and still need to be evaluated for metabolic stability.
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Introduction: Pulmonary arterial hypertension (PAH) is a disease in
which pulmonary arterial obstruction increases vascular resistance,
leading to right ventricular failure [1]. Inhibition of transforming
growth factor-β (TGF-β) signalling via activin-receptor-like kinase 5
(ALK5) prevents progression and development of pulmonary hyper-
tension [2]. To further understand the role of ALK5 in PAH, the pur-
pose of this study was to synthesize a carbon-11 labeled ALK5 tracer
(IC50 = 5.5 nM) [3] and to assess its potential as a positron emission
tomography (PET) ligand for measuring ALK5 expression and activity
in vivo.
Materials and methods: The [11C]ALK5 tracer was synthesized by a
carboxylation reaction. The radiolabeling was carried out by heating
[11C]CO2, the precursor molecule, isobutyl iodide and BEMP in DMSO
for 10 minutes at 75°C. The tracer was evaluated using biodistribu-
tion and metabolite studies in Wistar rats (n=4 per time point at 15
and 60 min). In addition, specific binding was assessed using auto-
radiography on ALK5 expressing MDA-MB-231 tumor sections.
Results: The [11C]ALK5 tracer was synthesized with a yield of 18±6 %,
a specific activity of 116±31 GBq·μmol-1 and a purity of > 95 %. The
tracer showed a normal biodistribution ex vivo and a moderate stabil-
ity in vivo. The autoradiograms presented binding of the tracer to
the tumor sections. Pretreatment of the tumor sections with ALK5
blocking agents (EW-7197, SB-431542 and the ALK5 inhibitor) de-
creased the binding of the tracer significantly.
Conclusion: The ALK5 tracer was synthesized successfully, and initial
in vitro and ex vivo studies indicate its potential as a putative tracer
of ALK5, warranting further in vivo evaluation.
Acknowledgment: CVON is acknowledged for funding of this project and
the BV Cyclotron VU for providing [11C]CO2.
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Introduction: Radiolabelled antibodies and peptides hold promise
for molecular radiotherapy but are often limited by low payload
resulting in delivery of inadequate amounts of radioactivity to
tumour tissue and, therefore, modest therapeutic effect. We have de-
veloped PEGylated epidermal growth factor (EGF)-gold nanoparticles
(NP) with a high indium-111 (111In) payload (111In-EGF-Au-PEG NPs)
as a prototypic NP-based theranostic radiopharmaceutical.
Materials and methods: EGF-Au-PEG NPs were prepared via an inter-
action between gold and the disulphide bonds of EGF followed by
PEGylation by mPEG-thiol (MW: 800, 2000, 6000) and characterised
by SEC-HPLC, DLS and zeta potential. The targeting property of NPs
with various PEG MWs was investigated by confocal imaging follow-
ing exposure of MDA-MB-468 (1.3 x 106 EGFR/cell) and MDA-MB-231/
H2N (105 EGFR/cell) cells to Cy3-EGF-Au-PEG NPs. 111In-EGF-Au-PEG
(MW: 6000) and 111In-EGF-Au NPs were chosen for SPECT imaging
and biodistribution studies using MDA-MB-468 xenograft-bearing
mice.
Results: Successful PEGylation was confirmed by DLS and zeta poten-
tial measurements, showing the hydrodynamic sizes of NPs were
18.5, 19.4, 24.8 and 32.5 nm; the zeta potentials in water were -24,
-15, -14 and -9 mV for EGF-Au and EGF-Au-PEG with MWs of 800,
2000 and 6000, respectively. SEC-HPLC showed that the retention
time of EGF-Au-PEG NPs was shorter than EGF-Au NPs as PEGylation
resulted in larger NPs. Confocal imaging demonstrated that both
EGF-Au and EGF-Au-PEG NPs were efficiently bound and internalised
by MDA-MB-468 cells. In vivo SPECT studies in mice bearing MDA-
MB-468 xenografts revealed high tumour uptake in animals that
received 111In-EGF-Au-PEG (MW: 6000) compared to 111In-EGF-Au.
The tumour/muscle radioactivity ratios for 111In-EGF-Au-PEG and
111In-EGF-Au were 7.2 and 2.5.
Conclusion: An 111In-labelled EGF-Au-PEG nanosystem was devel-
oped. It enabled targeted delivery of a high 111In payload to an
EGFR-positive cancer model that can be potentially exploited for
molecularly targeted radiotherapy.
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Introduction: Malignant melanoma is the most lethal form of skin can-
cer and the most commonly diagnosed malignancy among young
adults with an increasing incidence. Hence, the development of new
melanoma-specific pharmaceutical for diagnosis and/or therapy is a
subject of great interest and intense research. The purpose of this study
was to examine the effect of cyclization on the biological profile of
[99mTc(N)(PNP3)]-labeled α-MSH peptide analogs (PNP3 = N,N-
bis(dimethoxypropylphosphinoethyl)methoxyethylamine).
Method: A lactam bridge-cyclized H-Cys-Ahx-βAla3-c[Lys4-Glu-His-D-Phe-
Arg-Trp-Glu10]-Arg11-Pro-Val-NH2 (NAP―NS2) and the correspondinglinear H-Cys-Ahx-βAla-Nle-Asp-His-D-Phe-Arg-Trp-Gly-NH2 (NAP-NS1) pep-
tide were synthetized, characterized by ESI-MS spectroscopy and their
MC1R binding affinity were determined in B16/F10 melanoma cells. In
vitro stability and pharmacological parameters of [99mTc(N)(NAP―
NS1)(PNP3)]+ (1) and [99mTc(N)(NAP―NS2)(PNP3)]+ (2) were assessed.
Challenges with an excess of glutathione and cysteine and Log P values
were also investigated. Furthermore, 1 and 2 were applied to study
in vivo stability and the pharmacokinetic profiles on healthy rats.
Results: 1 and 2 were obtained in high yield (RCY > 90%). Log P
values demonstrate the hydrophilic nature of the radiolabelled pep-
tides: -1.43 for 1; - 2.087 for 2. No significant variations in RCPs of
both the complexes were observed in challenge experiments with an
excess (10 mM) of glutathione and cysteine. A high in vitro stability
was observed for both complexes after incubation in human and rat
sera as well as in rat liver homogenate; a fast degradation of 2 was
detected in kidneys homogenate. 1 retains a high receptor affinity
(Kd=7.1 ± 0.5 nM). Biodistribution data of 1 display a favorable phar-
macokinetic profiles characterized by a fast blood clearance and
elimination from normal tissues. A rapid excretion via the renal path-
way was observed according to the high hydrophilic character of the
radio-conjugate. The effect of the cyclization on the pharmacokinetic
profile of 2 was reflected in a reduction of the blood clearance and
of the elimination from the other organs, in particular, from excretory
organs such as liver and kidneys.
Conclusion: Compared with the linear peptide, cyclization negatively
affects the biological properties of NAP-NS2 peptide by reducing its
binding affinity for MCR1R (Ki: 0.9±0.3 nM for NAP_NS1; 7.1±2.4 nM
for NAP_NS2) and decreasing the overall excretion rate of the corre-
sponding [99mTc(N)(PNP3)]-labeled peptide from the body as well as
its stability. Thus only the linear [99mTc(N)(PNP3)-labeled peptide is
suitable for further investigations in tumor bearing animals. This re-
search was supported by MIUR through PRIN 20097FJHPZ-004 and
FIRB “RINAME”2010-RBAP114AMK.
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Introduction: Preclinical studies demonstrated that [68Ga]NODAGA-
RGD allows imaging of integrin αvβ3 expression using PET. Here we
present all data (quality control, toxicological study, and dosim-
etry estimation) necessary to initialize clinical studies, the estab-
lishment of the remote controlled synthesis, and data from the
phase I clinical study.
Methods: Labelling was carried out in a remote controlled synthesis
unit under clean room conditions. Quality control included TLC,
HPLC, GC, pH control, Ge-breakthrough, half-life, endotoxin content,
and control of sterility. Storage stability after 4 h was studied and
dose estimations based on animal data were carried out using
OLINDA. Sprague-Dawley rats were used for an extended single dose
toxicity study. The phase I clinical study included 9 patients with
hepatocellular carcinoma (HCC). Static scans at 5, 30, and 60 min p.i.
including 5 bed positions each were performed using the Discovery
690 PET/CT. Blood was sampled 30 and 60 min p.i. and urine 60 min
p.i. and used for stability studies via HPLC.
Results: [68Ga]NODAGA-RGD could be produced in high radiochem-
ical yield and radiochemical purity (HPLC and TLC >99%). The pH in
the final isotonic saline formulation was approx. 6. Ethanol content
was between 2.5 and 3.0% v/v. No detectable 68Ge-germanium was
found. LAL test revealed 0.7 EU/ml. Sterility tests showed that all
samples met the specifications according to Ph. Eur.. No radiolysis of
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 13 of 37the tracer was found in the formulated solution. The single dose tox-
icity study showed that the compound was well tolerated in animals.
This was confirmed by the clinical study where no severe side effects
were observed. High metabolic stability of [68Ga]NODAGA-RGD was
found based on the analysis of blood and urine samples. The static
scans showed rapid tracer elimination from the body with low back-
ground activity in almost all organs. The calculated effective dose
was 21.5±5.4 μSv/MBq. Unfortunately, the investigated tumors did
not show increased tracer accumulation indicating no or low integrin
αvβ3 expression.
Conclusion: This study revealed that [68Ga]NODAGA-RGD can be eas-
ily produced under GMP conditions and met the requirements for
the clinical use. The phase I clinical study with patients bearing HCC
did not allow identification of the lesions but demonstrated rapid
elimination from the body, high metabolic stability and low radiation
burden. The low tracer accumulation in the tumor might be related
to low receptor expression, thus further studies are needed to verify
the integrin αvβ3 imaging properties.
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Introduction: In the Netherlands, a modified “light” version of the
European GMP, i.e. GMP-z, for the (kit-) production of registered ra-
diopharmaceuticals for individual patients in hospital pharmacies is
in effect. However, GMP-z does not allow to synthesize radiopharma-
ceuticals for clinical trials or therapeutic applications, in which case
the European GMP applies. At the MUMC, a growing interest in per-
forming in-house clinical trials with new radiopharmaceuticals and in
the synthesis of radiotherapeuticals led to the decision of upgrading
the current Radiopharmacy facility. Several restrictions applied: radio-
pharmaceuticals will not be sold to third parties and the surface area
of the entire facility is limited to 55 m2 (including the production lab,
QC lab and separate sluices for personnel and goods). Additionally,
the facility had to allow both preparation of routine 99mTc-com-
pounds as well as GMP-grade radiopharmaceuticals. This study exam-
ines the time line of implementation for such a small scale facility
and may be relevant to other hospitals considering to comply with
this regulation.
Materials and methods: A team was founded late 2012, including a
radiochemist, QA officer, radiopharmacist, radiation safety officer,
clinical physicist and a construction project leader (totaling nearly 5
fulltime-equivalents). User requirements for the facility, hotcells and
laboratory equipment were determined. Preliminary building plans
were drawn up and several expert companies chosen, specialized in
HVAC, cleanroom construction and area and radiation monitoring.
Results: For the hotcells, a successful Factory Acceptance Test
was performed in February 2015. Construction of the new facility
started end of May 2015, starting with the planned installation of
the hotcells for which removal of a section from the outer wall
was necessary. The second phase of the reconstruction (setting
up of a GMP-compliant cleanroom) is scheduled to start January
2016, leading to full operability in April 2016 and, upon inspec-
tion by the Dutch Inspectorate (IGZ), GMP-compliant production
is expected by the end of 2016.
Discussion/conclusion: It is essential to have a high degree of in-
house expertise when starting a radiopharmacy building project.
Completely documented construction planning, based on a solid list
of requirements, takes 2-3 years to build up and is a necessity to
allow timely and high-quality construction.OP45
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Introduction: Good Manufacturing Practice (GMP) sets strict
requirements for the manufacturing conditions, synthesis and
quality of radiopharmaceuticals. Robust production and quality
control methods for radiopharmaceuticals are essential for diverse
and effective clinical utilization of Positron Emission Tomography
(PET). This presentation describes the set up procedure of a new
radiopharmaceutical in Turku PET Centre (TPC). All issues other
than directly related to GMP such as toxicology, labeling chemis-
try, analytical methods or documentation for the authorities (i.e.
IMPD) are not discussed here.
Materials and Methods: Quality standards and product specification
are expressed in EU (Annex 15 Qualification and Validation, revision
into operation 1 Oct 2015) and European Pharmacopoeia (8th Edi-
tion). The setup of a new radiopharmaceutical at TPC requires exist-
ence of the following: Established quality system, Documentation
system, Competent personnel, Classified clean rooms, Qualified
equipment, System for material management. Initially the specifica-
tions for critical materials and primary packing materials of the new
radiopharmaceutical must be defined. At TPC specifications for new
radiopharmaceutical are: Appearance, Identification, Radioactivity,
Radionuclidic identity, Radionuclidic purity, Radiochemical purity,
Chemical purity, Residual solvents, Content of ethanol, pH, Sterility,
Bacterial endotoxins, Shelf life.
Results: After ensuring that the production of a new radiophar-
maceutical is robust and repeatable and all analytical methods in-
cluding sterility and endotoxin tests are validated, the process
can be validated according to a written validation plan. In
addition bioburden (number of bacteria living on the drug solu-
tion before sterilization) must be determined. The aseptic pro-
cessing of operators must also be confirmed by performing
media fills (the performance of an aseptic manufacturing proced-
ure using a sterile microbiological growth medium in place of
the drug solution). At TPC the process validation includes three
consecutive process validation batches which shall fulfill all speci-
fications for the given radiopharmaceutical. This also qualifies the
operator for production. Additional batches must be done in
order to qualify more operators. Finally, process validation and
documentation is compiled. Process validation report, method de-
scription for preparation and quality control and master batch
record are written.
Discussion/conclusion: After all documentation has been accepted
by QA, the new radiopharmaceutical is ready for clinical production
and all changes to the process must be performed via change con-
trol process.
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EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 14 of 37Introduction: The combination of different imaging modalities has
received increasing interest over the past decade, as it enables to
overcome the limitations of a single imaging modality and ensures
enhanced interpretation of diseases and abnormalities in vivo. Dual
modality PET/MRI imaging agents, such as radiolabeled magnetic
nanoparticles, are promising candidates for a number of diagnostic
and therapeutic applications (i.e. MRI-magnetic hyperthermia and
radiotherapy). The aim of the present study is to evaluate the efficacy
of 68Ga labeled Fe3O4 superparamagnetic iron oxide nanoparticles
(SPIONs) coated with DPD phosphonate, as potential PET/MRI
imaging agents.
Materials and methods: SPIONs coated with biocompatible DPD-
phosphonate were radiolabeled with positron-emitting Gallium-68 to
quantify the accumulation of the nanoparticles in vivo. In vitro stabil-
ity studies, in PBS, saline and human serum, were performed to
evaluate their aqueous solubility in vivo. In vivo biodistribution study
was performed in 9 healthy mice at 30, 60 and 120 min post-
injection.
Results: 68Ga-Fe3O4-DPD SPIONs presented high radiolabeling
yield (95%) and proved stable in vitro. The in vivo study exhibited
significant liver and spleen uptake at all examined time points in
healthy mice, whereas minor fractions attained in other organs. A
small fraction of radiolabeled nanoparticles presented in bones is
indicative of high affinity of phosphonate to bone tissue. The bio-
distribution profiles between 68Ga-Fe3O4-DPD SPIONs and free
68Ga-acetate were also compared, indicating different pharmacoki-
netic behavior for 68Ga-acetate, with no target tissue and excre-
tion via the kidneys.
Conclusion: 68Ga-Fe3O4-DPD SPIONs demonstrated high radiolabel-
ing efficiency and in vitro stability and satisfactory in vivo behavior.
Cytotoxicity studies to explore the potential toxic effects of the nano-
particles, as well as biodistribution studies in tumor models, are in
progress.
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Introduction: 68Ga-citrate is one of the radiotracers for PET imaging
of inflammation/infection. Gallium (like iron) has high affinity to
blood transport proteins (e.g. transferrin) due to their similar phys-
ical/chemical properties [1]. One of the functions of transport pro-
teins is delivery iron (gallium too) to inflammation/infection foci for
inclusion in metabolic pathways related with eradication of path-
ology [2]. But excessive gallium bindings with proteins are cause of
slow blood clearance, long accumulation time in foci (24-72 h) and
exception of application possibility of the short-lived 68Ga (T½ = 1,13
h) unlike 67Ga (T½ = 78,26 h). Injection of additional nonradioactive
chemical agents (e.g. Fe3+ containing salts of hydroxy acids: citrate,
tartrate, lactate, etc.) competing with gallium to the protein joining
(blocking of its metal binding capacity) is one of the ways to solve
formulated problem. It can be used for correction of 68Ga-citrate
pharmacokinetics for increasing of the blood clearance, accumulation
in foci and fast imaging.
Materials and methods. 68Ga-citrate without/with extra injection of
Fe3+ containing salts (citrate, tartrate, lactate, malate, and ascorbate)
was injected mice with modeled lung infection (was got using intra
lung injection of cell suspension of E. coli; acute phase of infection
was evoluted for 3-4 days). PET/X-RAY Genisys4 (Sofie Bioscience,
USA) was used for noninvasive PET imaging with subsequent recon-
struction of imaging and their analysis (value of clearance, distribu-
tion volume). Scanning time is 10 min.Results: I. v. injection of Fe3+ containing salts of hydroxy acids
blocked the metal-binding capability of transferrin serum and
others and allowed decreasing gallium-68 radioactivity in blood
significantly and increasing accumulation in inflammation (3-5
time). It allowed receiving more informative PET-images of inflam-
mation early (for 30-60 min after injection). Pharmacokinetic
parameters proved it.
Discussion/conclusion. There was no statistically significant differ-
ence between 68Ga-citrate accumulation for different inflammation
model because PET imaging is indication of pathological processes
and isn't their identification.POSTER PRESENTATIONS
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Introduction: In the installation of methionine as our latest tracer
we chose the Eckert and Ziegler Modular-Lab PharmTracer as
production module, utilizing the so called «wet-method» for pro-
ducing methyl iodide. After complete installation in the hot cell,
a simplified version of Ph.Eur (Ph Eur monograph 1617) release
criterions was used, and the product was found to pass. HPLC
showed excellent radio purity and the installation was
completed.
Materials and methods: Homocysteine thiolactone, iodic acid,
0.1M lithium aluminum hydrid in THF, potassium dihydrogen
phosphate were used in the C11-Met synthesis, Methods used
are described in Ph.Eur, with the exception of chiral HPLC, in
which an Astec Chirobiotic T column with 70:30:0.02, MeOH:-
H2O:HCOOH eluent was employed.
Results: During later analyses for residual solvents in connection
with a GC-PQ, THF was found present in the product, 3-4 times
above recommended level. The HPLC method in the Ph.Eur is
10 minutes, however, by increasing acquisition time, a radio
peak appeared at about 18 minutes in the chromatogram. This
peak was about 10-15% of total radio signal, meaning the re-
quired radio purity limit in Ph.Eur was not met. When analysing
for enantiomeric purity, which was not initially done, about 12%
of the d-enantiomer was found, not meeting the Ph.Eur limit.
Increasing the flow of helium during the azeotropic distillation
decreased residual solvent, and subsequently the ICH residual
solvent limits was met. The radio peak in the HPLC was found
to be methyl iodide (MeI) which is adsorbed and co-eluted from
the C-18 Sep-Pak cartridges. Eckert and Ziegler proposed a re-
arrangement of the module tubing and a new synthesis tem-
plate program enabling direct helium flushing of the C-18 Sep-
Pak. By the use of this new configuration, removing excess MeI
was achieved and the radio purity limits described by the
Ph.Eur monograph was finally met. Different protocols are called
for in the initial phase dissolving the precursor in ethanol and
NaOH solution, however, tweaking these had little effect of the
enantiomeric purity. Different batches of precursor was later
analysed for enantiomeric purity. Large discrepancies were
found between batches which directly influenced the enantio-
meric ratio of the final product.
Conclusion: Great care should be taken in the installment of new
synthesis systems, and all available tests should be run before
system installation is approved. The Ph.Eur. methods may not al-
ways be sufficient to prove radio or chemical purity, even if a
monograph exist.
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Introduction: The interest in 68Ga-tracers has been growing strongly
over the last years, mainly due to new developments in prostate cancer
imaging and therapy.1,2 In collaboration with IBA, we have established
an automated synthesis of 68Ga-labelled peptides including 68Ga-
DOTA-TATE/-NOC,68Ga-PMSA-11 and 68Ga-PSMA-617 on Synthera®.
Materials and methods: During the tests, an IBA Synthera® and the
new Synthera® Extension module were used. 68Ga was obtained ini-
tially from an old iGG 100 generator in 5 mCi. The final tests were
carried out in combination with a new GalliaPharm 68Ge/68Ga gener-
ator loaded with 50 mCi. A modified standard nucleophilic IFPTM
(IFP™ FDG) was designed for the synthesis process. Synthera® Exten-
sion was used for the elution of the generator. The eluate was
loaded on a Chromafix PS-H+ cartridge and the hydrochloric acid
waste - which contains most of the 68GeCl4 - was transferred into the
waste container. The activity was eluted from the cation exchange
cartridge using a solution of 5 M sodium chloride in 0.1 N hydro-
chloric acid3 and transferred directly into the reaction vessel which
was pre-loaded with precursor in 1.5 M HEPES buffer. Labelling was
carried out at 95 °C for 7 minutes. Purification was performed using a
Sep-Pak® Light C18 cartridge. The product was eluted with a 1:1-mix-
ture of ethanol/water and dispensed into the final vial through a
sterile filter. Further dilution was performed with 0.9% saline by pass-
ing through the sterile filter. The peptides were synthesized in a
GMP-compliant qualified area at ABX. For the DOTA-peptides, stock
solutions were prepared (1 mg/ml) and freezed. For PSMA-11, vials
with 10 μg of precursor were used.
Results: With 50 μg of DOTA-TATE, DOTA-NOC and PSMA-617, the
final radiolabelled products were obtained in >60% uncorrected
yield. For PSMA-11, only 10 μg of precursor were used. The radio-
chemical purity was >98% in all cases. The Ph. Eur. spot test for
HEPES was performed and showed HEPES < 200 μg/V with V being
12 to 14 ml. The pH of the final solution was 5 to 5.5. Ethanol con-
tent was < 10%.
Discussion/conclusion: We have developed a dedicated disposable
IFP cassette for the IBA Synthera® and Synthera® Extension modules,
which delivers all common 68Ga-tracers in high yield. The use of ded-
icated single -use Gallium-68 IFPTM allows for production of 18F-FDG
on the same module with no cross-contamination.
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Introduction: The most common tracer used for measuring brain
perfusion is [15O]H2O. In general [
15O] is produced using a cyclotron
that accelerates deuterons onto a target filled with 14N2 with a trace
of oxygen. Nowadays, cyclotrons have been developed that are only
capable of accelerating protons. This abstract describes the perform-
ance of Cyclone 18 twin from IBA, which accelerate only protons, for
production and administration of [15O]H2O.Methods: The Cyclone 18 twin from IBA is a fixed energy cyclo-
tron using 18 MeV protons in which H- particles are accelerated
and converted into protons (H+). Bombardment with protons of
the special designed target filled to 25 bar takes place, initiat-
ing the nuclear reaction: 15N(p,n)15O. [15O]H2O was produced by
conversion of the [15O]O2 using a new designed IBA chemistry
module and placed in a shielded class A foam hood located in
the GMP laboratory.During preparation, 15O gas flows from the
cyclotron into the IBA chemistry module and is mixed with
hydrogen gas and passed through a palladium column. The pro-
duced [15O]H2O is collected in a sterile 0.9% saline solution to
obtain a final product suitable for patient administration. Valid-
ation of the production process included: (1) assessment of
practical yields, (2) check on pharmaceutical requirements and
(3) reproducibility of performance of both cyclotron and water
module.
Results: According to our knowledge, this is the first time that GMP-
production of 15O labeled water using IBA 18 MeV proton cyclotron
is described. The method was validated and met all pharmacopeia
specifications, and was subsequently approved for patient studies.
The practical production yield of 15O labeled water using this
method was ranged between 1300-1700 MBq measured in the syr-
inge. This method is suitable for multiple batches within a time
frame of 8 minutes. After validation more than 50 patient runs were
performed with a reliability of > 99 %.
Conclusion: A new production method for 15O-labeled water using
Cyclone 18 and dedicated chemistry module from IBA was described
and qualified according to GMP regulations. It was demonstrated to
be suitable for clinical use.PP04
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Introduction: Cancer caused by abnormal cell proliferation has
become a very common disease in recent years. Nuclear imaging
has a significant place in cancer diagnosis. Photosensitizers (PS)
such as chlorine, phthalocyanine, porphyrin and tetraprol deriva-
tives are come up PDT applications. Furthermore, PSs accumu-
late selectively in the tumor tissue compared to normal tissue.
Therefore, such compounds labeled with a radionuclide can be
used as a probe for nuclear imaging. In present study, we
synthesized a new Subphthalocyanine (SubPc) and Zinc phthalo-
cyanine [Zn(II)Pc] and determined in vitro nuclear imaging
potential.
Materials and methods: SubPc and Zn(II)Pc were synthesized ac-
cording to published methods of Ince et al.The radiolabeling with
131I via iodogen method was carried out and optimization condi-
tions (pH, amount of iodogen and reaction time) were deter-
mined. We will use EMT6/P (mouse mammary carcinoma), HeLa
(human cervix adenocarcinoma) Hep G2 (human liver hepatocel-
lular carcinoma), HT-29 (human colon colorectal adenocarcinoma),
WI38 (human normal lung fibroblast) cell lines for the intracellular
uptake studies. The intracellular uptake efficiency of 131I labeled
Pcs are determined according to published study of Ocakoglu
et al. in mentioned cell lines.
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and Zn(II)Pc were significantly high (91.9±3.1% and 97.2±1.4%, re-
spectively). The optimization conditions were determined as pH
9, 1 mg amount of iodogen and 30 minutes of reaction time for
SubPc; pH 7, 1 mg amount of iodogen and 45 minutes of reac-
tion time for Zn(II)Pc. In vitro cell line studies are in progress.
Acknowledgement: The authors gratefully acknowledge financial sup-
port by The Scientific and Technological Research Council of Turkey,
TUBITAK (Grant no: 114Z430).
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Introduction: In recent years, photodynamic therapy (PDT) gained
speed in cancer treatment. This method is based on two steps.
Firstly, a photosensitizer (PS) is accumulated in cancer tissue
then flowed by light irradiation. During a photoreaction Type II,
energy transfer occurs between the PS and molecular oxygen
(O2), the exposed photosensitizers produce highly toxic singlet
oxygen (1O2). The singlet oxygen is responsible for the cell
damage.1-3 Pthalocyanines have high tumor uptake efficiencies.
This property allows them to be used as bifunctional agents for
PDT and nuclear imaging. In the present study, symmetrical
Zn(II)Pc 1 and unsymmetrically substituted Zn(II)Pc 2 were
synthesized and examined as a bifunctional agent for nuclear
imaging and PDT.
Materials and methods: Zn(II)Pcs were synthesized according to a
published procedure.4 The Zn(II)Pcs were radiolabeled with 131I
by using iodogen method. Optimization conditions of radiolabel-
ing (pH, amount of iodogen and reaction time) were determined.
Biodistribution studies were performed with Albino Wistar female
healthy rats. The radiolabeled Zn(II)Pcs were injected into the tail
vein of each rats and then the rats were sacrificed at 30, 60 and
120 min post administration. Tissue samples were collected and
counted using a Cd(Te)-RAD-501 single channel analyzer. In vitro
the photodynamic therapy studies, EMT6/P (mouse mammary
carcinoma), HeLa (human cervix adenocarcinoma) cell lines were used.
Zn(II)Pc 1 and Zn(II)Pc 2 were exposed to red light (650 nm) at the
doses of 10-30 J/cm2.
Results: The Zn(II)Pc 1 and Zn(II)Pc 2 were radiolabeled with 131I
with high efficiency (93.4±1.6% and 91.4±1.6%, respectively). The re-
sults of biodistribution study showed that radiolabeled Zn(II)Pc 1 has
high uptake on lung, large intestine, ovary and pancreas. However,
the uptake of radiolabeled Zn(II)Pc 2 was determined as to be static-
ally significant in pancreas and large intestine. Zn(II)Pc 1 was showed
no phototoxic effect in both cell lines although PDT activity of
Zn(II)Pc 2 in HeLa cell line was determined.
Conclusion: In conclusion the radiolabeled Zn(II)Pc 1 might be a
promising imaging agent for lung, ovary pancreas, and colon tumors.
However, the radiolabeled Zn(II)Pc 2 might be a promising nuclear
imaging agent for colon and pancreas tumors, also promising PDT
agent for cervical tumors.
Acknowledgement: The authors gratefully acknowledge financial sup-
port by The Scientific and Technological Research Council of Turkey,
TUBITAK (Grant no: 112T565).PP06
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Introduction: Radio-HPLC is routinely used for analysis and quality
control of radiopharmaceuticals. The introduction of U(H)PLC enabled
decreased detection levels, improved resolution and significant
shorter analysis times; crucial parameters for radiotracer analysis.
Despite these benefits only a few examples of radio-U(H)PLC have
been reported; one reason may be the absence of a suitable γ-
detector with a flow cell which is compatible to UPLC conditions. We
used a commercial γ-detector in combination with different flow cell
inserts and report on their effect on the sensitivity and resolution of
the γ-signal.
Materials and methods: An ACQUITY UPLC H-Class System (Waters)
was used with a GABI Star γ-detector (Raytest) equipped with a 2”x 2”
pinhole scintillation crystal in combination with three different flow
cells. UPLC was performed on an ACQUITY HSS C18 column (2.1 x 100
mm, 1,8 μm) with a flow rate of 0.65 mL/min and a 3 min gradient of
30/70 acetonitrile/0.1% TFA. The sigma-1 receptor imaging probe
[18F]fluspidine served as analyte with 2 μL injection volume, containing
8 – 400 kBq of [18F]fluspidine.
Results: For best resolution and avoiding an excessive back-pressure
to the PDA cell (<70 bar) the capillary between PDA and γ-detector
should be as short as possible. This was realized by placing the γ-
detector in 30 cm distance to the PDA-detector on a special table.
Three different flow cells were applied:
a) Raytest standard flow cell (5 μL),
b) Raytest 2” capillary holder equipped with a UPLC capillary 0.004”
ID (9/5/2 nL),
c) self-build lead insert with a 5 mm hole and UPLC capillary (2 nL).
By injecting 400 kBq of [18F]fluspidine and using the different flow
cells, γ-signals having a peak width between 0.13 and 0.20 mm and
a peak intensity 750 - 4400 cps were obtained. The capillary holder
(5 nL) and the self-build insert (2 nL) showed a comparable peak
width, but differentiated sensitivity. To determine the minimum de-
tectable level samples between 170 kBq and 8 kBq of [18F]fluspidine
were injected; with 15 kBq of [18F]fluspidine a good signal to back-
ground ratio of 6:1 was achieved.
Conclusion: By performing radio-U(HPLC) with a GABI Star γ-detector
equipped with a Raytest 2” capillary holder (5 nL), γ-signals with good
sensitivity and peak width can be obtained. In addition, the self-build
flow cell insert (2 nL) gave the highest sensitivity and the best signal
to background ratio.
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Introduction: Several studies are available, which highlight the use
of Schiff based as ligands for radio-labeling, but very little work has
been reported with Marcepto compounds. It is desirable to include
such compounds in the design of radiopharmaceuticals due to their
importance in the biological system.
Materials and methods: Equimolar L – cysteine and salicylalde-
hyde in distilled water and ethanol were heated to form a white
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thermo gravimetric analysis and elemental analysis. Radiolabeling
of the ligand was performed using 99mTc from 99Mo generator.
SnCl2.H2O was used as a reducing agent. Radio TLC was per-
formed using SG plates, 0.9% NaCl and acetone as the mobile
phases. Geiger Muller counter detected the counts on the SG
plates. After quality control the radiolabeled drug was injected IV
into the animal ear. Scanning was performed under the gamma
camera.
Results: Ligand synthesis was verified from IR indicating the pres-
ence of the closed ring structure Thiozolidine ring 1. IR showed
absence of chromophore group hence the ligand was colorless.
DSC peaks indicated the reaction type as endothermic. Ligand
appeared to be stable in DMSO. Effective radiolabeling was
achieved using lyophilized tin chloride pyrophosphate cold kit in
NaCl (0.9%). Optimization of ph, temperature and radioactivity
was done using DOE. Maximum radiolabeling was achieved at pH
5.Animal study was performed for bio distribution of the radio-
pharmaceutical. 99mTc – ligand uptake was seen in the soft or-
gans immediately after injection. The areas showing higher
radiotracer uptake were kidney (20 %), liver (35 %), bones (15%)
and brain (10 %). Delayed images showed the radiotracer reten-
tion in the soft organs as well as in the spine of the animals.
Comparative study was performed using 99mTc – MDP and 99mTc
PHYTATE.
Conclusion: Salicylaldicysteine is efficiently labeled with 99mTc and
is suitable in simultaneous scanning of liver, kidney and brain.
Due to uptake in all soft organs in dynamic flow followed with
delay images, radiotracer retention in the brain is worth consider-
ation. This indicates the ability of drug in crossing the blood
brain barrier. This study also highlights the importance of sulfur
containing ligands in brain scanning
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Introduction: Radiolabelled nanoparticles have gained a wide-
spread application in the diagnosis and therapy of several
diseases (inflammation/infection, cancer, and others). PLGA
Nanoparticles (NPs) prepared by solvent emulsion evaporation
method [1] have shown more suitable characteristics with
regard to those produced by nanoprecipitation: better size, a
higher homogeneity and higher encapsulation efficiency. The
combination of 99m Tc + PLGA nanoparticles (platforms with
excellent biodegradability and biocompatibility) could allow
obtaining a suitable nanosystem for theranosis. The aim of the
present work is to optimize the radiolabelling of PLGA nanopar-
ticles with 99mTc.
Materials and methods: PLGA nanoparticles were prepared using
the nanoprecipitation method [1]. Then, 5 mg of lyophilized
NPs were dispersed in 1 mL 0.9% NaCl and stored in a vacuum
vials. Different amounts of stannous chloride dehydrate in
aqueous solution (30, 20, 4, 2, 1 and 0,1 μg) were added. Then,
was added ≈74 MBq (2 mCi) of 99mTc in 1 mL of 0.9% NaCl. Fi-
nally, the suspension was incubated for 10 min. 99mTc -NPs sus-
pensions were analyzed by thin layer chromatography (TLC)
with silica gel strips (10 x2,5 cm). With 0.9% NaCl as the mobilephase, free pertechnetate ran with the front, meanwhile parti-
cles stayed in the start. Using a solution of pyridine: acetic
acid: water (3: 5: 15), radiocolloids remained at start, NPs
migrated with Rf = 0.3 and free pertechnetate moved with Rf =
0.7-0.8 [2].
Results: Using 1 μg of SnCl2*2H2O as a reducing agent, PLGA
nanoparticles (without surface modification) were labeled with
99m Tc with a yield ≥ 90 %.PLGA nanoparticles size ranged from
160-180 nm in diameter with an electric surface of -36 mV.
After radiolabelling, particles increased in size up to a diameter
≈ 380 nm.
Conclusions: Results obtained, indicate that the procedures of nano-
particle synthesis, radiolabelling and quality control were reprodu-
cible and right to design a biodegradable nanosystem suitable for
in vivo theranosis.
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Introduction: The Gastrin Releasing Peptide (GRP) receptor has
high expression on prostate cancer cells. Consequently, bombesin,
a 14-amino acid peptide that binds with high affinity to GRP re-
ceptors, has been widely studied for the development of radio-
peptides for application in prostate cancer imaging. To overcome
some limitations of radiolabelled peptides, we developed a small
molecule non-peptidic radiotracer targeting GRP receptors. Small
molecules offer various advantages over peptides since they can
be suitably designed to modulate potency, selectivity, lipophilic-
ity, and cell permeability and do not suffer from poor tissue
penetration, poor serum stability, and quick elimination. The aim
of the present study is to develop a non-peptidic fluorine-18 PET
radioligand with antagonist properties, for visualization of GRP
receptors. PD-410 ((S)-3-(1H-indol-3-yl)-N-[1-[5-(2-fluoroethoxy)pyri-
din-2-yl]cyclohexylmethyl]-2-methyl-2-[3-(4-nitrophenyl)ureido]pro-
pionamide) was selected as potent compound for 18F-radiolabelling (Ki
was 38 ± 2 nM).
Methods: [18F]PD410 was synthesized by reaction of [18F]fluor-
oethyl tosylate with the corresponding phenol precursor in pres-
ence of NaH followed by HPLC-purification. Cell experiments were
carried out with PC3 cells to determine cell uptake, efflux and
in vitro binding affinity.
Results: In contrast to other [18F]fluoroethylation reactions, RCY
was low (<5%) because of substantial defluorination. The uptake
of [18F]PD410 in PC3 prostate cancer cells gradually increased
within 60 minutes of incubation, thereafter reaching a plateau.
The maximum cellular associated radioactivity was found to be
70%. Non-specific binding accounted for 40%. The efflux kinet-
ics of [18F]PD410 showed rapid dissociation of the tracer,
remaining only 6% of the tracer within 120 min. This radioactiv-
ity decreased exponentially with a half-life of 13 minutes. In
vitro binding affinity of [18F]PD410 was plotted as sigmoid
curves for the displacement of [18F]PD410 as a function of in-
creasing concentrations of the GRP receptor specific inhibitor
Glu[Aca-BN(7-14)]2. The IC50 value was 0.10 nM for Glu[Aca-
BN(7-14)].
Conclusions: [18F]PD410 displayed high affinity for GRP receptor and
the in vitro results warrant further in vivo PET-studies.
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Introduction: Substituted benzotiazoles (BT) are a class of compounds
with high affinity and selectivity to aryl hydrocarbon receptor (AhR), a
receptor often expressed in breast cancer tissue. Among them 2-(3,4-
dimethoxyphenyl)-5-fluorobenzothiazole (PMX 610) exhibited very
potent (GI50 < 0.1 nM) antitumor properties in vitro in human breast
cancer cell lines. Based on that scaffold we recently suggested 18F-fluor-
oethylated analogue of PMX 610, the 2-(3,4-dimethoxyphenyl)-6-(2-
[18F]fluoroethoxy)benzothiazole ([18F]FEDMBT)1. Preliminary studies
showed high accumulation of the radiotracer in MCF-7, MDA-MB468
and MDA-MB231 breast cancer cells. Here we report an improved
synthesis and purification of [18F]FEDMBT for preclinical trials.
Materials and methods: The extent of 18F-fluorination of labeling
precursor was followed via radioTLC (EtAc:hexane 1:2). The HPLC
purification was performed using Waters C18 XBridge 250 x 10 mm
column, 0.05M NH4OAc:EtOH, 50:50, 3 ml/min, UV 254 nm. For SPE
purification 1.2 mL of aqueous 25% EtOH was added to the reaction
mixture (5 mg of precursor, 0.6 mL of DMF) to prevent precipitate
formation. The resulting solution was passed through the Sep-Pak
tC18 Plus Long cartridge. The cartridge was then rinsed with 2 mL of
50% aq. EtOH allowing for complete removal of the precursor. The
product, [18F]FEDMBT, was recovered by successive elution of the
cartridge with 2 and 1 mL of 55% aq. EtOH.
Results The [18F]FEDMBT was prepared via direct nucleophilic fluorin-
ation of the corresponding tosyl precursor1. Under optimal reaction
conditions (kryptofix 2.2.2., DMF, 140°C, 5 min) a high 18F-incorpor-
ation rate of 80-85% was achieved. The HPLC purification afforded
the product in >99% radiochemical purity and RCY of 55% (decay
corrected). Isolated product fraction was mixed with phosphate buff-
ered saline to adjust the pH and ethanol concentration, without final
re-formulation step. Fractionated SPE purification afforded product
with >99% RCP and 60% RCY (decay corrected). While SPE technique
allowed for complete removal of precursor, a minor chemical impur-
ity (not identified) remained in the final formulation. Work is being
undertaken now to resolve this issue.
Discussion/conclusion: An optimized synthesis of [18F]FEDMBT
afforded product with radiochemical purity and high yield. It can be
easy automated using TracerLab FX-N Pro platform. The suggested
“HPLC free” SPE purification can be applied in the production of
[18F]FEDMBT for ongoing in vitro cell lines experiments and preclin-
ical trials. This study was supported by RFBR grant 15-54-52026/15
and MOST 104-2923-B-010-001-MY2.
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nostic nuclear medicine. It is available from 99Mo/99mTc generators,
where 99Mo is obtained by a fission reaction in nuclear reactors. Dir-
ect reactions using proton beams [e.g. 100Mo(p,2n)99mTc] are a reli-
able and relatively cost-effective method to fulfill the shortage of this
isotope given the imminent closure of the existing old reactors. How-
ever, the results of LARAMED project from the LNL-INFN showed that
the extracted solution of 99mTc from the proton-bombarded 100Mo-
enriched target contains small quantities of several technetium radio-
isotopes (93Tc, 94Tc, 95Tc, 95mTc and 96Tc)[1]. The aim of this work
was to estimate the total contribution of technetium radioisotopes to
the patient radiation absorbed dose after administration of four
radiopharmaceuticals prepared with technetium-99m obtained from
the 100Mo(p,2n)99mTc reaction.
Methods: The internal radiation absorbed doses of pertechnetate,
sestamibi, hexamethylpropyleneamine oxime (HMPAO), and diso-
dium etidronate (HEDP) radiopharmaceuticals, were assessed consid-
ering both technetium-99m prepared from the 100Mo(p,2n)99mTc
reaction as well as from generators. Time-integrated activity in the
main source organs [Ã(rs,TD)] for each radioisotope was calculated
using the radiopharmaceutical biokinetic models published by the
International Commission on Radiological Protection (Publication 53
and 80, ICRP). OLINDA/EXM 1.1 software was applied for dose calcu-
lations using an adult male phantom as a program input and the
above Ã(rs,TD) calculated values. The total absorbed dose in the tar-
get organs, produced by the mixture of technetium radioisotopes,
was calculated for 3 time periods after 100Mo irradiation.
Results: The amounts of other technetium radioisotopes in the
99mTc-radiopharmaceuticals produced a low increase of radiation
doses. Bone marrow is the organ that exhibited the highest differ-
ence between the dose obtained from the generator-produced
99mTc and the accelerator-produced one. For example, HEDP bone
marrow dose (4.41E-03 mSv/MBq) showed an increase in the of 8.5%
(4.79E-03 mSv/MBq), 11.8% (4.93E-03 mSv/MBq) and 17.7% (5.19E-03
mSv/MBq) using 99mTc obtained at 9, 14, and 19 h after 100Mo ir-
radiation, respectively. The corresponding differences for sestamibi,
pertechnetate and HMPAO were less than 8%, 10% and 14% for the
same irradiation times.
Conclusion: The increase of radiation doses caused by 93Tc, 94Tc,
95Tc, 95mTc and 96Tc, compared with the dose from 99mTc is rela-
tively low. However, its impact should not be underestimated.
Administering the labeled radiopharmaceuticals at least nine hours
after the target irradiation is advisable to reduce the irradiation
caused by the other technetium radioisotopes.
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Introduction: The use of pharmacokinetics modeling in preclinical
nuclear medicine is very limited although it is well known that such
models could be valuable tools to study radiopharmaceutical-
properties1. Nowadays, the preclinical evaluation of new radiophar-
maceuticals is still focused only on biodistribution studies, mainly
because of the lack of currently available user-friendly specialized
programs to assist researchers in calculating radiopharmacokinetic
parameters.
Methods: A dedicated spreadsheet software to calculate pharmacoki-
netic parameters such as tracer-biological half-life (T1/2), mean resi-
dence time (MRT) for each compartment, as well as the fraction of
the tracer leaving the compartments per unit time (transfer rate
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 19 of 37constant, TRC), has been developed. The menu-driven spreadsheet soft-
ware is based on five-Compartment Kinetic Model (CoKiMo). CoKiMo
was used to study pharmacokinetic parameters of 11 99mTc-nitrido
complexes, reported as potential myocardial perfusion-imaging agents
(MPIAs), of general formula [99mTcN(DTC-Ln)(PNP)]+ (DTC-Ln= alicyclic
dithiocarbamates; PNP= diphosphinoamine)2, and the results were
compared with those of 99mTc-Sestamibi and 99mTc-Tetrofosmin. Bio-
distribution studies for all MPIAs have been performed in Sprague-
Dawley rats (n = 312) to determine organ uptake.
Results: MPIAs time-activity curves have been obtained using CoKiMo
for 5 compartments, by interpolation of organ activity values measured
at different time points. Curves have been integrated to calculate T1/2
and MRT in the studied organs of all MPIAs. Subsequently software em-
ploys a module with implemented optimization procedure, dedicated
to calculate the values of the TRCs. Finally, CoKiMo calculations were
validated by comparison with two different software: Olinda/Exm and
SAAM II. [99mTcN-(PNP)]+-complexes showed a faster blood and liver
clearance as compared to 99mTc-Sestamibi and 99mTc-Tetrofosmin, in
agreement with some previous reported studies2. However, it was
found that when CoKiMo pharmacokinetic data were used, a wide
quantitative comparison between all MPIAs was possible, which in fact,
was not possible using only the biodistribution data. The analysis of the
results showed that 99mTcN-PDTC3 turned out to be the best candi-
date for translation into clinical practice due to its rapid and high heart
uptake, and fast liver and lung clearance, which enabled an early
visualization of myocardial tissue.
Conclusion: CoKiMo proved to be an easy to use and flexible special-
ized software to study the kinetic of a great number of pharmaceuti-
cals labeled with an unlimited number of radionuclides. Therefore, it
can be a useful tool for an extensive preclinical characterization of
new radiopharmaceuticals.
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Introduction: PEGylation is a methodology that is commonly used to
improve the PK profile of radiotracers. In recent years biocompatible
poly(2-alkyl-2-oxazoline)s (PAOx) gained a lot of attention as alterna-
tive to PEG because of their much higher chemical versatility. PAOx
can be equipped with side-chain functionalities, allowing loading
multiple targeting molecules, while the chain-end can be selectively
radiolabeled. We previously evaluated the PK behavior of 89Zr-la-
beled poly(2-ethyl-2-oxazoline)s (89Zr-PEtOx) in a molecular weight
(MW) range of 5-110kDa using μPET imaging. While we found the ex-
pected increase of circulation time with increasing MW, the 5kDa
[89Zr]-PEtOx demonstrated unusual high kidney retention. We now
developed [18F]-PEtOx 5kDa and compared its pharmacokinetic
behavior to [89Zr]-PEtOx 5kDa.
Materials and methods: PEtOx was radiolabeled with 18F using SPAAC.
For this, PEtOx was first derivatized with bicyclononyne (BCN). Auto-
mated 18F-labeling of BCN-PEtOx was performed by reaction of azi-
doethyl tosylate with azeotropically dried 18F- followed by distillation of
the formed [18F]-fluorethylazide into a second reactor for reaction with
BCN-POX. The reaction mixture was purified using a PD-10 cartridge
and QC was performed using a Zenix-C 80Å column. To evaluate the
PK profile, C57BL/6 mice (n=4) were intravenously injected with [18F]-
BCN-PEtOx (16.47±1.68Mbq, ~100μg) and dynamically scanned over
the first 2h. Volumes of interest were delineated for heart, liver and kid-
neys to calculate standard uptake values (SUV).Results: [18F]-BCN-PEtOx was obtained with a RCY of 4.30% (n=4,
decay corrected to EOB) and a RCP of 100% after PD-10 purification.
As was previously demonstrated for [89Zr]-PEtOx 5kDa, μPET imaging
revealed rapid and complete blood clearance of [18F]-PEtOx 5kDa
(SUV=2.42±0.16 at 10min pi and SUV=0.27±0.08 at 1h pi). Peak liver
uptake related to perfusion was reached within 1min pi (SUV=2.92
±0.18) and quickly decreased (SUV=0.50±0.03 at 10min pi and
SUV=0.07±0.00 at 1h pi) indicating only minor contribution of the
liver in the clearance of [18F]-PEtOx 5kDa. The kidneys displayed a
high initial uptake (SUV=5.67±0.87 at 3.75min pi versus 7.58±2.54 at
3.75min pi for [89Zr]-Df-PEtOx 5kDa) but where [89Zr]-Df-PEtOx 5kDa
was not cleared from the kidneys (SUV=2.36±0.84 at 24h pi), [18F]-
PEtOx 5kDa showed a fast and almost complete clearance (SUV=0.27
±0.08 at 1h pi and SUV=0.12±0.05 at 2h pi).
Conlusions: [18F]-PEtOx 5kDa is quickly cleared from the body and
does not display high kidney retention. The unusual kidney retention
of [89Zr]-Df-PEtOx 5kDa is therefore most likely related to endocytosis
and lysosomal degradation of the radiolabeled polymer followed by
trapping of radiometal 89Zr in the proximal tubules.
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Introduction: The interest towards use of 6-[18F]fluoro-L-DOPA as a
PET radiotracer for the evaluation of dopaminergic system’s state and
also as tumor diagnostic agent has been steadily increasing during
the last decade. Considerable work is being undertaken to overcome
the practical difficulties encountered in the production of 6-
[18F]fluoro-L-DOPA and other ring-fluorinated amino acids via
nucleophilic substitution route. Aromatic amino acids carrying mono-
fluoro methyl group in the α-position have also been considered as
potential PET radiotracers, with nucleophilc synthesis of racemic α-
[18F]fluoromethyl phenylalanine using cyclic sulfamidate precursor
already reported1. Recently our group has suggested a route towards
enantiomerically pure α-[18F]fluoromethyl-p-tyrosine via direct nu-
cleophilic fluorination of a NiII complex2. However, 18F-fluorination
of the precursor bearing α-MeSO3 (mesyloxy) leaving group was inef-
ficient, possibly due to the steric hindrance at the α-carbon of the
tyrosine moiety. In continuation of that previous work we have inves-
tigated the synthesis of the α-[18F]fluoropropyl-L-DOPA via 18F-
fluorination of a similar precursor.
Materials and methods: Radiofluorination of I was performed in the
presence of kryptofix/K2CO3 (acetone, 10 min, 85oC, 10 mg of precur-
sor). The extent of 18F-fluorination was followed by radioTLC
(EtAc:CHCl3:CH3COOH 4:1:1). After solvent removal the 18F-fluorinated
intermediate was treated with 6M aq. HCl at 140oC for 10 min. The
product was analyzed by radioTLC (EtOH:n-Butanol:CH3COOH 4:1:1)
and HPLC (Lichrosphere 100-RP-18, 250 x 4 mm, 0.1% CH3COOH).
Results The precursor, NiII complex of Schiff base of (2S)-1-benzyl-N-
(2-formylphenyl)pyrrolidine-2-carboxamide (BBA) with (S)-2-amino-2-
(3,4-bis((methylsulfonyl)oxy)benzyl)-5-((methylsulfonyl)oxy)pentanoic
acid (Ni-(S)-BBA-(S)-MsO propyl-DOPA(OMs)2 (I)), was prepared from
the corresponding NiII complex of BBA Schiff base with (S)-
DOPA.18F-fluorination efficiency of I was 15%, with room for
optimization. Acid hydrolysis of the intermediate afforded protected
derivative of (S)-α-[18F]fluoropropyl-L-DOPA, but removal of the
mesyl protective groups proved problematic - use of 2M potassium
methylate in MeOH (60oC, 10 min) was ineffective.
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 20 of 37Discussion/conclusion The nucleophilic fluorination of NiII-based
labeling precursor offers potential novel route towards a new deriva-
tive of DOPA with 18F-label in the α-fluoropropyl group. Preparation
of precursor employing methoxy methoxy (MOM) protective groups
instead of mesyl ones, something that should resolve the deprotec-
tion problem, is currently in progress.
This study was supported by SNF grant IZ73ZO_152360/1.
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Introduction: [18F]Clofarabine has recently emerged as a promising
radioligand for in vivo imaging of deoxycytidine kinase activity using
PET. In the reported protocols by Shu and Wu (1,2), 3 is prepared in
a two-step process with an intermediate purification that proceeds
with 10-15% radiochemical yield (RCY). We herein report a simplified
procedure for the preparation of 3, in which the intermediate purifi-
cation was eliminated.
Materials and methods: [18F]Fluoride was produced using a GE PET-
trace cyclotron and dried azeotropically with acetonitrile (MeCN), potas-
sium carbonate and kryptofix (K2.2.2). Radiofluorination was performed
in MeCN at 90 oC for 20 minutes, after which solvents were removed in
vacuo and deprotection was performed using 10% trifluoroacetic acid
(TFA) in dichloromethane (DCM) at room termperature (rt) for 5 min.
Following an additional evaporation, the crude product was dissolved
in mobile phase and purified using semi-preparative HPLC (ACE, C18,
5μm, HIL 250×10 mm, eluted with MeCN: aq. NH4OH (0.6%) 90.5:9.5 (v/
v) at 6 mL/min). 3 was isolated from the eluent using a C-18 SepPak
cartridge (Waters) and formulated for intravenous injection in a solution
of ethanol and phosphate buffered saline (10:90).
Results: The radiochemical conversion (RCC) of 18F-fluoride into 3
was between 25-30%. Higher reaction temperatures or prolonged
heating did not improve the RCC. Removal of MeCN from the reac-
tion mixture prior to deprotection was found to be essential and
may be ascribed to the known inhibiting properties of MeCN on
trityl-group hydrolysis (3). By-product formation, sometimes observed
when refluxing 2 with aqueous HCl, could be effectively eliminated
by employing mild conditions for the deprotection (10% TFA in DCM,
rt, 5 min) without compromising the RCY. No intermediate purifica-
tion was required in the process, that produced >99% radiochemi-
cally pure 3 in 20% RCY with a specific activity >100 GBq/μmol.
Discussion/conclusion: A simplified one-pot radiosynthesis of 3 was
developed in which intermediate purification was eliminated. The
RCY is on par with previously reported protocols for 3 synthesis.
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human breast cancer is a potential tool to stage disease, guide treat-
ment protocols and follow-up on treatment outcome. Among various
techniques to detect ligand–ER interaction both positron emission
tomography (PET) and fluorescence imaging have received ample
attention.
Materials and methods: In this study we use 4,4-difluoro-4-bora-
3a,4a-diaza-s-indacene (BODIPY) as a fluorescent probe and pre-
cursor for 18F-labelling to develop estradiol-based ligands for ER.
The synthesis involves attachment of a BODIPY moiety to the
C17α-position of estradiol using Sonogashira cross coupling reac-
tion of iodo-BODIPY and various 17α-ethynyl estradiol (EE2)
derivatives. Confocal laser scanning microscopy was used to
monitor cellular uptake of the EE2 conjugates after 1 h of treat-
ment without and with estradiol to block ER. Flow cytometric
analysis was performed to determine the relative fluorescence in
the nuclei. The relative binding affinities to the estrogen recep-
tors (ERα and ERβ) was assessed by a competitive radiometric
assay.
Results: The Sonogashira coupling reaction of EE2 derivatives with
iodo-BODIPY(1:1 molar ratio) in THF/toluene (1/2) and using
PdCl2(PPh3)2 as catalyst, NEt3 as a base and CuI at room
temperature gave the desired EE2-BODIPY conjugates in 45-86%
yield (after purification by silica gel column chromatography). In
vitro fluorescence imaging of the basic EE2-BODIPY conjugate
confirmed ER-mediated uptake by the nuclei of ER-positive MC7-
L1cells.
Discussion and conclusion: The synthesis of a series of EE2-BODIPY
conjugates was achieved via Sonogashira cross-coupling in moderate
to very good isolated yields. Our in vitro nuclear cell uptake and
receptor binding results warrant further studies to evaluate the po-
tential of the EE2-BODIPY conjugates for fluorescence/PET imaging of
breast cancer that overexpress ER. Fluor-18 labelling of the BODIPY
moiety of the conjugate, and in vivo fluorescence/PET imaging stud-
ies, are in progress.
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Introduction: 68Ga-labelled PSMA inhibitor analogues are one the
most important class of new radiotracers under clinical observa-
tion and development for the detection of prostate cancer le-
sions and metastases. 68Ga- PSMA-11 (68Ga-PSMA-HBED-CC) has
already attested its suitability in the clinical practice and 68Ga-
PSMA-617 (68Ga-DOTA-PSMA) has recently demonstrated its
potential in individual first-in-man studies gaining importance
above all in view of its theranostic application as it can be
labelled also with 90-Yttrium and 177-Lutetium. In this study the
two 68Ga-labelled radiotracers were synthesized using an auto-
matic Modular-Lab Eazy synthesizer (Eckert & Ziegler) and the re-
liability of the system was validated to guarantee preparations of
pharmaceutical grade.
Materials and methods: The system was assembled with a dispos-
able cassettes and the vials were filled with commercial precur-
sors and ready to use pharmaceutical grade reagents. After
clicking the start button the following steps were performed: a
1850 MBq GalliaPharm 68Ge/68Ga generator (Eckert & Ziegler)
was eluted with 0.1 M HCl by a peristaltic pump by passing
through a cation exchange cartridge into a waste vial. The cart-
ridge was dried and the blocked activity was eluted with 0.55 ml
of a 5.5 M HCl/5 M NaCl solution into the reaction vial pre-filled
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 21 of 37with 40 ug of precursor (PSMA-11 or PSMA-617) and 2.6 ml of
Sodium Acetate/HCl/EtOH buffer. The reactor was heated at 110°C for 4
(PSMA-11) or 8 (PSMA-617) minutes. The mixture was diluted with
7 ml of 0.9 % NaCl solution and transferred into the final product
vial by passing through a light CM cartridge and a sterilizing
filter.
Results: Both radiopharmaceuticals were produced in high yield.
Starting from an activity of 700±20 MBq the radiochemical yield
were 75.6±10 and 75.2±7 % for PSMA-11 and PSMA-617, respect-
ively (n = 5) after 15 minutes. RCP was assessed by HPLC and
was always > 98 % (for 68Ga-PSMA-11 the sum of the peaks of
the two isomers was considered). All the preparations were sterile
and the endotoxin content was < 0.5 EU/ml.
Discussion/conclusions: The Modular-Lab Eazy synthesizer works
with a new technology which uses a pressure distribution
system to transfer the liquid instead of solenoid valves or stop-
cocks. A disposable, easy to assemble cassette allows the syn-
thesis of 68Ga-PSMA-11 and 68Ga-PSMA-617 in high RCY and
quality.PP18
Synthesis and evaluation of fusarinine C-based octadentate
bifunctional chelators for zirconium-89 labelling
Chuangyan Zhai1, Christine Rangger1, Dominik Summer1, Hubertus
Haas2, Clemens Decristoforo1
1Department of Nuclear Medicine, Medical University Innsbruck,
Innsbruck, Austria; 2Division of Molecular Biology, Medical University
Innsbruck, Innsbruck, Austria
Correspondence: Chuangyan Zhai – Department of Nuclear Medicine,
Medical University Innsbruck, Innsbruck, Austria
EJNMMI Radiopharmacy and Chemistry 2016, 1(Suppl 1):PP18
Introduction: 89Zr has received considerable interest as a positron
emitting radionuclide for immuno-PET imaging due to the excel-
lent nuclear and physical properties. Recently we reported that
fusarinine C (FSC) is a promising alternative chelator for 89Zr-
based PET imaging agents, exhibiting superior stability and
kinetic inertness as compared to 89Zr-desferrioxamine B
([89Zr]DFO).[1] Here we designed FSC derivatized chelators for
89Zr labeling which were expected to on the one hand improve
the stability of 89Zr-complexes by saturating the 8 coordination
sphere of 89Zr and on the other hand, reduce the number of
functionality making it suitable for the conjugation to monoclonal
antibodies.
Materials and methods FSC(succ)2 and FSC(succ)3 were synthesized
by FSC reacting with succinic anhydride, and FSC(succ)2AA was syn-
thesized by FSC(succ)2 reacting with acetic anhydride. The complex-
ation properties of FSC(succ)2AA and FSC(succ)3 with Zr4+ were
studied by reacting with ZrCl4. For in vitro evaluation partition coeffi-
cient, protein binding property, serum stability as well as acid dissoci-
ation and transchelation studies of 89Zr-complexes were evaluated
and compared with [89Zr]DFO and 89Zr-triacetyfusarinine C
([89Zr]TAFC). The in vivo properties of [89Zr]FSC(succ)3 were further
compared with [89Zr]TAFC in nude mice.
Results FSC(succ)2AA and FSC(succ)3 were synthesized with satis-
fying yield. The complexation with ZrCl4 was achieved using a
simple strategy resulting in high-purity [natZr]FSC(succ)2AA and
[natZr]FSC(succ)3 with a 1:1 stoichiometry. Distribution coefficient
of 89Zr-complexes revealed improved hydrophilic characters com-
pared to [89Zr]TAFC. All radioligands showed high stability in PBS
and human serum and low protein-bound activity over a period of 7
days. Acid dissociation and transchelation studies exhibited the different
in vitro stabilities following the order of [89Zr]FSC(succ)3 > [89Zr]TAFC >
[89Zr]FSC(succ)2AA > [89Zr]DFO. Biodistribution study of [89Zr]FSC(succ)3
exhibited a slower excretion compared to [89Zr]TAFC.
Conclusion [89Zr]FSC(succ)3 showed best stability and inertness and
[89Zr]FSC(succ)2AA predicts the potential of FSC(succ)2 as a monova-
lent chelator for the conjugation to targeted biomolecules in particu-
lar monoclonal antibodies.PP19
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Introduction: We modified a fully automated method for [18F]NaF
synthesis by re-configuring a commercial FDG synthesis module (Sin-
gle synthesis module, Advanced Cyclotron Systems, Inc.).
Materials and methods: The Lookout program was used to sequence
the steps for automated synthesis using excel spreadsheet. The
[18F]fluoride solution is transferred to synthesis module. The [18F]fluor-
ide ions are trapped in QMA. The QMA cartridge is then washed with
sterile water for injection and eluted with 0.9% NaCl. The final product
was passed through 0.22 μm sterile filter to sterile product vial.
Results: [18F]NaF was successfully produced consistently with high
yield. The non-decay corrected yield after synthesis is at least 85%.
Quality control of [18F]NaF is performed according to USP and EP
requirements. The QC results are passed.
Conclusions: This modified fully automated synthesis showed repro-
ducible and very good radiochemical yields. This module could be
used for [18F]NaF production in our department.
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Introduction: [11C]CO2 and [
11C]CO are undoubtedly highly versatile
radiolabeling agents with many applications. The formation of
[11C]CO from [11C]CO2 has become convenient and difficulties have
been overcome for its further implementation in radiochemistry.
Likewise, many reactions are being explored and many applications
are already possible.[1] However, there is still a need for expansion of
the carbon-11 chemistry toolbox. We here present unprecedented
Michael addition reactions with carbon-11 labeled synthons 1 – 3 as
Michael donors.
Methods: The synthesis of [11C]Methyl acrylate 1 was performed with
[11C]CO2 by fixation in a Grignard reaction with vinyl magnesium
bromide (0.16M in THF) and subsequent Fisher esterification under
acidic conditions. Alternatively, a palladium-mediated carbonylation
reaction with [11C]CO [2] in the presence of tert-butanol or trityl-
amine with vinyl-halides afforded [11C]Tert-butyl acrylate 2 and
[11C]Trityl-acrylamide 3. Michael addition reactions were performed
with N-(diphenylmethylene)glycine tert-butyl ester 4 by adding the
synthons to the reaction solution using TBAF as a base in DMSO.
Synthon 1 was distilled into the reaction mixture. Synthons 2 and 3
were purified by solid-phase extraction and the Michael addition was
performed at 100 °C for 5 min, respectively.
Results: The synthesis of 1 was successful with over 70% radiochem-
ical conversion (RCC) and >95% radiochemical purity determined by
HPLC. After screening and optimization 2 was obtained in 79 ± 10%
and 3 in 73 ± 5% RCC. The subsequent conjugate addition yielded
[11C]N-(diphenylmethylene)-glutamic acid 5-methyl 1-tert butyl ester
5 in 90 ± 5%, [11C]N-(diphenylmethylene)-glutamic acid di-tert butyl
ester 6 in 93 ± 6% and [11C]N-(diphenylmethylene)-glutamine 5-trityl
1-tert butyl ester 7 in 78 ± 3% RCC.
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 22 of 37Conclusion: The successful synthesis of 1 - 3 has been achieved in
good radiochemical yields. Furthermore, conjugate addition to 5 - 7
is possible and we are currently working on expanding the variety of
reactions with these small synthons.
Acknowledgements: RADIOMI FP7-PEOPLE-2012-ITN; [11C]CO2 provided
by BV Cyclotron.
PP21
In vitro studies on BBB penetration of pramipexole encapsulated
theranostic liposomes for the therapy of Parkinson’s disease
Mine Silindir Gunay1, A. Yekta Ozer1, Suna Erdogan1, Ipek Baysal3, Denis
Guilloteau2, Sylvie Chalon2
1Department of Radiopharmacy, Faculty of Pharmacy, Hacettepe
University, 06100, Ankara, Turkey; 2UMR INSERM U930,Université François
Rabelais de Tours, Tours, France; 3Department of Biochemistry, Faculty of
Pharmacy, Hacettepe University, 06100, Ankara, Turkey
Correspondence: Mine Silindir Gunay – Department of Radiopharmacy,
Faculty of Pharmacy, Hacettepe University, 06100, Ankara, Turkey
EJNMMI Radiopharmacy and Chemistry 2016, 1(Suppl 1):PP21
Introduction: Brain penetration and targeting is hard due to complex
structure with different barriers such as blood–brain barrier (BBB) with
blood–cerebrospinal fluid (CSF) interface and CSF–blood interface. Al-
though these tight and rigid barriers protect brain, they also prevent
penetration of molecules, drugs and radiopharmaceuticals for diagnosis
and therapy of many neurodegenerative diseases. Parkinson’s disease (PD)
is assumed to be one of the most frequently observed neurodegenerative
disease among geriatric disorders. PD comprises motor symptoms result-
ing from the death of dopamine generating cells in the substantia nigra.
By using the imaging modalities such as single photon emission com-
puted tomography (SPECT), the decline in the accumulation of specific ra-
diotracer in the striatum can be detected. For PD treatment, limited brain
penetration of drug is a major concern. Passively or actively targeted,
nanosized drug delivery systems such as liposomes have different inter-
ests for either therapy or diagnosis. Recent studies generally depend on
the development of new delivery systems, theranostics, in which diagnosis
can be managed together with therapy by evaluating therapeutic effect.
Materials and methods: Theranostic liposomes were formulated by
polyethylene glycole (PEG) coated, nanosized, either neutral or posi-
tively charged, 99mTc labeled for SPECT imaging and pramipexole en-
capsulated for PD therapy. Their characterization and in vitro release
kinetics were evaluated. In vitro penetration of both formulations
was evaluated in a BBB cell co-culture model.
Results: Both neutral and positively charged liposomes showed
proper characterization with about 10% encapsulation efficiency and
around 100 nm particle sizes. All formulations fitted to the first-order
release kinetics. Both formulations were found BBB permeable in cell
culture studies with fluorescent images and fluorospectroscopy.
Conclusion: Promising characterization and release profiles were ob-
tained with theranostic liposomes for both diagnosis and therapy of PD.
Both neutral and positively charged formulations found BBB permeable
in vitro. In vivo animal studies are continuing to obtain more accurate
data. (The authors thank to Abdi Ibrahim Ilaç for Pramipexole. This study
was supported by the grant of TUBITAK, Project No: 112S244).
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tion and its principal effector is the vascular endothelial growth factor
(VEGF) secreted by cancer cells and other components of tumor micro-
environment. Nowadays, many anti-angiogenic therapies have been
developed and radiolabelled VEGF analogues may provide a useful tool
to non-invasively evaluate the efficacy of such drugs. Aim of the
present study was to radiolabel the human VEGF-A165 analogue with
99mTechnetium (99mTc) and evaluate the expression of VEGFR in both
cancer and endothelial cells in the tumor microenvironment by nuclear
medicine imaging and immunohistochemistry.
Material and methods: The human VEGF-A165 analogue was radiola-
belled with 99mTc using succinimidyl-6-hydrazinonicotinate hydro-
chloride as a bifunctional chelator. In vitro quality controls were
performed to assess its retained structure and biological activity. In
vivo studies included biodistribution studies and tumor targeting ex-
periments in athymic nude CD-1 mice bearing xenograft tumors from
ARO, K1 and HT29 cell lines. Immunohistochemistry was performed
on excised tumors to evaluate VEGF and VEGF receptor (VEGFR) ex-
pression in the lesion and endothelial cells.
Results: The analogue was labelled with high labelling efficiency
(>95%) and high specific activity, with retained biological activity and
structural integrity. Tumor targeting experiments revealed a focal up-
take of radiolabelled VEGF165 in tumor xenografts with different
tumor-to-background ratios. Immunohistochemical analysis tumors
revealed an inverse correlation between VEGF and uptake of the
radioactive hormone. A positive correlation between radioactive
VEGF165 and VEGFR1 was also observed.
Conclusion: Radiolabelled human VEGF-A165 is a promising radio-
pharmaceutical to image angiogenesis and evaluate the efficacy of
anti-angiogenic drugs. However, VEGFR imaging may suffer from
quenching effects of endogenous VEGF produced by cancer and
other cells of the microenvironment.
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Introduction: Among radioisotopes for targeted therapeutic applica-
tions, 188Re is very promising, thanks to its suitable properties (β-
emitter, Emax = 2.12 MeV, t1/2 = 17 h, γ-emission of 155 keV, con-
veniently obtained through a generator), and to the fact that it is a
homologous element to 99mTc, the radioelement of choice in
nuclear medicine. Inside the “Vectorisation & Radiotherapy” Axis of
the Canceropole Grand Ouest and the IRON Labex, our teams have
developed a strong expertise on the chemistry and targeting of
rhenium labelled radiotracers, from bench to bedside. Some exam-
ples of what we have been developing are given below. 188Re-la-
belled Lipiodol: We have developed a stable and efficient labelling
of Lipiodol with 188Re as a potential treatment for HCC. A phase 1
clinical trial is currently running. 188Re-labelled particles: 188Re has
been used to label micro- and nanoparticles. Radiolabelled starch-
based microspheres are investigated in HCC, while lipid nanocap-
sules, also investigated in HCC and adenocarcinoma models, gave
prominent results in glioma, for which transfer to clinic is underway.
188Re-labelled peptides: We are also developing a new bifunctional
chelate for the Re(I) tricarbonyl core, able to link a biomolecule (pep-
tide, protein…).
Conclusions: For more than 15 years, our teams, working closely
together, have developed a series of potential therapeutic radio-
tracers, some of which are now investigated in man, or about to be.
Table 1 (abstract PP25) See text for description
68Ga-DOTANOC preparation Starting
activity
68Ga-DOTANOC
(EOS)
Synthesis-
time
Yield
(uncorr.)
Standard Single generator 1.73 GBq 0.87 GBq 32 min 50 %
Experimental Dual generator 2.56 GBq* 1.10 GBq 44 min 43 %
*Theoretical starting activity of both 68Ge/68Ga-generator corrected to elution
start of the second one
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Introduction: PET molecular imaging and receptor binding peptides
are emerging as powerful tools for imaging. Somatostatin analogues
labeled with 68Ga are the most widely used and have proven useful
for the management of patients with neuroendocrine tumors. How-
ever, within the past few years several other receptor binding com-
pounds labeled with 68Ga have shown promising results with
potential clinical applications in PET centers that lack in site cyclo-
trons. The aim of this study was to develop a single vial kit solution
for the production of 68Ga radiopharmaceuticals for clinical
applications.
Materials and methods: Chemical precursors DOTA-NOC, DOTA-
RGDfK dimer, DOTA-Ubiquicidin (29-41), and PSMA-11 were acquired
from ABX. Gallium-68 was obtained from an ITG generator while la-
beling was performed in an iQS module (ITG GmbH). Stock solutions
of different concentrations were prepared by dissolving the precur-
sors in 0.25M NaOAc. Aliquots of 100 μl of the stock solutions were
dispensed in Eppendorf vials and stored at -20°C. For labeling, the al-
iquots were diluted with 900 μl of 0.25M NaOAc, mixed with 4 ml of
68GaCl3, and incubated for 10 min. Purification was made by SPE
eluting the product with 1ml 50% EtOH. Final product was diluted
with physiological saline and sterilized by filtration (0.22 μm, Millex-
GV). Radiochemical purity (RCP) was determined by gradient HPLC
using a Nova-Pak C18 column (3.9 x 150 mm), 2.5 ml/min flow rate.
Eluents were A=0.1N TFA and B=MeCN.
Results: Non-decay-corrected yields (mean±SD, n=10) were 60±12,
61±6, 56±10 and 70±10% for NOC, RGD, UBI and PSMA, respectively.
RCP was >98% for all the radiopharmaceuticals. HPLC retention times
were 0.5±0.1 min and 2.5±0.2 min for free 68GaCl3 and labeled com-
pounds, respectively. No 68Ge was detected in the final product.
Conclusion: This labeling method using a single vial kit solution is
simple, efficient and reliable, suitable to be used for the production
of a variety of 68Ga radiopharmaceuticals for clinical diagnostic
applications.
Acknowledgments: Research supported by CONACYT Grant 179218, and
IAEA RC16467.
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Introduction: The clinical demand for 68Ga-labelled peptides is con-
stantly rising, but the achievable radioactivity per batch is limited by
the inventory of the 68Ge/68Ga generator. One possible approach to
raising the radioactive yield is to merge the radioactive contents of
two 68Ge/68Ga generators for one batch of 68Ga-peptide. The key
to this method can found in frame with the cationic purification (1)
merging two generator eluates. Our aim was to establish this method
in the synthesis of 68Ga-DOTANOC.
Material and methods: The experimental setup considered two 1.85
GBq (50 mCi) iThemba 68Ge/68Ga-generators with calibration Feb/15
and Oct/15 and a Scintomics GRP synthesis module. SC-01 peptidecassettes including the reagents were applied in the synthesis of
68Ga-DOTANOC. The automatic synthesis sequent was modified by
us as followed: After the initial conditioning of the C18-SPE with
ethanol, water and subsequent drying with N2 the “older” 68Ge/
68Ga-generator was eluted with 7 mL 1M HCl by the motor syringe.
10 mL water was added for dilution, and the mixture was transferred
over a PS-H+ SCX column (Machery-Nagel). The sequent stopped for
the manual change of the generator tube. After continuing the
sequent, the “newer” Generator was eluted in the same manner as
described above. Once washing and drying the valve seats, 68Ga
was delivered from PS-H+ into the reaction vessel with a solution of
1.4 mL 5M NaCl and 0.2 mL 6M HCl. The further labelling with 40 μg
precursor in HEPES were performed as usual.
Results: We found in our preliminary experiments more the 98% of
the theoretical 68Ga radioactivity after “double elution” adsorbed on
the PS-H+ SCX cartridge. About 15 % of 68Ga retained on the PS-H+
SCX after transfer of the 68GaCl3 into the reaction vessel. The
followed labelling of 68Ga-DOTANOC revealed an uncorrected yield
of >40%.
Conclusion: The promising preliminary results with a yield of 1.1 GBq
68Ga-DOTANOC (EOS) in a merging operation of an “old” and a
“new” 68Ge/68Ga generator indicates a high potential for improve-
ment in routine preparation. Therefore, we extend our synthesis sys-
tem with an additional valve actuator unit, which should handle the
68Ga elution from both generators automatically and under GMP
conditions.PP26
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Introduction: HEPES (2-[4-N-(2-hydroxyethyl)-1-piperazinyl]-N’-etha-
nesulfonic acid) is widely used as a “good” reaction buffer in the
labelling of 68Ga-peptides. The final, injectable solution of 68Ga-
peptide may contain traces of HEPES as an impurity. The European
Pharmacopoeia limited the HEPES content in 68Ga-Edotreotide
(68Ga-DOTATOC) with 200 μg per patient dose (1). This limit test is
performed by TLC and developed by the exposing to iodine vapour.
Alternatively, an HPLC method for HEPES has been published (2). Our
aim was to approve this method of the quality control of 68Ga-
peptides.
Material and methods: 68Ga-peptides (68Ga-DOTANOC, 68Ga-
DOTATOC, 68Ga-DOTATATE) were synthesised with a Scintomics GRP
synthesis module using SC-01 cassettes. The determination of HEPES
was performed by HPLC Agilent 1260 equipped with a DAD detector
on an Obelisc N column (4.6 x 150 mm, Sielc Technologies): isocratic
eluent 20% ACN/80% water/0.05% phosphoric acid; 0.8 mL/min; UV
detection at 195 nm.
Results: Due to the polar characteristic of the Obelisc N column,
a good separation of the sulfonic acid HEPES was achieved with
a retention time of about 9 min. A system suitability test with a
solution of 100 μg/mL HEPES and 1 μg/mL gentisinic acid was in-
troduced. The analysis method was successful validated according
to ICH in a concentration range of HEPES from 10 μg/mL to 200
μg/mL. This assay of HEPES was applied effectively in the
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 24 of 37refinement of synthesis sequence to the 68Ga-peptides. The ac-
curate measurement of HEPES did help us to optimise the auto-
matic workup of the reaction mixture via C18-SPE, that we reach
an HEPES content in the final solution below 10 μg/mL routinely.
A disadvantage of the Obelisc N is that the HPLC column is very
sensitive to alcohol and neutral media. To avoid damage, for the
Obelisc N column an acid media of about pH 2 must use to
store. Otherwise due to irreversible deactivation of groups on the
column material the signals of NaCl from the sample will shift in
the retention time and interfere with the signal of HEPES, which
disables the interpretation of the analyse results.
Conclusion: We have demonstrated that HEPES impurities in 68Ga-
peptides can analyse by HPLC with respect to the limit of the
European Pharmacopoeia. We validated this analysis method and
used it in the development of the preparation of 68Ga-peptides. The
HEPES determination by HPLC replaces in our laboratory the test by
TLC and is integrated into the parametric release of our routinely
prepared 68Ga-peptides.
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Introduction: The “organometallic” complexes have been used in
the development of new diagnostic as well as therapeutic radio-
pharmaceuticals.1 The organometallic labeling approach has led
to the creation of a precursor [M(H2O)3(CO)3]+ (M = Tc, Re),
which exhibits several useful characteristics. These include the
small size of the core, easy preparation with aqueous-based pre-
cursor kit formulations, and readily substituted water molecules
of the precursor fac-[99mTc(H2O)3(CO)3]+ by a variety of functional
groups.2 The aim of this study is to label diethyl ester (S,S)-ethylenedi-
amine-N,N´-di-2-(3-cyclohexyl)propionic acid (L) with 99mTc(I)-tricarbo-
nyl precursor. The stability of the formed complex and its in vitro and
in vivo properties were investigated.
Materials and methods: 99mTc(I)-L complex was prepared by a
two-step procedure involving the preparation of the precursor
[99mTc(CO)3(H2O)3]+, followed by the addition of L. The labelling
efficiency and challenge with histidine and cisteine were deter-
mined using gradient HLPC. The in vitro stability of the radio-
chemical complex was determined in saline and human plasma.
TCA precipitation method for determining the percentage of
complex bound to proteins was very useful. Lipophilicity
measurements were done by solvent extraction method with n-
octanol. The overall complex charge was determined by electro-
phoresis on paper strips (Whatman no. 1) after exposure to a
constant voltage (300 V) in phosphate buffer (pH 7.4) for 1 h.
Organ distribution studies were carried out on normal and
tumor-bearing mice (c57).
Results: Radiolabeling yield was higher than 98% and remained high
and practically unchanged at 24h post-labeling. 99mTc(I)-L complex
was stable and resistant histidine challenges. The percentage of
protein binding was 19.62±2.02%. It showed a lipophyilic character.
Biodistribution data, 5 min post injection, showed a very high uptake
in liver and intestine. The majority of the radioactivity of 99mTc(I)-L
complex was eliminated via the liver into the intestine. The organ
distribution in B16-melanoma-bearing mice showed increase in
uptake by the tumor.Discussion/conclusion: 99mTc(I)-L complex revealed high radio-
chemical purity and stability in vitro, without any measurable decom-
position. A significant difference of 99mTc(I)-L complex uptake
between melanoma model and the normal mice was observed.
Biodistribution studies showed high tumor uptake in B16-melanoma-
bearing mice. This study indicates that 99mTc(I)-L complex may be a
potential agent for melanoma detection.
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Introduction: The synergistic interaction between hyperthermia and
radiation therapy is based on the heat effect that may make some
cancer cells more sensitive to radiation or harm other cancer cells
that radiation cannot damage. In the present work two different
types of magnetic nanoparticles (MNPs), Fe3O4-Naked and polyethyl-
ene glycol 600 diacid functionalized Fe3O4 (Fe3O4-PEG600), were
synthetized in order to compare their efficiency as radioactive vec-
tors. They were 90Y-labeled for the potential use in localized
hyperthermia-radionuclide therapy.
Materials and methods: MNPs were synthesized by co-precipitation
of ferric and ferrous salts in a basic solution. Radiolabeling was per-
formed by mixing 0.5 mL of aqueous Fe3O4-Naked and Fe3O4-
PEG600 MNPs suspension with 37 MBq 90YCl3 (0.001 mL) and incu-
bating at room temperature on a shaker for one hour. Radiolabeled
particles were then separated from free 90Y activity by precipitation
with the help of permanent magnet. Radiolabeled MNPs were further
used for in vitro stability studies in saline and human serum, and
in vivo biodistribution studies in normal Wistar rats.
Discussion/conclusion: The Fe3O4-PEG diacid MNPs showed high
phase purity and favorable physicochemical and magnetic charac-
teristics for in vivo use. The obtained SPA value for Fe3O4-PEG
diacid MNPs (200 W/g) indicates that these MNPs could be used
as heating agents for in situ magnetic fluid hyperthermia proto-
cols. Besides, high labeling yield (97%) and in vitro and in vivo
stability of 90Y-labeled-PEGylated magnetite nanoparticles create
opportunities for their use in the combined radio-hyperthermia
cancer treatment.
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Introduction: Optimized automated process for the GMP produc-
tion of 68Ga-DOTA-NOC and 68Ga-PSMA-11 using a cassette-
based synthesizer (Synthera®, IBA, Louvain-la-Neuve, Belgium) in
combination with a recently commercialized 68Ge/68Ga generator
(Galli EoTM, IRE-Elit, Fleurus, Belgium) have been developed in
this work.
Materials and methods: The generator outlet is connected to an un-
modified FDG-type disposable cassette with the appropriate reagent
set and loaded onto the synthesizer. Once the automated process is
started, vacuum elution takes place using only 1.1 mL of a 0.1 M HCl
solution from the generator integrated reservoir. No purification be-
ing required, Ga-68 activity is directly sent to the reaction vessel.
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 25 of 37DOTA-NOC labeling is conducted as follows: a solution of 50 μg pep-
tide in 1 mL 250 mM acetate buffer at pH 5 is added and the mixture
is heated at 120°C for 5 min. The reaction bulk is then loaded on an
HLB cartridge and washed with 10 mL of water. 68Ga-DOTA-NOC is
then eluted with 1 mL of EtOH/water 65:35 v/v mix followed by 1 mL
of saline 0.9% and collected through a 0.22 μM Millex®-GV filter into
a sterile vial containing 8 mL of saline 0.9%. PSMA-11 labeling is con-
ducted as follows: a solution of 10 μg peptide in 1 mL 1.5 M acetate
buffer at pH 4.5 is added and the mixture is heated at 95°C for 5
min. The reaction bulk is then loaded on a Sep-pak® Light C18 cart-
ridge and washed with 10 mL of water. 68Ga-PSMA-11 is then eluted
with 2 mL of EtOH/water 1:1 v/v mixture followed by 2 mL of phos-
phate buffered saline (PBS) and collected through a 0.22 μM Millex®-
GV filter into a sterile vial containing 6 mL of PBS.
Results: 68Ga-DOTA-NOC is produced in r <20 min with 81.5±5.2 %
radiochemical yield (RCY) (decay-corrected-d.c.) and 68Ga-PSMA-11 is
produced in 13 min with 97.4±2.5 % RCY (d.c.). Reported process times
include generator elution and formulation. In both cases, final products
show high radiochemical purity (TLC > 97 % and 99 % respectively).
Discussion/conclusion: Automated processes for the production of
both 68Ga-DOTA-NOC and 68Ga-PSMA-11 have been successfully
achieved using a commercial synthesizer and a 68Ge/68Ga gener-
ator. The labeling procedures are straightforward and efficient,
thanks to the low elution volume and high purity of the generator
eluate (no need for fractionation or post-elution purification).
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Introduction: Mono-product facilities are turning to multi-product to
cope with decreasing prices of [18F]-FDG (FDG) and to support R&D
programs. The aim is to demonstrate that in the same facility and
equipment, a busy research program can be safely integrated into
commercial production.
Materials and methods: To be able to safely combine both activities
a risk-assessment should be designed to identify key control points.
The use of a fully automated platform (e.g. IBA Synthera) and its
disposable cassettes can prevent human errors, reduce risk of cross-
contamination and improve reliability. A production schedule, train-
ing and labeling procedures should also be considered.
Results: Positronpharma in Chile delivers FDG daily to several hospitals
and produced > 1600 Ci FDG in the last 3 years. In addition, [18F]-(FCH,
NaF, FET, FLT, F-MISO, DMFP), [68Ga]-DOTA-peptides and PSMA-11
have been implemented as well as two more INDs: [18F]-PR04MZ and
MHMZ were translated into clinical studies. ICNAS is a research unit of
the University of Coimbra that hosts a GMP-compliant PET production
facility which supports clinical and pre-clinical R&D programs and sup-
plies RPs to nearby hospitals. The unit is in operation since 2012 and
currently has five radiopharmaceuticals authorized in the market (18F-:
FDG, FCH, NaF) and 68Ga-DOTA-NOC. All are produced on IBA Synthera
and together represent >2000 production cycles. An extensive R&D
program is in place with plans for production of other [18F]-tracers (F-
DOPA nucleophilic route, FMISO, FLT, FES), [68Ga]- (PSMA, DOTA-TOC)
and [64Cu]- (ATSM). BV Cyclotron VU in Amsterdam is a private com-
pany with a GMP-compliant PET production facility. Since the 90’s FDG
is delivered for the Dutch hospitals (annual output of > 7300 patient
doses (11 TBq)). FCH and FBB (Florbetaben) are also commercially pro-
duced with annual output >1400 (1.7 TBq) and >340 patient doses (1.1
TBq), respectively. Besides the commercial productions there is also
room for an R&D program, e.g., currently improvement of the produc-
tion of FCH is examined.Discussion/conclusion: As a conclusion, the sites described have
been functioning for several years and are able to safely combine
commercial daily production while keeping a highly active R&D pro-
gram with more than ten different tracers developed for pre-clinical
and clinical applications.
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Introduction: There is a continued interest for development of radi-
olabeled RGD peptides as integrin αvβ3 receptor targeted molecular
probes possessing favorable pharmacokinetic behavior.1,2 In this
study, two click chemistry modified cRGDfK peptide analogues have
been synthesized 3 and radiolabeled with [99mTc(CO)3(H2O)3]+ pre-
cursor. Comparative in vivo evaluation of the two radiotracers was
carried out to determine the pharmacokinetics and integrin αvβ3
targeting potential.
Materials and methods: cRGDfK was functionalized with N3CH2COOH
and N3PEG7COOH at ε-amino group of lysine. The two azide-
modified derivatives (with PEG7and without) were then clicked
with propargyl glycine to introduce a tridentate chelating unit for
radiolabeling with [99mTc(CO)3(H2O)3]+ precursor. The radio-
tracers, 99mTc(CO)3-Pra-Tz-CH2-cRGDfK and 99mTc(CO)3-Pra-Tz-
PEG7-cRGDfK were analyzed by HPLC. Analogous rhenium
complexes were synthesized for characterization of 99mTc(CO)3-
labeled radiotracers. Biodistribution study of the two radiotracers
was carried out in C57BL/6 mice bearing αvβ3-positive melanoma
tumors. The radioactive preparation (~3.7 MBq/animal, 100 μL)
was injected intravenously through the lateral tail vein. At differ-
ent time intervals after injection (30, 60, and 180 min), the ani-
mals (n = 4/time point) were sacrificed and the relevant organs
excised for measurement of retained activity.
Results: The two radiotracers, 99mTc(CO)3-Pra-Tz-CH2-cRGDfK and
99mTc(CO)3-Pra-Tz-PEG7-cRGDfK were prepared in >90% radiochem-
ical yield and exhibited excellent stability in saline as well as in
serum. Maximum tumor uptake was observed at 30 min p.i. for the
two radiotracers and was higher for 99mTc(CO)3-Pra-Tz-PEG7-
cRGDfK (4.11 ± 0.51 %ID/g) as compared to that for 99mTc(CO)3-
Pra-Tz-CH2-cRGDfK (3.01 ± 0.77 %ID/g). Tumor accumulation of
both the radiotracers reduced to 50-60% during blocking studies
with cold cRGDfK peptide, suggesting receptor-mediated uptake
of radiotracers.
Conclusion: The two neutral 99mTc(CO)3 radiotracers prepared ex-
hibited receptor mediated uptake in melanoma tumor. Increased
tumor uptake on introduction of PEG7 unit was compromised with
slow clearance from other organs. Further modification of the pep-
tide with a different spacer or a smaller PEG unit may lead to more
favorable pharmacokinetics.
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EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 26 of 37Introduction: The shortage of 99Mo (fission) has renewed interest in
alternative technetium-99m production methods either in nuclear re-
actor starting from 98Mo or in accelerator with 100Mo as a target
material. Adsorption chromatography on alumina is not sufficient for
alternative production methods due to high amount of Mo in the
dissolved target solution. Several chromatographic resins were de-
scribed for the separation of pertechneate from molybdate including
Dowex or ABEC. Here we focused our attention on application of
AnaLigTc-02 resin for efficient recovery of 99mTc from large molyb-
denum excess.
Methods: To simulate a target dissolution mixture, 10 mL of sodium
molybdate solution and a small amount of Na99mTcO4 in NaOH or
(NH4)2CO3 was delivered on the column containing 100 mg of
AnaLig resin using the flow rate of 0.4 mL/min. Before 99mTc elution,
the column was fed with 3 mL of sodium hydroxide or ammonium
carbonate solution and subsequently with 1.5 mL of water. The
99mTc was recovered in 5 mL of water. The eluate and other efflu-
ents activities (one after introduction of Mo solution and two after
rinsing columns in term with NaOH or (NH4)2CO3 solution and
water) were measured with the dose calibrator Capintec CRC-55tR.
The sorption yield was studied as a function of NaOH and (NH4)2CO3
for concentration of 1.05, 1.4, 2.8 and 4.2 M for the former and 0.5,
1.5 and 2.5 M for the latter.
Results: Best 99mTc recovery was obtained in 2.8M NaOH or 1.5M
(NH4)2CO3 solution. Under these conditions, more than 86% adsorp-
tion and elution were achieved. Most 99mTc losses occurred during
rinsing the column with water, even approaching 10% of activity and
due to rinsing the column with NaOH or (NH4)2CO3 after sorption
Tc-99m on Analig resin (up to 3.5%). The activity retained on the
column was around 1% for solution in NaOH and about 3% for
(NH4)2CO3, respectively.
Acknowledgements: This project was supported by the grant ALTECH
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Introduction: The fluorine-18 labelled nortropane derivative 2β-
carbomethoxy-3β-(4-chlorophenyl)-8-(2-fluoroethyl)-nortropane
([18F]FECNT) is a Positron Emission Tomography (PET) radioligand of
reference for imaging the dopamine transporter (DAT). The use of
this radioligand as a clinical marker is highly dependent on the ro-
bustness of the radiochemical process used for its preparation.
[18F]FECNT has been previously synthesized in a two-step chemical
process with 16% decay-corrected yield in total time of 150 min.
Recently, more effective (25-33% decay-corrected yield, 80-90 min)
one-step synthesis of [18F]FECNT by direct nucleophilic [18F]fluorin-
ation from N-mesyloxy precursor was reported in literature. However,
the use of a mesylate as a leaving group in such a nucleophilic sub-
stitution reaction has some drawbacks. Mesylates are rather hard to
detect using UV-absorption, which complicates the final HPLC purifi-
cation of the radiotracer and also characterized by higher susceptibil-
ity to decomposition. Herein, we reported a fully automated
synthesis of [18F]FECNT from the chlorinated precursor, which was
earlier found to be the most stable of the studied halo- and sulfony-
loxy- analogues.
Materials and methods: The commercially available SynChrom [18F]
R&D synthesis module was readily configured for the one-step syn-
thesis according to conditions achieved for the fluorination with
non-radioactive fluoride. The radiolabelling process involved aclassical [18F]fluoride nucleophilic substitution from the chlorinated
precursor (5mg) was performed at 110°C for 12 min. Crude product
was purified using preparative HPLC and SPE methods.
Results: The obtained yields for a chlorine-for-[18F]fluorine substitu-
tion of 59±12% (n=5) were higher than those (45-48%) reported for
the [18F]FECNT batches prepared from the N-mesyloxy precursor.
The total synthesis time was 80-90 min and [18F]FECNT batches of
about 2.0±0.5 GBq (n=3) with high radiochemical purity over than
99% were obtained with 32±7% overall decay-corrected yields. These
yields were comparable with previously reported results for the one-
step synthesis of [18F]FECNT and significantly higher than yields ob-
tained in two-step syntheses [2]. The specific activity of the final
[18F]FECNT product was 55 GBq/μmol, which is consistent with litera-
ture synthesis results (38-72 GBq/μmol) of this radiotracer and suffi-
cient for the DAT density determination in the human PET imaging
studies.
Discussion/conclusions: In this study, the new chlorinated precursor
was successfully used for one-step automated radiosynthesis of
[18F]FECNT. Considering these promising results as well as long-
term storage stability of this precursor, reported procedure may pro-
vide a straightforward and reliable method for the production of
radiotracer suitable for human use.
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Introduction: The in-time diagnosis of bacterial infection is extremely
significant for the accurate treatment. Nuclear medicine scintigraphic
imaging is an excellent non-invasive method of whole-body scan-
ning, allow to determinate infectious foci in all parts of the body,
based on pathophysiological changes which occur earlier in the in-
fection process. The aim of this study was to perform gamma scintig-
raphy studies with bacterial infected and sterile inflamed rats with
newly developed radiopharmaceutical 99mTc-amoxicillin sodium
(99mTc-AMOX).
Method: E.coli suspension was intramuscularly injected into the right
thigh muscle of rats to create infection model. Turpentine oil was
intramuscularly injected into the left thigh muscle of rats to create
sterile inflammation model. After the infection and sterile inflamma-
tion focus were allowed to develop for 24 hours swelling appeared
and gamma scintigraphy studies were performed. 99mTc-AMOX
(3.7MBq) was intravenously injected via tail vein to the rats. After
administration of radiopharmaceuticals, serial static images were
acquired at different time intervals (5 minutes, 1, 2, 3, 4 and 5 hours
post injection).
Results: The uptake of 99mTc-AMOX following intravenous adminis-
trations was assessed on static images. The images depicted rapid
distribution throughout the body and uptake in the bacterial infected
and sterile inflamed thigh muscle within one hour after injection.
There was a higher activity in both bacterial infected and sterile in-
flamed thigh muscle as compared to healthy thigh muscle. For quan-
titative evaluation, regions of interest were drawn around the target
(infected and inflamed thigh muscle) and non-target (healthy thigh
muscle) regions of the rats. The 99mTc-AMOX uptake was calculated
by dividing the average counts per pixel within the region of target
to the average counts per pixel within the region of non-target.
Conclusion: Based on the in vivo studies, 99mTc-AMOX has higher
uptake in infected and inflamed thigh muscle than healthy muscle.
The data suggest that 99mTc-AMOX remained at the infection
and inflammation foci during the whole experiments, there being
no statistically significant differences in the ratios during the
studied period (p≥0.05).
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Introduction: Infection detection by nuclear medicine imaging
techniques based on pathophysiological changes which appear
much earlier than anatomical changes in the infection process
(1,2). To develop a better infection imaging which will accumu-
late efficiently to inflammatory foci, clear rapidly from back-
ground tissue, discriminate between bacterial infection and sterile
inflammation, cost low and prepare easily we labeled amoxicillin
sodium (AMOX) with 99mTc. The aim of this study is to prepare
99mTc-AMOX in a simple method with good labeling efficiency
and evaluate the ready to use cold kit formulation thus making
it available to the other nuclear medicine centers. The stability of
99mTc-AMOX in human serum was identified; sterility and pyro-
genicity of the radiopharmaceutical was estimated.
Method: To investigate the optimum radiolabeling conditions,
radiolabeling was tested with different concentrations of redu-
cing (stannous chloride and stannous tartrate) and antioxidant
(ascorbic acid) agent. Radiochemical analysis was performed
with Radio Thin Layer Chromatography (RTLC) and Radio High
Performance Liquid Chromatography (RHPLC) studies. Two dif-
ferent freeze dry kits were formulated with optimum labeling
conditions and stability, sterility and pyrogenicity of the kits
were performed.
Results: The effect of reducing agent concentration on the
radiochemical purity was evaluated and optimum reducing
agent amount found 200 μg. Under these conditions labeling
efficiency was around 90%. In the presence of ascorbic acid,
stability of the complex was slightly increase while labeling effi-
ciency for early hours was not affected significantly. According
to the experiments, the formation of the 99mTc-AMOX complex
was very fast and reached the radiochemical purity over 95 %
in 15 min after radiolabeling. While keeping other reaction con-
ditions constant and varied the pH of the reaction from 4.8 to
7.4 radiochemical purity was slightly decreased. 99mTc- AMOX
was found stable during to 24 hours incubation in saline and
human serum. Kits were labeled with 37MBq, 185MBq and 370
MBq 99mTc. Slightly decrease in radiochemical purity was ob-
served with increasing of radioactivity. According to sterility
test, since there was no growth in batches, kits were sterile.
Also gel clot test showed that kits were pyrogen free. The
freeze dry kits developed in this study were found to be stable
with a shelf–life of six months when preserved at both at +5
±3°C and +25±2°C/60 ±5% RH.
Conclusion: Simple method for radiolabeling of AMOX with 99mTc
has been developed and standardized. Labeling efficiency of 99mTc-
AMOX was assessed by both RTLC and RHPLC and found higher
than 90%. The resulting complex was quite stable and labeling of
˃90% was maintained for up to 6 hours. Two different freeze dry
kits was developed and evaluated. Based on the data obtained from
this study, both products was stable for 6 months with high labeling
efficiency.
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often directly suitable for the production of different labeling agents.
Modification of Tracerlab FXC-Pro synthesis module to perform both
[11C]methylation and [11C]carboxylation1 and the set-up of [11C]radio-
pharmaceuticals for clinical use are described.
Materials and methods: Commercial GE Tracerlab FXC-Pro synthesizer
was modified to enable 11C-methylation with both [11C]methyl iodide
and [11C]methyl triflate as well as direct 11C-carboxylation with
[11C]CO2. Additional magnetic valves were installed to bypass the
[11C]methyl iodide recycling system for direct use of [11C]CO2 and to
bypass the [11C]methyl triflate oven when using [11C]methyl iodide
as such. The valves are operated by Tracerlab software. The HPLC op-
erations were modified by installing pneumatic column selector and
a syringe operated loop injector. A sterile filtration unit (SFU) was
coupled with synthesizer to allow online filter integrity test. For mon-
itoring purposes more GM tubes were also installed. [11C]PK11195
was labeled with [11C]methyl iodide while [11C]methionine and
[11C]metomidate were labeled with [11C]methyl triflate. [11C]Acetate
was synthesized using direct carboxylation with [11C]CO2. Semi-
preparative HPLC was used for the purification of [11C]PK11195 and
[11C]methionine. Solid phase extraction cartridges were used for the
purification of [11C]metomidate and [11C]acetate.
Results: The average synthesis times were 30 minutes for [11C]me-
thionine, 38 minutes for [11C]PK11195, 20 minutes for [11C]metomi-
date and [11C]acetate including purification, formulation and online
sterile filter integrity test. [11C]Radiopharmaceuticals were obtained
in good radiochemical yields, sufficiently for several simultaneous
clinical doses. The radiochemical purity exceeded 95% in all synthe-
ses. The use of column selector enables easy change of HPLC col-
umns between syntheses. The filling of the injector loop with
pneumatic syringe decreases losses of the injection solutions com-
pared to the inbuilt fluid detector. Due to the limited number of
electrical connections in Tracerlab FXC-Pro the column selector, loop
syringe and SFU are remote controlled from external touch screen.
Readings from additional GM tubes are also shown on the touch
screen.
Conclusion: Reliable and robust routine procedures for the production
of [11C]methionine, [11C]PK11195, [11C]metomidate and [11C]acetate
were developed using a modified Tracerlab FXC-Pro module. The synthe-
sis module can be easily modified and re-modified for production of
many different [11C]radiopharmaceuticals.
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Introduction: Cu(I)-catalyzed 1,3-dipolar cycloadditions is widely used in
labeling azido-functionalized peptides and small-molecules with18F-
alkynes. We report on the microfluidic (ADVION) synthesis of 5-
[18F]fluoro-1-pentyne (5-[18F]-FP) and 6-[18F]fluoro-1-hexyne (6-[18F]-FH)
and application in labeling an azide-functionalized Factor-H.
Materials and methods: 5-tosyloxy-1-pentyne (5-TP) and 6-
tosyloxy-1-hexyne (6-TH) were obtained from the corresponding
alcohols [1]. [18F]fluoride (0.3 GBq) was produced by irradiation
of >98% 18O-water (nyobium target), trapped on a trap&release
column and eluted with K222/K2CO3 (15mg/3mg) in dry aceto-
nitrile (1ml). The K222/K[18F]F complex was dried by azeotropic
distillation in the Concentrator module, recovered in the reaction
solvent (600ul) and uploaded in a storage loop (P3). 5-TP or 6-TH
was dissolved in 1 ml of solvent and uploaded in a storage loop
(P1). Boluses of precursor and K222/K[18F]F solutions were
pushed (total flow 40μL/min; P1=P3) through the reactor (2m
fused-silica coil-reactor i.d.=100μm, 15.6μl) at 90, 110, 130, 150
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sulfoxide, tert-butanol and different P1:P3 ratios (1:1 and 1:5).
Products were purified by distillation and analyzed (radio-TLC,
radio-HPLC). Factor-H was reacted with an azido-(PEG)4-carboxyl-
ate linker (azido-PEG) targeting protein amino groups. Factor-H
(1.6nmol in 250μl of pH 9 PBS buffer), was reacted (4h at RT)
with 48nmol of NHS-activated azido-PEG. The azido-protein was
purified by ultracentrifugation, suspended in water and lyophi-
lized. 5-[18F]-FP was distilled into a vial containing 2-6nmol of
azidoPEG-Factor-H, 1.4 μmol of Cu(I), 1.9μmol of TBTA in 150μl of
THF/H2O (2:1) and reacted at 45°C for 10'. Unreacted 5-[18F]FP
was removed under nitrogen flow. 5-[18F]-FP-Factor-H was puri-
fied by gel filtration (RCP> 97%) and the yield (92±3% d.c.y.,
n=5) determined by HPLC.
Results: Best yield for 5-[18F]-FP and 6-[18F]-FH (91±6% and 83±5%
d.c.y, n=3) were obtained in acetonitrile (130°C), P1:P3 1:1. Reaction
yield was lower in DMSO for both 5-[18F]-FP and 6-[18F]-FH (68±11%
and 71±9%, d.c.y, n=3) and worse in tert-butanol (33±5% and 45
±2%, d.c.y, n=3). Increasing P1:P3 ratio did not influence yield and
resulted in a more frequent reactor clogging.
Discussion/conclusion: We describe a microfluidic approach for the
synthesis of C5 and C6 18F-alkynes and the on-line radiolabelling of
an azido-functionalized Factor-H with 5-[18F]-FP. The proposed
method is applicable to a broad group of compounds (small mole-
cules, peptides and nanoparticles).
References: 1 - Wang, Zhe et al., (2000), J. Org. Chem. 65(6):1889-1891.
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Introduction: Production of 18F-flumazenil from 2-nitroflumazenil
under GMP conditions is primarily performed with manipulators or
custom built radiosynthesis modules with fixed components, as the
use of N,N-dimethylformamide (DMF) at 160°C prohibits the use of
commonly available disposable cassettes. Cassettes for the GE TRA-
CERlab MXFDG synthesis modules are commercially available in dif-
ferent materials. ROTEM Industries and GE Healthcare use
polysulfone as the main component, and it is known that this poly-
mer is not compatible with DMF. Cassettes from ABX are reportedly
more chemical resistant, with polypropylene as its main constituent.
The aim of this work was to establish a robust automated radiosynth-
esis procedure for 18F-flumazenil on the GE TRACERlab MXFDG,
where staff previously trained on the same equipment can easily
perform the radiosynthesis.
Materials and methods: Fragments of the ABX FDG cassette were ex-
posed for 1 or 24 h to various solvents including acetonitrile and
DMF at room temperature (RT) or 60°C to assess its chemical resist-
ance. A new synthesis sequence was written for the GE TRACERlab
MXFDG. A non-radioactive test run was performed with the ABX FDG
cassette, and radiosynthesis was carried out with the cassette com-
ponents replaced by chemically resistance manifolds (ABX).
Results: Incubation of the PP ABX FDG cassette fragments in aceto-
nitrile at RT showed no macroscopic influence on the polymer while
the fragment became soft and mouldable at 60°C. Visible changes
occurred after 1 h incubation with DMF, with the polymer having
completely dissolved after 24 h, regardless of temperature. To verify
the implication of these results on a 1 h radiosynthesis, a test run
was performed using the same cassette material and synthesis condi-
tions without radioactivity. Parts of the manifold was found to have
cracked, and a valve blockade was observed due to polymer melting.
Radiosynthesis was carried out with the manifolds replaced by chem-
ically resistant ones, and 18F-flumazenil was successfully obtained in
4 % decay corrected yield.Conclusions: Disposable cassettes assembled with chemically resist-
ant manifolds is a requirement for the automated synthesis of 18F-
flumazenil from 2-nitroflumazenil using the GE TRACERlab MXFDG
synthesis module. Neither reagent kits nor program sequences are
hitherto commercially available, but GMP grade production can
nonetheless be successfully carried out with modifications on exist-
ing equipment.
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Introduction: [18F]Fluoromethylcholine ([18F]FCH) proves to be a
unique radiotracer for the detection of prostate cancer as well as
brain and lung tumors with Positron Emission Tomography (PET).
The aim of this work was to improve radiochemical yields of 18F-
Fluoromethylcholine ([18F]FCH) with high reproducibility. The used
eluent solution plays an important role in production of [18F]FCH ra-
diotracers. [18F]FCH is manufactured under GMP conditions using
one of two eluent solutions namely Tetrabutylammonium Bicarbon-
ate (TBAHCO3) and Kryptand 2.2.2., each time.
Method: [18F]FCH was radiosynthesized using a fully automated syn-
thesis module TRACERlab MX. Hardware cassette and reagents kit
purchased from ABX..[18F]FCH is synthesized by 18F-Fluoroalkylation
of N-N-Dimethylaminoethanol (DMAE) in presence of Dimethyl Sulf-
oxide (DMSO) using 18F-Fluorobromomethane [18F]FBM as an alkyl-
ating agent.
Results: [18F]Fluoromethylcholine radiosynthesis assisted by Kryptand
2.2.2 shown irregular or poor distillation of 18F-Fluorobromomethane,
which is observed by pressure trending window on TRACERlab MX dur-
ing distillation step very poor gas flow through the four silica cartridges
been observed which in turn leads to production of very less amounts
of [18F]FCH. Tetrabutylammonium Bicarbonate (TBAHCO3) assisted
18F-FCH radiosynthesis observed with regular and continuous distilla-
tion of 18F-Fluorobromomethane through the four silica cartridges.
[18F]FCH solution proved high radiochemical purities (>99%), Residual
solvents analyzed using Gas Chromatography (GC), DBM & DMAE is not
identified.
Conclusion: Choice of Tetrabutylammonium Bicarbonate (TBAHCO3)
as eluent solution shown very consistent and improved radiochem-
ical yields decay corrected 20-25% over Kryptand 2.2.2 as eluent
solution.
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Introduction: Targeting short peptides are gaining interests in the
molecular imaging field. Choosing the radioisotope to label those
peptides is a challenging stage in the process of identifying the right
imaging modality.
Method: All needed reagents and solvents were used with no further
purifications unless it’s necessary. Peptide used was purchased from
GenScript and used without further purifications. Reaction progress
was monitored using both radio-analytical thin-layer chromatography
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Radio-HPLC analyses were carried out on semi-preparative Phenom-
enex C-18 (250 mm x 10 mm). Radiolabeled peptide was detected
with the eluting of 0.065% TFA in water and 0.05% TFA in MeCN at 2
ml/min applying gradient elution mode. Radiochemical yields were
calculated based on the Radio-HPLC collections. Sodium Citrate
Buffer (PH=7.5) wa the Radio-TLC mobile phase.
Synthesis of DOTA- Peptide Conjugate: 9.97 E-7 mol of the
intended peptide dissolved in DMSO reacts with 1.18 E-6 mol of
(DOTA-NHS-ester) that was prepared in MeCN. The reaction was
done in a phosphate buffer with PH=8 and heating at 90°C for
30min.
68G -labeling of DOTA-Peptide: 68G solution was added to 60 μg of
conjugated DOTA-Peptide in 100 μl of HEPES buffer (PH=4) and the
mixture allowed to react for 30 min at 80°C.
Result: [68G-DOTA-Peptide] was analyzed on Radio-HPLC; the ration
time of the product was 8.4 min and Radio-TLC checks for the col-
lected product confirm the high radiochemical purity.
Discussions: The labeled peptide is produce in good radiochemical
yields and high radiochemical purity. Initial biological works are
ongoing to evaluate its imaging potential mainly on a melanoma cell
line. The findings will be presented.
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Introduction: Pharmacopoeial or manufacturer’s radiochemical pur-
ity (RCP) analysis methods are not always practical in a hospital
setting, leading to modifications or substitution with quicker, sim-
plified, or cost effective analytical procedures. This study aimed
to determine whether appropriate validation procedures based
on ICH Q2A and Q2B guidelines are feasible in a resource limited
environment, such as most hospital radiopharmacy settings in
Southern Africa.
Materials and methods: Alternative RCP test methods for Tc-99m
sestamibi involving the use of Whatman 31 ET (Wh) and Schleicher
and Schuell (SS) chromatography paper were used. Locally procured
Macherey-Nagel (MN) aluminium oxide TLC strips were intended as
control method, as strips described in the manufacturer’s instructions
were unavailable. All analyses were performed on the 3 different
strips in parallel, and in triplicate. In-house prepared Tc-99m sesta-
mibi, colloid and pertechnetate were assumed to be 100% pure.
Samples containing mixtures of varying concentrations of the radio-
chemical components were analysed. Results from tests performed
by different operators were used to judge intermediate precision,
and time delay between spotting and developing was used to evalu-
ate robustness.
Results: RCP of sestamibi without added impurities was
99.8%±0.0% MN, 99.5%±0.1% for Wh and 99.3%±0.2% for SS
strips. Addition of pertechnetate and colloid to Tc-99m Sestamibi
after completion of kit reconstitution, resulted in values for
sestamibi higher than the calculated RCP for all 3 methods. The
radiochromatogram scanner’s limit of detection and limit of
quantitation were determined.
Discussion and conclusion: Due to the unexpected high RCP
values after addition of impurities to sestamibi, all the analytical
methods lacked specificity and accuracy. The MN test method
showed exceptionally high values for sestamibi due to co-elution
of the free pertechnetate with sestamibi. The MN RCP test
method could therefore not be used as a reference standard. All
three methods met the acceptance criteria for repeatability, inter-
mediate precision, and robustness. Validating an analytical pro-
cedure in a hospital setting is only possible once some importantprerequisites are met, such as availability of specified materials
for the reference procedure, reliable reference standards, and
availability of HPLC for radiopharmaceuticals that have impurities
other than pertechnetate and colloid. A template validation
protocol for TLC and paper chromatography was developed.
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Introduction: The translocator protein (TSPO) has been proposed as
a biomarker for several conditions, including neurodegenerative dis-
orders, cancer and non-alcoholic fatty liver disease. Hence, a number
of PET ligands have been developed to image the TSPO, including
the aryloxyacetanilide derivative [18F]FEPPA, which is currently in clin-
ical use [1]. The synthesis of [18F]FEPPA was first reported by Wilson
et al. [2] and successively fully automated [3]. Nevertheless the purifi-
cation of the crude product by means of semipreparative HPLC is un-
satisfactorily time consuming (retention time tR ≈ 23 min). Therefore,
the aim of this study was to establish a new set of conditions, which
can reduce the retention time of the product and consequently re-
duce the total time of the synthesis.
Methods: [18F]FEPPA was synthesized as described elsewhere [3]
with minor modifications in a Nuclear Interface synthesizer (GE
Healthcare, Sweden). Briefly, the tosylate precursor dissolved in
acetonitrile was added to the azeotropically dried [18F]fluoride and
the reactor was heated at 90° C for 10 minutes; after cooling, the re-
action was quenched with a solution 50:50 acetate buffer:acetonitrile
(pH=3,6) and automatically injected onto a semipreparative HPLC
Column (Merck Chromolith® RP-18e, 100×10 mm). The product frac-
tion was collected in water and the new aqueous solution was
passed through a pre-conditioned C-18 plus SepPak cartridge. Finally,
the product was eluted with ethanol and formulated with saline and
phosphate buffer.
Results: The new procedure yielded 3.2 ± 0.3 GBq of [18F]FEPPA
(27% ± 3%, not corrected for decay) within 17 min after the azeo-
tropic drying of the [18F]fluoride. Specific activity ranged from 430 to
600 GBq/μmol. Radiochemical purity exceeded 98%.
Conclusions: A fast and reliable procedure for the production of
[18F]FEPPA was successfully implemented, drastically reducing the
total time of the radiosynthesis compared to the previous published
method (17 min compared to 36 min).
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Introduction: Indium-111 and gallium-68 labelled octreotide deriva-
tives [1] are widely used in SPECT and PET imaging of somatostatin
receptor expressing tumours and pancreatic dysfunction. In perspec-
tive of advantages of fluorine-18 (favourable half-life, high produc-
tion capacity, low β-energy), more recently, derivatives based on
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achieve high labelling efficiency at biomolecule compatible condi-
tions and improve radiotracer properties in vivo, we synthesized an
octreotate conjugate with an acyclic trans-cyclohexane spanned pen-
tadentate chelator: Restrained complexing agent 1, RESCA1 (1). After
low-temperature Al18F-complexation, in vitro and in vivo characteris-
tics of the new radiotracer were studied.
Materials and methods: Radiolabelling was achieved manually start-
ing from 50-860 MBq of [18F]sodium fluoride. Al18F-RESCA1-TATE
([Al18F]2) was purified by SPE and analysed with iTLC, LC-MS and RP-
HPLC. Stability of the radiotracer was investigated in vitro over a period
of 3 h in EtOH/Saline 1:9 (RT), PBS (37 °C) and rat plasma (37 °C). Ex vivo
biodistribution data were acquired at 10 and 60 min p.i. of 1.8 MBq
[Al18F]2 in healthy male mice (n=4 per time point), and compared with
those of 68Ga-DOTA-TATE.
Results: Complexation of {Al18F}2+ with 1 succeeded with 54-77% of
product formation within 15 min at room temperature and with 85-
96 % after 12 min at 40 °C. 28-298 MBq of [Al18F]2 were obtained
with 94-98% RCP after SPE. After 3 h of incubation, the content of
parent compound was 99% in formulation, 95% in PBS and 91% in
plasma. Distribution of [Al18F]2 in mice showed negligible bone up-
take, but in comparison with 68Ga-DOTA-TATE less binding in endo-
crine tissues, 4 times higher uptake in kidneys, and lower excretion
via the urinary pathway: 33.2%ID at 10 min and 62.2%ID at 60 min
p.i,, compared to 44.1%ID at 10 min and 77.9%ID at 60 min. p.i.,
respectively.
Discussion/conclusion: RESCA1-TATE easily forms a chemically and
biologically stable complex with {Al18F}2+. The radiotracer, how-
ever, showed lower uptake in organs known for high somatosta-
tine expression in comparison with the clinical standard. This
could be caused either by in vivo binding competition with non-
labelled RESCA1 conjugate, accelerated clearance or lower bind-
ing affinity of [Al18F]2. Future experiments with HPLC purified
radiotracer in competition binding studies in vitro and in vivo,
and investigation in a high somatostatin receptor expressing
tumour mouse model will have to clarify, whether specific activ-
ity, receptor affinity and/or in vivo kinetics of [Al18F]2 can explain
these results.
Research support: This research has received support within the SBO
project MIRIAD, funded from the IWT Flanders.
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Introduction and aims: Zein is the major storage protein of maize,
with a “GRAS” status, that can be easily processed to form nano-
particles. Due to its amphiphilic character, mucoadhesive proper-
ties and a relatively high resistance to the effect of digestive
enzymes, the resulting nanocarriers offer great potential for oral
drug delivery purposes.The aim is optimization of 99mTc radiola-
belling of different kind of zein nanoparticles (ZNP) and the study
by molecular imaging of their biodistribution in Wistar rats after
oral gavage. The evaluated nanoparticles were bare zein nanopar-
ticles (ZPN) and decorated with 3 different slippery polymers
(ZNP-A, ZNP-B and ZNP-C).
Materials and methods: All nanoparticles were prepared by a des-
olvation technique. For this purpose, zein were first dissolved inan ethanol:water solution, obtained by the addition of an aque-
ous solution and spray-dried. NP were pre-tinned with SnCl2 and
labelled with 99mTcO4
- . Different SnCl2 concentrations ranging
from 0.005 to 1.0 mg/mL were used for radiolabelling
optimization. RCP was analysed by radio-TLC. For biodistribution
studies 4 MBq (0.33mg NP) of 99mTc-nanoparticles were used per
animal (n=12). SPECT/CT studies were performed 1,2,4,6 and 8h
post-administration. SPECT acquisition protocol was set to ac-
count for radionuclide decay. For quantitative analysis data sets
were exported to PMOD software and VOIs drawn over CT im-
ages on stomach and intestine, count ratios calculated in respect
to total animal counts and maximum counts normalized to the
last image (8h) for each nanoparticle type.
Resuts: Radiochemical purity was >95% for ZNP-A and NPZ using
[SnCl2]=0.5 mg/mL, while 1.0 mg/mL was needed for ZNP-B and
ZNP-C to get similar results. SPECT/CT images showed that unmodi-
fied NPZ had a biodistribution in stomach and intestine almost con-
stant during the first 4 hours. 99mTc-NPZ-B had a higher stomach
mucoadhesion while 99mTc-NPZ-A showed a similar behaviour but
with faster gastric drainage and 99mTc-NPZ-C quickly moved to intes-
tine. All these results were confirmed by the ratios obtained from
PMOD processed images.
Conclusions: All Zein nanoparticles could be easily radiolabelled with
99mTc with >95% RCP. The results show a clear relationship between
the biodistribution and the superficial properties which the coating
material gives to the nanoparticle.
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Introduction: 68Ga-DOTANOC is an excellent radiopharmaceutical for
imaging neuroendocrine tumours and gives superior quality images
to equivalent peptides labelled with 111In. For that reason, we have
been developing our 68Ga-DOTANOC radiolabelling service over the
past 3 years. It is essential that we provide a high quality product
and that the production is robust, reproducible and in line with GMP.
Therefore, we have reviewed our quality data from the production of
68Ga-DOTANOC
Materials and methods: 68Ga-DOTANOC has been prepared using
an iTG 68Ge/68Ga generator and iQS fluidic labelling module. DOTA-
NOC (ABX) 50-100 μg was dissolved in 0.25M sodium acetate and
heated for 5 min at 110°C before elution of the generator in 4mL
0.05M HCl. The reaction was allowed to proceed for 10 min before
purification over a Sep-Pak C8 Plus cartridge eluted with 50% ethanol
and washed with 0.9% NaCl. The generator was flushed each day
with 5ml 0.05M HCl when not used for radiolabelling and with
20ml 0.05M HCl on Monday mornings. The 68Ga-DOTANOC prod-
uct was tested for free 68Ga and colloids by TLC and analysed
by HPLC, pH was measured, endotoxin content assessed and
radioactivity, volume and the presence of particles were checked
prior to release of the product. 68Ge content and sterility were
assessed retrospectively.
Results: A total of 746 elutions were carried out between May 2013
and December 2015, the average elution yield was 85.5%. The aver-
age production yield (decay and generator yield corrected) was
66.5%. The average 68Ge breakthrough was 0.0028% for the 68Ga
elution but 68Ge was not seen in the 68Ga-DOTANOC product. 296
production batches were made with 7 failures (2.4%) and these could
all be put down to human error (leaks in the fluidic path, incorrect
purification method etc.) and so have been minimised with training.
No product has failed quality control tests for any reason. 499
patients have been imaged with the average number of patient’s per
production run being 1.7.
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very robust process giving a high quality product in a very reli-
able manner. In spite of high 68Ge content in the 68Ga elution
with the iTG generator, the product has negligible 68Ge content.
The product has very low levels of 68Ga colloids and negligible
amounts of free 68Ga and gives a very clean HPLC trace. We
conclude that this method of production gives a safe, high qual-
ity product.
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Introduction: The application of adult human mesenchymal stem
cells from bone marrow (MSCs-ah) is being considered a promising
treatment of musculoeskeletal injuries, however, their trafficking and
homing are still controversial issues with further studies needed. Our
work is focused on in vivo biodistribution of 99mTc-HMPAO labelled
MSCs-ah after both intravenous and intra-articular injection in an ani-
mal model.
Materials and methods: 2 x 106 MSCs-ah isolated from bone marrow
of healthy subjects using SEPAX system were suspended in 1 ml of
PBS and labeled with up to 9.3 Bq/cel of 99mTc-HMPAO. Radiola-
beled cell suspensions were administered to 8 adult male New
Zealand rabbits (3.5-4 k) randomized in two groups. In group A
(n=4), cell suspensions were administered via intravenous (mar-
ginal ear vein) and in group B (n=4) by intra-articular injection.
After dynamic acquisition of images every 30 s for 25 min, whole
body static images in anterior projection at 1,6 and 24 hours
were acquired, previous sedation. No immunosuppressive agents
were administered.
Results: Early immune response to xenogenic MSCs-ah was not de-
tected during the study. Neither adverse reaction nor technical com-
plications were registered, so any and every animal was recruited for
the study. In group A, high retention of the activity was observed in
lung parenchyma, with kidney and bladder visualization from the
start, and biliary and abdominal uptake from 1h, maintaining the pat-
tern of distribution at 24h, with no significant activity in liver and
spleen. Group B show activity in heart, spleen, liver, kidneys and
bladder from the start to the late acquisition of 24h, with biliary and
intestinal uptake from 6 h. No activity was observed in the lung par-
enchyma in this group.
Discussion/conclusion: Exogenous MSCs-ah administered via intra-
venous are trapped mainly in lungs, with slight posterior retrafficking
to other organs. On the other hand, no lung trapping is observed
after intra-articular injection, pointing out the suitability of this route
of administration for the therapeutic potencial of MSCs-ah in muscu-
loskeletal pathology.
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tion of beta-cell mass in human pancreas is needed to understand
the pathophysiology of type 1 and 2 diabetes. Based on animal stud-
ies, the [18F]F-exendin-4-peptide looks promising for imaging pan-
creatic beta cells but further development of the tracer synthesis is
needed to obtain high specific activity (SA) and synthesis procedures
amendable for GMP production. A proof-of-concept study in type 1
diabetic patients and healthy subjects showed a correlation between
beta cell mass and uptake of 111In-exendin-4, which could lead to
further insight into the pathophysiology of diabetes. Recent results
with [18F]F-exendin-4 analogues demonstrate enhanced pharmacoki-
netic properties, as compared to radiometal-labelled counterparts.
Here we describe a synthesis of [18F]F-exendin-4 aiming at high SA
for the product
Materials and methods: We have investigated several conditions
and solvents for synthesizing [18F]F-exendin-4. Alkyne tosylate and a
[18F]fluoride-Kryptofix complex were allowed to react in DMSO for 5
min at 80 °C. 18F-labelled tosylate precursor ([18F]FP) was isolated
by semi-preparative HPLC and concentrated with a HLB cartridge,
followed by elution with THF from the cartridge. Exendin-4-azide was
allowed to react with [18F]FP in presence of CuSO4/Na-ascorbate for
5 min at room temperature using vigorous mixing. [18F]F-exendin-4
was isolated by semi-preparative HPLC and concentrated with a Sep-
Pak C8 cartridge. [18F]F-exendin-4 was eluted with ethanol and PBS.
Radio-TLC and radio-HPLC was used for radiochemical analysis and
SA determination of the [18F]FP and [18F]F-exendin-4.
Results: 18F-labelling of [18F]FP proceeded in an 50% radiochemical
yield (RCY). Isolation of [18F]FP by HPLC was efficient and the radio-
chemical purity was > 99%. The RCY of [18F]F-exendin-4 ranged
between 25-60% (calculated from [18F]FP, uncorrected) and the
radiochemical purity was > 96%. The SA was up to 350 GBq/
μmol at EOS.
Discussion/conclusion: We now can produce [18F]F-exendin-4 with a
SA of 350 GBq/μmol for synthesis batches of >500 MBq. Our further
aim is to automate all synthesis procedures in order to have a GMP-
level production of the tracer, suitable for clinical evaluation of
[18F]F-exendin-4.
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Introduction: Radiolabelled cyclic minigastrin-analogues are promis-
ing candidates for possible clinical application in diagnosis and ther-
apy of cholecystokinin-2 receptor (CCK2R) expressing tumours, such
as medullary thyroid cancer (MTC) and SCLC. Within an international
collaboration of the IAEA we performed biodistribution studies and
an experimental radionuclide therapy in a CCK2R-specific mouse
tumour model using two 177Lu-labelled cyclic minigastrin-analogues:
DOTA-cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Met-Asp-Phe-NH2 (DOTA-cy-
clo-MG1) and DOTA-cyclo[γ-D-Glu-Ala-Tyr-D-Lys]-Trp-Nle-Asp-Phe-
NH2 (DOTA-cyclo-MG2). Based on results of biodistribution studies
dosimetric considerations for humans were extrapolated to evaluate
the possible injected activity in first applications in patients.
Materials and methods: For biodistribution studies BALB/c nude
mice were xenografted with A431 human epidermoid carcinoma
cells transfected with the human CCK2R (A431-CCK2R) and trans-
fected with the empty vector alone (A431-mock) in both flanks.
Tumours were allowed to grow for 2 weeks. Biodistribution studies
with 177Lu-DOTA-cyclo-MG1 and 177Lu-DOTA-cyclo-MG2 were
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at 30min, 4h, 24h, 48h, 72h and 168h p.i. (5 animals/group). Dose ex-
trapolation to humans was based on linear scaling of injected activity
per gram tissue between animals and humans and computed using
OLINDA software. For experimental radionuclide therapy the animals
were injected with both 177Lu-labelled DOTA-peptides at two differ-
ent dose levels of 15 and 30 MBq corresponding to 0.6 and 1.2 nmol
peptide (6 animals/group). For up to five weeks after treatment
tumour volume and body weight was evaluated in comparison with
a control group injected with physiological saline.
Results and conclusion: Biodistribution studies in tumour-bearing
mice revealed an uptake of >3.5% ID/g for both 177Lu-labelled
DOTA-peptides in the A431-CCK2R-tumour 30min p.i.. This uptake
remained stable for 4h p.i. and declined to >2% ID/g at 24h p.i..
A much lower uptake was observed in the A431-mock tumour.
The tumour-to-kidney ratio resulted to be in the order of 3. In
the experimental radionuclide therapy a clear therapeutic effect
could be observed. In comparison to the control group the mean
tumour volume doubling time of A431-CCK2R-tumours was in-
creased by a factor of 1.8 and 2.6 in the 15 and 30 MBq group,
respectively. For the A431-mock-tumours lower factors of 1.2 and
1.7 were observed in both treatment groups proving a receptor-
specific effect. On the basis of dosimetric extrapolation to
humans first therapeutic applications in patients should start with
4 repeated administrations of 3-5 GBq to limit the cumulative
kidney dose to <27Gy. Based on patient individual dosimetry ac-
companying the first therapy the injected activity may be
adapted accordingly.
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Introduction: 111In labelled radiopharmaceuticals are extensively
used for cell labelling in routine clinical practice. Being members of
coordinating radiometals group 68Ga and 89Zr are suitable candi-
dates for synthesis of radiopharmaceuticals used for cell labelling.
Due to its half life (78,4h) 89Zr labelled radiopharmaceuticals, could
possibly enable long-term “in vivo” cell tracking with several attract-
ive clinical applications (imaging of infection and inflammation, stem
cell therapy). Aim of study was to develop a novel, versatile approach
to prepare tracers (oxine, tropolone) using concentration on an anion
exchange column.
Materials and methods: The column (SepPAK QME) was washed
with 2 ml of water. Samples of 68Ga, 111In, 89Zr-HEPES (0,5M, 1M)
solutions, samples varying in pH (3-9) and volume were prepared
and applied on column. Activity retained on, activity washed from
column and pH of the solution were measured. Samples of 0.3 ml lig-
and solution (tropolone:1mg/ml, water; oxine:1mg/ml, 20%, 50%
EtOH) were applied on the column and incubated. The column con-
tent was washed with 2 ml of PBS. Activity and pH measurements
were performed as described above. Complex formations were ana-
lyzed using extraction method into octanol.
Results: With 68Ga-HEPES (1M) yield of activity retained on the
column was above 89% and was not pH (3.7-7.3) and volume
dependent (0.5-2.5ml). Yield of 68Ga-oxine solution (20%EtOH)
was between 43-77% with pH between 6.1-7.4 and extraction
into octanol above 96%. Yield of activity retained on column with
111In-HEPES (1M) varied 31–98% and was pH and volume
dependent. Yield decreased with volumes applied greater than
0.5 ml and pH bellow 4. Yield of 111In-tropolone solution was
between 41 - 61% with pH between 6-6.7 and extraction into
octanol above 82%. Yield of 111In-oxine solution (20%EtOH) wasbetween 41-96% and extraction into octanol above 92%. 89Zr-
HEPES (0.5M) yield of activity retained on column was above 96%
and was not pH (5.5-9) and volume dependent (0.3-1.5ml). Yield
of 89Zr-tropolone solution was above 85% with pH between 7-
7.5 and extraction into octanol above 94%. Yield of 89Zr-oxine
solution (50%EtOH) was between 25-71% with pH between 7-9
and extraction into octanol above 86%.
Conclusion: Concentration of coordinating radiometals 111In,
68Ga and 89Zr on an anion exchange column in HEPES allows
on-column formation of tracers (oxine, tropolone) in very small
volumes suitable for cell labelling with good yields and quality.
This is a versatile and promising tool to prepare tracers on auto-
mated systems further used for cell labelling and potentially suit-
able for clinical practice.
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Introduction: Gallium-68 is a metallic positron emitter with a half-life
of 68 min that is ideal for labelling small peptides as radiopharma-
ceuticals thanks to the use of a chelating agent with several clinical
applications. Numerous gallium-68 labelled peptides (eg.
[68Ga]DOTA-TOC/-NOC, [68Ga]HBED-PSMA-11, [68Ga]NODAGA-RGD)
have shown their interest [1,2]. Developing an easy, rapid and perfor-
mant labelling method is important. Different methods for the pre-
purification of the generator eluate have been explored in the litera-
ture, although recent improvement on some generator brands (i.e.
low 68Ge breakthrough and low metallic impurities content), makes
this pre-purification unnecessary. Development of a labelling process,
GMP-compatible and reproducible, using a commercial synthesis
module for every peptide labelling is a real challenge for the nuclear
medicine. The method presented herein uses a cassette-based ap-
proach and a MiniAIO (mAIO, Trasis®) module and has been tested
with the IGG100 68Ge/68Ga generators.
Materials and methods Preclinical IGG100 was used as 68Ge/68Ga
generator. Precursors of radiolabelling were bought from ABX.
Automated 68Ga-labelling was performed without pre-purification
in mAIO module. Reaction parameters such as sodium acetate
concentration, precursor quantity, temperature and time were op-
timized for each peptide. Labelling efficiency was determined on
Waters HPLC system.
Results: DOTANOC, DOTATOC, HBED-PSMA-11 and NODAGA-RGD
were tested for 68Ga-labelling without pre-purification. Optimal and
reproducible conditions were determined for each peptide. 68Ga-
peptides were synthesised with excellent incorporation yields, (90-
99%) and high synthesis yields > 60% in less than 15 min.
Discussion/conclusion: We developed an efficient automated strat-
egy for peptide labelling with gallium-68. [68Ga]DOTANOC, DOTA-
TOC, [68Ga]HBED-PSMA-11, [68Ga]NODAGA-RGD were obtained in
high radiochemical yield. Their preparation could be performed
with this automation and their use in human could be done
under clinical trial.
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gredient and suitable excipients permits more efficient use of 68Ge/
68Ga radionuclide generators, despite the limitations in the variety of
generator eluent’s composition and pH. Our aim was to develop a
dry kit formulation for 68Ga radiolabeling of the PSMA inhibitor,
PSMA-11 (Glu-CO-Lys(Ahx)-HBED-CC).
Methods: A series of experiments on “wet” labelling in the pres-
ence of various amounts of sodium acetate and ascorbic acid
were performed taking into consideration the challenge to find
the composition of buffering agents ready to maintain pH value
between 4 and 5 after addition of various volumes of 68Ga
eluate (volumes of 1-4mL 0.1M HCl). For quality control of the
68Ga–PSMA-11 the RP-RadioHPLC (Kinetex C18 150mm; A:
0.1%TFA/H2O, B: 0.1%TFA/CAN) was used with gradient condi-
tions (according to M. Eder et al. Pharmaceuticals 2014, 7, 779-
796) as well as in isocratic elution (optimally set to 17% B) which
visualized the radiolabelled and non-labelled PSMA-11 in UV
chromatogram. The radiochemical purity also was tested by TLC
(ITLC SG; 1: 0.9%NaCl/MeOH 80/20 v/v; 2: 0.9%NaCl/MeOH/
25%NH3, 80/20/5 v/v/v; 3: 1M NH4OAc/MeOH 50/50 v/v).
Results and discussion: Ascorbic acid (25mg/mL) added to the “wet”
labelling mixture increased the radiolabeling yield (98.8%) compared
to the labelling performed in acetate buffer only (95.0%). It also in-
creased the buffering capacity of the formulation. These results were
further used to formulate the dry kit composition using 30μg of
PSMA-11, 60mg of sodium acetate and 12,5mg of ascorbic acid. The
yield of 68Ga labelling of PSMA-11 from the freeze-dried kit was >
95%. The biodistribution of such prepared 68Ga-PSMA-11 was inves-
tigated in healthy Balb/c mice (n=5) after intravenous injection of
0.1mL (38 MBq/mL) (at 15, 30, 60 and 120min). 68Ga-PSMA-11 was
rapidly cleared from the blood and excreted by kidney route with
>70% urine elimination at 1h p.i. These results confirmed high stabil-
ity of the 68Ga-PSMA-11 complex in vivo, with low contribution of
free gallium-68, which circulates longer in blood stream. It is worth
noting that the addition of ascorbic acid changes the biodistribution
of free gallium and favors its blood clearance. This is probably due to
the formation of week Ga complex with ascorbic acid which blocks
Ga access to ferritin, hence resulting in lower liver and spleen
accumulation.
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Introduction: The low energy electrons emitted in the Auger cas-
cade of certain isotopes are expected to have a disproportion-
ately high radiobiological effect. This is seen as the effect of the
multiplicity and predominance of very low energy electrons in
dose delivery. Despite many years of research in Auger emitters,
only few direct measurements of the radiobiological effect of
such Auger cascades have been published. One problem in mak-
ing such fundamental dose-effect experiments is the method to
bring Auger-emitting isotopes inside the cell and close to the nu-
cleus in a predictable and quantifiable manner. Only when the
location, activity, and time-activity profile are known it is possible
to compare the observed damage with damage induced by the
same dose and dose rate given by external irradiation. We have
used the biological uptake of the Auger-emitting potassium
analogue Cs-131 (9.7 d) into mammalian cells in culture as a test
system for measuring the dose-effect of Auger electrons.
Materials and methods: Cs-131 was repeatedly extracted from Ba-
131 (11.5 d) made by high flux neutron irradiation at ILL (6 to 10
days at (1.1-1.3) 1015 n.cm-2s-1) of either natural Ba (17 mg ascarbonate) or 49% enriched Ba-130 (0.15 mg as nitrate). Such tar-
gets were dissolved in hydrochloric acid, and re-precipitated with
ammonium carbonate. The supernatant was spiked with sodium
hydroxide, then dried and fired, leaving cesium-131 as a chloride
salt with NaCl carrier. The re-precipitated targets were stored for
1-2 weeks for buildup of Cs-131, and then the process can be re-
peated. We have milked up to 4 batches of useful Cs-131 activity
from a single activated barium batch from ILL. The harvested,
131Cs/NaCl salt was dissolved in water to reach isotonicity, and
was offered to V-79 and HeLa cells in normal growth media. The
cells invariantly up-concentrated the cesium activity, reaching a
plateau after 8-10 hours.
Results: Using enriched Ba-130, higher activity is obtained, but
even with natural barium activities up to 80 MBq have been
available repeatedly for the uptake experiments. Under optimal
conditions, the cells in culture can reach intracellular activities
over 1 Bq/cell during 4 hours incubation. The alkali-metal nature
of cesium gives us reasons to assume a homogeneous intracellu-
lar distribution, allowing a first-principles calculation of the
absorbed dose. With this method and unique isotope, we can
compare the effect of equivalent absorbed doses of external
gamma and internal, predominantly Auger delivered dose.
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Introduction: The αvβ3 integrin receptors, expressed on tumor cell
membranes can be preferentially targeted by peptides containing
the RGD sequence. NOTA-SCN-Bn-E-[c(RGDyK)2], NODAGA-RGDfK,
DOTA-E-[c(RGDfK)2], and DOTA-RGDfK were labelled with Ga-68 and
tested for radiolabelling yield, purity, stability, in vitro binding,
ex vivo biodistribution, and in vivo imaging.
Materials and Methods: The radiolabelling was performed using
an automated system with inline quality control. Fraction of
68GaCl3 eluate from an organic matrix based 68Ge/68Ga gener-
ator, 400-700 MBq in 2 mL, was used to label NOTA/NODAGA/
DOTA-derivatised cRGD peptides. Elution, labeling and purification
procedures were performed in 20-25 min. The biodistribution was
tested in tumor bearing animal models (U87MG, Walker 256, B21
and AR42J). The affinity of cyclo-RGD peptides to tumor cell-
surface receptors was determined by real-time quantification
using Ligand Tracer.
Results: Nanomoles of peptides were labeled with high yields. NOTA-
SCN-Bn-E-[c(RGDyK)2] and NODAGA-cRGDfK was labelled at room
temperature, while DOTA-cRGDfK, both monomer and dimer, were
labeled at 95°C, with over 90% yield. The biodistribution pattern of
68Ga-NOTA/NODAGA/DOTA-cRGD peptides shows high tumor up-
take, fast blood clearance, high tumor to background ratios and renal
elimination. Up to 5.3% ID/g of 68Ga-DOTA-E-[c(RGDfK)2] was found
on U87MG tumor; the biological behavior of the four tracers will be
discussed in detail. Binding to receptors was achieved in the first 3
min of incubation of all tracers, however the retention 68Ga-DOTA-E-
[c(RGDfK)2] on both AR42J and U87MG was the highest, up to 58%
from activity in the cells.
Discussion/conclusions: The radiolabelling with Ga-68 of very prom-
ising candidates for imaging targets of interest in cancer diagnosis
and therapy follow-up such as αvβ3 receptors, were successfully
adapted on the automated module, reducing the reaction time and
operator exposure. The preclinical biological evaluation of proposed
EJNMMI Radiopharmacy and Chemistry 2016, Volume 1 Suppl 1 Page 34 of 37tracers show that the uptake and retention on different tumor cells
depends on tumor type, receptors expression and dimerization. Very
good uptake-retention profile of 68Ga-DOTA-E-[c(RGDfK)2] makes it
our option for further investigations as therapeutic agent. Research
contracts CRP16500 IAEA and MEN UEFISCDI, PN II 228/2014 are
acknowledged for financial support.
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Introduction: Prostate cancer (PCa) is the most common cancer in
men and the second most common cause in cancer-related deaths.
68Ga-RM2 is a nona-peptide with optimized binding sequence for
Gastrin Releasing Peptide receptor (GRPr) which is overexpressed in
PCa.1 In clinical studies 68Ga-RM2 has demonstrated its ability for
detection of primary prostate cancer with high specificity due to its
low uptake in normal prostate and in benign hyperplasia.2 Recent
studies showed further potential of 68Ga-RM2 for detection of recur-
rent PCa and for imaging of estrogen receptor positive breast can-
cer.3,4. To provide 68Ga-RM2 for further clinical research, robust
methods for preparation of this promising tracer are needed. Herein
we describe the results of automated synthesizer based 68Ga-
radiolabelings of RM2 as well as of simplified “shake-and-bake” kit-
preparations.
Materials and methods: The automated 68Ga-radiolabeling was opti-
mized on a PharmTracer module (Eckert&Ziegler). The influence of
several scavengers was investigated, as well as a processes with and
without subsequent purification via C18 cartridge. Optimized condi-
tions were used on further synthesizers (Scintomics, ITG). In a second
approach, a simplified kit preparation was established. The 68Ga-
generator eluate was added directly into a vial containing RM2-
precursor, buffer and scavenger. The vial was heated and optionally
buffer was added for pH-adjustment.
Results: Automated procedures on various synthesizers provided up
to 850 MBq of 68Ga-RM2 in >70% uncorrected yield in 20 min in-
cluding purification and formulation. The radiochemical purity was
>97% (HPLC and TLC) if ascorbic acid was used as scavenger. The
simple and easy to use kit preparation approach provided 68Ga-RM2
in 90% uncorrected yield and purity of >95%.
Discussion/conclusion: 68Ga-RM2 can be reliably obtained on auto-
mated synthesizers as well as by a simple “shake-and-bake” kit prep-
aration strategy. Both methods provided 68Ga-RM2 in high yields
and high radiochemical purity.
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Introduction: Diabetes has dictated many lives, and its lifetime treat-
ment has accumulated into one of the most costly medical condi-
tions, and yet, its pathophysicology is still undisclosed. However,
efforts to develop sensitive noninvasive methods to quantify beta
cell mass, which underlies the development of diabetes, have been
challenged by the low abundance (1-2 %) and high dispersion of
beta cells in the pancreas [1]. Recent preclinical studies using 18F-
labelled exendin-4 showed specific targeting of pancreatic islets and
insulinomas with favourable clearance kinetics that would potentiate
clinical utility [2]. The focus of the present study is the radiosynthesisof a novel 18F-labelled exendin-4 analogue with a clear clinical pro-
spective for imaging pancreatic beta cell mass.
Materials and methods: The synthesis of [18F]fluoro-exendin-4 is
depicted in Scheme 1. The dried [18F]fluoride-Kryptofix complex was
reacted with tosylated prosthetic compound 1 in dimethylsulfoxide
at 80 °C. After chromatographic isolation, the 18F-labelled azide 2
was allowed to react with cyclooctyne-derivatised exendin-4 in etha-
nol/water at 60 °C for 30 min. Isolation and radiochemical analysis of
[18F]fluoro-exendin-4 was performed using high performance liquid
chromatography (HPLC) with radiodetector.
Results: Preliminary results showed efficient reaction between pros-
thetic reagent [18F]2 and exendin-4 precursor with a radiochemical
yield of 30 %. The absence of major radioactive by-products assured
neat purification using HPLC. The average isolated yield of [18F]exen-
din-4 after HPLC purification was 180 MBq starting from 3.5 GBq
aqueous [18F]fluoride.
Discussion: Currently, the scope of this reaction is being explored and
its labelling conditions optimized. Preclinical studies with [18F]fluoro-
exendin-4 will include in vivo stability, in vivo distribution kinetics, and
dosimetry calculations in healthy and diabetic animal models.
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Introduction: Automated modules for target processing and production
of radiopharmaceuticals become to be a more and more required in
both R&D and routine practice. However, it turns out that available sys-
tems for processing of targets for radiometal production and for labeling
performed via microfluidic technology are still rather limited. Our aim
was to develop a multipurpose automated systems for processing solid
state targets and for operating microfluidic PMMA-based chip.
Materials and methods: Stingray – Automated microfluidic system.
The device is a versatile automated system that allows for control of var-
iety of processes performed on a microfluidic chip. The system makes
possible operations like precise mixing, separation, extraction or small-
scale nanoparticle formation. It consists of 3 independent inlets for 3 dif-
ferent mobile phases with an in-built degasser, 4 peek solenoid valves, 2
independent nano piston pumps, 2 selectors (6/7), 2 manual inject valves
with 100 μl loop volume (adjustable), 2/10 valve, 3 check valves and
unique automated manifold for inserting microfluidic chip. This platform
offers enough variability of reaction parameters and allows for a repeated
return of a sample to the microfluidic chip. It may enhance the yield dra-
matically. CRAB – versatile platform for separation, formulation and simple
labelling processes. The main parts of the system are two reactors, two se-
lectors, peristaltic pump, 3/2 way valves, and the column. Prime reactor
R1 allows for transport solid target material from shielding container to
process position and for handling liquid target content. It is leak-
proof for 5 bars. There is an in-built solid phase extraction (SPE)
column for separation processes driven by peristaltic pump and
solvents. Four positions are available for uploading the solvents
into the reactor R1 or on the SPE column. Splitting the separated
radionuclide from the target matrix, including enriched material,
is enabled thanks to the smart software checking the column
output activity and controlling the splitting valves position. Final
activity concentration can be precisely set via the case software
without losses on the walls of reactor R2. There are 3 positions
for uploading the solvents to the reactor R2 for formulation or
for simple labelling steps like chelation.
Results and conclusion: Both automated platforms are versatile, reli-
able tools that offer user-friendly settings for wide range of pro-
cesses. Stingray is operable up to 200 bar back pressure allowing
thus the flow rate of 20 ml/min. Crab was tested on separation of
61Cu and 64Cu from Ni targets in 99% separation yield of copper
radionuclides and almost quantitative recovery of target matrix.
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Introduction: Formulations of cyclotron-produced 99mTc contain
trace amounts of other Tc isotopes depending on the isotopic com-
position of starting 100Mo. Presence of other nuclides may affect
image quality and patient dosimetry. Therefore, quantification of
radioisotopic impurities is very important. Currently, radioisotopic
purity of cyclotron-produced 99mTc is measured using gamma-ray
spectrometry and is time-consuming. We sought to identify another
approach better suitable for quality control during routine
productions.
Materials and methods: 100Mo targets (99.815% enrichment) were
irradiated in a cyclotron at 24 MeV for 2 h. The targets were
processed and radioisotopic purity of resulted 99mTc was evalu-
ated using three different procedures. Method 1, “Dilution”: An
aliquot of diluted 99mTc solution was measured using gamma-
ray spectrometry. Percentage of each radioactive contaminant
was calculated dividing activity of each isotope by total activity
in the sample. Method 2, “Shielding”: A vial containing formu-
lated 99mTc was measured in a calibrated ionization chamber.
Then, it was inserted into a 6 mm thick lead canister, used in nu-
clear medicine for 99Mo breakthrough determination, and mea-
sured using gamma-ray spectrometry. The activity of each
radioactive contaminant was calculated and divided by total ac-
tivity in the vial as measured in ionization chamber. Method 3,
“High-energy breakthrough”: A vial containing formulated 99mTc
was measured in a calibrated ionization chamber as is and inside
the lead canister. The ratio of two measurements gave relative
proportion of high-energy gamma-rays.
Results: There was a tendency to slightly overestimate the radio-
isotopic purity of cyclotron-produced 99mTc with “dilution”
method (99.983±0.007%) compared to “shielding” method (99.979
±0.009%). Since both methods require measurements by gamma-
ray spectrometry, they are time-consuming, involve elaborate cal-
culations, and demand specific expertise. “High-energy break-
through” measurements showed good correlation with the results
of gamma-spectrometry.
Conclusions: With “shielding” method, lead canister attenuated
low-energy gamma-emission (including from 99mTc) and allowed
detecting impurities present in trace amounts with better sensi-
tivity. While “high-energy breakthrough” measured in ionization
chamber does not give true radioactivity values for each contam-
inant, it offers sufficient information about relative amount of
high-energy radioactive impurities in the product. This could
serve as a surrogate test during routine productions when cross-
calibrated with gamma-spectrometry data for given isotopic com-
position of 100Mo targets.
PP58
Effective dose estimation using Monte Carlo simulation for
patients undergoing radioiodine therapy
Marina Zdraveska Kochovska1, Emilija Janjevik Ivanovska2, Vesna Spasic
Jokic3
1Institute of pathophysiology and nuclear medicine, Medical faculty,
Skopje, Macedonia; 2Faculty of Medical Sciences, University of “Goce
Delcev”, Stip, Macedonia; 3Faculty of Technical Sciences, Universty of
Novi Sad, Novi Sad, Serbia
Correspondence: Marina Zdraveska Kochovska – Institute of
pathophysiology and nuclear medicine, Medical faculty, Skopje,
Macedonia
EJNMMI Radiopharmacy and Chemistry 2016, 1(Suppl 1):PP58Introduction: Therapeutic or diagnostic radiopharmaceutical capsule
containing Na131I stays in stomach for about 15 minutes before the
absorption starts, long enough to make possible risky exposure.
Material and methods: Investigations were performed at Nuclear
medicine department, Medical faculty, Skopje. Eighty seven patients
were reviewed, age between 21 and 73. Patients were divided in 20
groups receiving average dose per group 1813 MBq to 6105 MBq.
For this purpose we used Monte Carlo 4b code for nominal activity
of 6105 MBq. The new MIRD phantom model was used for calcula-
tion of doses absorbed in specific organs due to the presence of the
source in some other organ. The stomach wall is represented by the
volume between two concentric ellipsoids and the contents within
the inner ellipsoid. The composition of each tissue type is given in
ICRP reports 70 and 89 and ICRU 46.
Results: Calculated results are given for imparted energy per trans-
formation dose equivalent and effective doses for different organs.
The effective doses were between 9,17nSv for bone surface to 122.4
mSv for stomach. As the total dose is estimated to be 126.73 mSv it
is obvious that the highest part is received by stomach.
Discussion/conclusion: Capsules containing Na131I are widely used
as they are more comfortable for administration and there is less
possibility for local contamination of patient and medical staff. Dur-
ing the time before absorption starts a large amount of radioactivity
needlessly expose a part of stomach and several surrounding organs.
Obtained results indicate that values of local doses in stomach wall
could not be ignored. As it is not possible to measure these dose dir-
ectly Monte Carlo calculation seems to be good solution for this
problem.
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Introduction: For a protein based drug including antibody based ra-
diopharmaceuticals, a structural characterization is mandatory before
any possible start of a clinical trial. Vibrational spectroscopic tech-
niques, as Fourier transform infrared (FTIR) spectroscopy and Raman
spectroscopy are one of the biophysical methods for structural
characterization of proteins because of their sensitivity to the com-
position and architecture of molecules. Here we used vibrational
spectroscopy to characterize the physico-chemical stability and struc-
tural changes of three immunoconjugates of rituximab, intended for
labeling with radioisotope of choice (177Lu, 90Y and/or 68Ga), relevant
for the stability of therapeutic/diagnostic antibodies during prepar-
ation, storage and/or transport.
Materials and methods: Rituximab, conjugated with three different
bifunctional chelating agents (BFCAs), p-SCN-Bn-DOTA, p-SCN-Bn-
DTPA and 1B4M-DTPA in a form of lyophilized preparations non-
radioactive labeled with above mentioned radioisotope analogues,
was subjected to characterization and determination of secondary
structure and quality parameters (purity, integrity, fragmentation and
aggregation of the antibody) by FT-IR and Raman spectroscopy.
Results: Based on the frequencies assigned for amide I, II and III
bands, the studied formulations contain highest percentage of β-
sheet conformation (antiparallel and parallel) in the structure,
followed by α-helices. Significant changes upon processes of conju-
gation and lyophilization were not observed in comparison with
spectra of native antibody.Vibrational spectroscopic data allow detec-
tion of alterations in investigated protein models as well as rapid as-
sessment of conformational changes resulting from ligand binding,
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absorption bands below 1620 cm–1 can be correlated with
aggregation-usually associated with the formation of new strong β-
sheet structures. According to the obtained spectra, it is important
that we observed retaining of native structure of the antibody and
no obvious aggregation (the lowest band frequency detected was
1620 cm–1 with weak intensity) in all samples of lyophilizated
conjugates.
Conclusion: We investigated the application of vibrational spectros-
copy in assessment of conformational changes during stress condi-
tions, as lyophilization and non-radioactive labeling are, using
different rituximab-conjugates. The results are a good foundation for
further radiolabeling studies of the lyophilized formulations for pos-
sible therapeutic application.
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Introduction: Our work is to present the current status, and in
the same time the need and benefit of establishment of Radio-
pharmacy practice in Eastern Africa using the perspective of
Kenya and Ethiopia. The exact information on the status and
size of Radiopharmacy units, regionally, is still not clearly docu-
mented, as well human resources, education, suitable training
and local demand for the Radiopharmacy and Nuclear Medicine
services. The Radiopharmacy Practice requires well-defined and
controlled conditions to avoid the risk contamination with mi-
crobes, pyrogens and particulate matter as well as cross contam-
ination with other radiopharmaceuticals. Corresponding to the
expected improvement, the principles of Good Practices in all
levels should be planned, introduced by the planned priority
and strictly observed in the production, preparation, testing and
the packaging of the final product ready for use. Because non-
communicable diseases (NCDs) are a challenge of epidemic pro-
portion and that they will be the commonest cause of mortality
in Africa by 2030, early detection and treatment can significantly
improve patient outcomes. Radiopharmaceuticals should have
become of invaluable benefit because they offer the most sensi-
tive tools in the detection, diagnosis and targeted therapy of
NCDs and also infectious diseases. In light of the foregoing,
therefore, radiopharmacy has a huge role to play in responding
to the unfolding new disease trends in sub-Saharan Africa. The
preparation of radiopharmaceuticals for human use requires that
it is carried out in well-defined and controlled conditions to
avoid the risk contamination with microbes, pyrogens and par-
ticulate matter as well as cross contamination with other radio-
pharmaceuticals. Every procedure undertaken should be done
according to the clearly defined protocol and under the right
conditions so as to build quality into the product. Radiophar-
macy professionals should have adequate training in all aspects
of sterile production, quality control, GMP, GLP, radiation safety
and radiochemistry to ensure that they are competent to handle
radioactive materials and that they can take responsibility for
their level of practice.
Conclusions: We are expecting that the good education and continu-
ing training of all professionals working in Radiopharmacy will be the
key point how to create the network of all professionals and stateauthorities for establishing and develop Good Radiopharmacy Prac-
tice, qualified personnel and appropriate regulation according to the
local and international parameters will be step forward to have ad-
vanced health care system and confidence of the patients.
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Purpose: The importance of well-established and recognized educa-
tion in Radiopharmacy became a need all around the world as result
of different national regulation, different system of education and
mostly of the level of need, development and investment in clinical
and research usage of radiopharmaceuticals. The substantial confu-
sion and challenge in the same time is to define the appropriate and
sufficient knowledge, understanding and competences correspond-
ing to position of professionals in the working place, including the
type and level of formal education.
Methods: The goal of the Academic Master program for Radiophar-
macy in English, with the recognized accreditation from the National
Body in 2014 and recommended by the Ministry of Education and
Science in our country according to the Bologna system with 120
ECTS credits is to give the opportunity for all students with finished
academic undergraduate program (at least 240 ECTS) to follow it and
to receive academic title Master of Radiopharmacy. The Radiophar-
macy Education Program is organized according to the University
model including Obligatory and Optional Theoretical Courses, Obliga-
tory Practices and Master Thesis on the end of the second year using
the University laboratory of Radiopharmacy, that is under ISO ac-
creditation, new PET facilities and all other corresponding facilities
available in the university and in the country. The program use e-
learning platform from the University and IAEA contribution and col-
laboration related to the education and training of the students from
developing countries. The result of that collaboration is already
inscribed students from Kenya and Ethyopia.
Results: The syllabus include knowledge and skills in three categor-
ies: 1. Specific knowledge and skills:Design of Radiopharmacy facil-
ities and QA program, Production and synthesis of radionuclides and
radiopharmaceuticals, Quality control of radiopharmaceuticals 2.
Basic knowledge and skills: Leadership and collaboration, Communi-
cation, Negotiations, Analytical and critical thinking skills including
creativity and ethical considerations, Pharmaceutical and chemistry
knowledge 3. Fundamentals of Radiopharmacy: General models of
the area, Key specializations within the field, Evaluation of perform-
ance within the area.
Conclusions: The program creates academic staff able to work in all
spheres of the modern Radiopharmacy, conventional hospital Radio-
pharmacy and with the option of continuing their education in some
PhD program. The program can be also a basic platform for the more
advanced courses available for the professionals from the European
and world recognized associations.
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Introduction: The RGD-recognising αVβ3, αVβ5 and α5β1 integrins
are known to be involved in carcinogenesis and are overexpressed in
many types of tumours compared to healthy tissues; thereby they
have been selected as promising therapeutic targets. Positron emis-
sion tomography (PET) is providing a unique non-invasive screening
assay to discriminate which patient is more prone to benefit from
antiangiogenic therapies, and extensive research has been carried
out to develop a clinical radiopharmaceutical that bind specifically to
integrin receptors. However, despite promising clinical results, one
still needs to identify an integrin radioligand that could be easily de-
ployed. We herein report the synthesis of a 18F-labelled RGD pep-
tide, namely [18F]FPyPEGCBT-c(RGDfK), by condensation of a 2-
cyanobenzothiazole prosthetic group to a cysteine-modified cyclic
RGD peptide and the characterisation of its preclinical biologic
properties.Materials and methods: A novel bifunctional synthon ([18F]FPy-
PEGCBT) has been developed to accommodate: i) an efficient [18F]F-
incorporation and ii) a mild conjugation to biomolecules. Then,
[18F]FPyPEGCBT has been conjugated to a cyclic RGD peptide known
for its high binding affinity and selectivity for integrin αVβ3. The
in vitro binding characteristics of FPyPEGCBT-c(RGDfK) were analysed
by standard binding assay in U-87 MG and SKOV-3 cancer models
and its selectivity towards integrins by siRNA depletions. Its preclin-
ical potential was studied in mice bearing subcutaneous tumours by
ex vivo biodistribution studies and in vivo microPET/CT imaging.
Results: [18F]FPyPEGCBT was prepared from its corresponding 2-
trimethylammonium triflate precursor and purified by solid-phase ex-
traction. Ligation of [18F]FPyPEGCBT to the cysteine-modified cyclo-
(RGDfK) peptide was carried out in DMF at 43 oC. The 18F-peptide
was obtained, after HPLC purification and reformulation, in 124–132
min from the end of bombardment with a final decay-corrected yield
of 7% ± 1. In vitro, FPyPEGCBT-c(RGDfK) bound efficiently to RGD-
recognising integrins as compared to a control c(RGDfV) peptide
(IC50 = 30.8 × 10-7 M vs. 6.0 × 10-7 M). In vivo, this new tracer dem-
onstrated specific tumour uptake with %ID/g of 2.9 and 2.4 in U-87
MG and SKOV-3 tumours 1 h after injection. Tumour-to-muscle ratios
of 4 after 1 h of uptake allowed good visualisation of the tumours.
However, unfavourable background accumulation and high hepato-
biliary excretion were noticed.
Discussion/conclusion: [18F]FPyPEGCBT-c(RGDfK) specifically detects
tumours expressing RGD-recognising integrin receptors in preclinical
studies. Further optimisation of this radioligand may yield candidates
with improved imaging properties and would warrant the further use
of this efficient labelling technique for alternative targeting vectors.Submit your manuscript to a 
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